At the center of this fracture is a three-way divide:

• Between President Donald Trump and his own Health Secretary, Robert F. Kennedy Jr.

• Between Kennedy and the administration’s nominee to lead the CDC

• And between public health institutions and the scientific community itself

This is not a normal policy disagreement. It reflects a deeper shift in how decisions about vaccines are being made—and what those decisions are based on.

Subscribe now

Trump vs. RFK: policy shaped by politics, not data

The Trump administration is attempting to balance two competing realities.

On one side, Robert F. Kennedy Jr. has pushed an aggressive agenda that questions long-standing vaccine practices, reshapes advisory structures, and promotes skepticism about vaccine safety. On the other, the administration has shown signs of pulling back—softening messaging and recalibrating its approach in response to political pressure.

That shift is not being driven by new scientific findings. It is being driven by optics and timing.

When policy moves in one direction, then partially reverses without any meaningful change in underlying data, it signals something important: science is no longer the controlling factor.

Instead, vaccine policy is being influenced by political considerations—what resonates with the public, what avoids backlash, and what aligns with broader messaging strategies.

RFK vs. the CDC nominee: a government divided against itself

The second fracture is unfolding inside the administration itself.

The nominee to lead the CDC is widely viewed as more aligned with traditional public health principles. But even before taking office, there are serious concerns about whether that role will be allowed to function independently.

During recent discussions, Kennedy declined to clearly guarantee that the CDC would retain full autonomy over vaccine recommendations. That hesitation is telling.

At the same time, recent actions—reshaping advisory committees, influencing messaging, and inserting political oversight into scientific processes—suggest that control over vaccine policy may not rest with scientists at all.

This sets up a direct conflict:

• A CDC leadership structure expected to follow data

• A Health Secretary actively questioning or reshaping that data’s role

When those two forces collide, the result is not compromise. It is instability.

And for a public health system, instability is dangerous.

The public is drifting toward misinformation

While these internal divisions grow, public belief is shifting in a troubling direction.

Scientific American has reported that a staggering number of Americans now believe unproven claims about vaccines, raw milk, and other health issues. These are not fringe ideas anymore—they are entering mainstream thinking.

This reflects a broader trend: people are increasingly turning toward sensationalized or emotionally driven information rather than established science.

The problem is compounded when government messaging itself becomes inconsistent.

When the public sees:

• Conflicting statements from leadership

• Sudden policy changes without clear explanation

• Scientific institutions appearing politically influenced

It creates space for misinformation to thrive.

People do not just lose trust in one policy. They begin to question the entire system.

Science is no longer driving the decision-making process

Across multiple developments, a consistent pattern has emerged.

Vaccine-related decisions are being made that do not appear tied to new scientific evidence. Instead, they reflect:

• Changes in leadership priorities

• Political strategy

• Public perception concerns

There have been instances where scientific processes were bypassed or reshaped. Advisory structures have been altered. Messaging has shifted in ways that do not align with longstanding medical consensus.

At the same time, media coverage has highlighted growing tension between those trying to maintain evidence-based standards and those pushing alternative approaches.

Taken together, these developments point to a system where science is no longer the starting point.

It has become one factor among many—and not necessarily the most important one.

Why this matters beyond policy debates

This shift has real consequences.

From a public health standpoint, reduced trust in vaccines leads directly to lower vaccination rates. Lower vaccination rates lead to outbreaks. That relationship is well established and does not depend on politics.

From a legal standpoint, the implications are just as significant.

The vaccine injury compensation system—and vaccine litigation more broadly—relies on:

• Consistent scientific frameworks

• Credible public health guidance

• Reliable institutional positions

When those foundations weaken, it creates uncertainty across the board:

• Courts are left to navigate conflicting narratives

• Government positions become less predictable

• Petitioners face a more complex and skeptical environment

The system becomes harder to navigate—not because the science is unclear, but because the messaging around it is.

Where this leads

The United States is entering a period where vaccine policy is no longer anchored by a single, coherent scientific framework.

Instead, it is being shaped by competing influences:

• Political pressure

• Internal disagreement

• Public misinformation

That combination creates confusion at every level—from individual decision-making to national policy.

If this trajectory continues, the consequences will not be abstract. They will be measurable:

• In rising case numbers of preventable diseases

• In increased strain on healthcare systems

• In a growing disconnect between science and public belief

The path forward requires a return to a simple principle: science must lead, and policy must follow.

Right now, that principle is being tested.

And the outcome will define the future of public health in this country.

Subscribe now

This case represents an important step forward in how the Vaccine Program evaluates complex neurological injuries following vaccination. At its core, the case involved a petitioner who received an influenza vaccination on November 3, 2023, and subsequently developed progressive neurological symptoms that were ultimately diagnosed as CIDP—a chronic autoimmune condition affecting the peripheral nervous system.

The central factual dispute revolved around onset. Prior to vaccination, the petitioner had reported intermittent, isolated toe numbness. Respondent argued that this symptom represented the early onset of CIDP, effectively attempting to shift the timeline of the disease to before vaccination. However, the evidence told a different story. The pre-vaccination symptom was minor, static, and non-progressive. It was not associated with weakness, functional impairment, or any clinical suspicion of a demyelinating condition.

After vaccination, the petitioner experienced a clear and progressive neurological decline. Symptoms spread beyond the toes, weakness developed, and diagnostic testing confirmed a demyelinating polyneuropathy consistent with CIDP. The Court ultimately rejected the government’s attempt to retroactively characterize the earlier symptom as disease onset and instead credited the post-vaccination clinical progression. This distinction proved decisive.

The legal battle in this case centered on causation under the standard established in Althen v. Secretary of Health & Human Services. Specifically, the dispute focused on whether the petitioner could establish a medically plausible theory connecting the influenza vaccine to CIDP.

Petitioner’s experts advanced a theory grounded in immune-mediated mechanisms, including molecular mimicry and immune dysregulation. They explained how vaccination can, in certain individuals, trigger an autoimmune response that targets peripheral nerves, leading to demyelination and the clinical presentation of CIDP.

Respondent’s expert, by contrast, challenged both the strength of the medical literature and the reliability of the proposed mechanism. The government emphasized that CIDP is distinct from Guillain-Barré Syndrome (GBS), a condition more commonly associated with the flu vaccine, and argued that the scientific evidence linking influenza vaccination specifically to CIDP is limited. Respondent also criticized the reliance on molecular mimicry, arguing that it is frequently invoked without sufficient case-specific support.

The Special Master’s analysis of this issue was candid and, at times, critical of the petitioner’s theory. He observed that the theory was not particularly robust, noting its reliance on the better-established flu–GBS association and the relatively limited CIDP-specific literature. He also reiterated skepticism toward the routine invocation of molecular mimicry when not supported by evidence directly tying the mechanism to the vaccine and the condition at issue.

Yet despite these criticisms, the Court ruled in favor of the petitioner.

Rather than requiring a fully developed, case-specific scientific explanation, the Special Master relied in part on prior Vaccine Program decisions that have accepted some degree of overlap between flu–GBS and flu–CIDP claims. In doing so, the decision reflects an effort to maintain consistency in how similar claims are treated within the Program. Based on that framework, the Court found that the petitioner satisfied the requirements of Althen, even while acknowledging that the theory itself was somewhat “threadbare.”

At the same time, the ruling includes an important caveat. The Special Master made clear that this outcome is not guaranteed in every case going forward. He expressly noted that a stronger evidentiary showing by Respondent—particularly involving CIDP-specific scientific research—could lead to a different result in future cases. In other words, while the door is open, it remains subject to further development of the science and the evidentiary record.

Even with that qualification, the significance of this ruling should not be understated. It reinforces that flu–CIDP claims are viable within the Vaccine Program when supported by a credible factual record and a medically plausible theory. It also confirms that courts will carefully evaluate onset arguments and are willing to reject attempts to recharacterize minor, pre-existing symptoms as evidence of a pre-vaccination condition.

For individuals suffering from CIDP following a flu shot, this decision provides a meaningful path forward. It demonstrates that progressive post-vaccination symptoms, supported by appropriate diagnostic testing, can meet the legal standard for causation—even in the face of scientific uncertainty.

Looking ahead, this ruling is likely to influence how similar cases are litigated and evaluated. It may encourage more claimants to pursue compensation and may also prompt both sides to develop stronger CIDP-specific evidence in future cases.

About David Carney and Green & Schafle LLC

This case was litigated by David Carney of Green & Schafle LLC, a leading law firm in representing individuals injured in the National Vaccine Injury Compensation Program.

Carney has spent over 15 years litigating complex vaccine injury claims, with a particular emphasis on neurological conditions such as Guillain-Barré Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and other immune-mediated disorders. His practice has involved developing medical theories in cases where the science is still evolving—often requiring coordination with leading experts and building records that withstand aggressive challenges from the government.

This ruling reflects that approach. The case required overcoming a common defense strategy—recasting minor, pre-vaccination symptoms as evidence of a pre-existing condition—and advancing a causation theory in an area where the literature is still developing. The outcome reinforces that well-developed records and credible expert support can carry the day, even where the science is not fully settled.

Green & Schafle continues to handle cases involving complex neurological injuries following vaccination and remains at the forefront of litigating emerging issues within the Vaccine Program.

If you or someone you know is dealing with a similar condition following vaccination, it is worth exploring whether a claim may be viable.

📞 215-326-9256
📧 dcarney@greenlegalteam.com

Subscribe now

For more than seventy years, the United States military required service members to receive the annual influenza vaccine. That policy—dating back to World War II—was never accidental. It was grounded in a simple reality: infectious disease can undermine readiness faster than almost any external threat.

That policy has now been reversed.

The Department of Defense has eliminated the mandatory flu vaccine requirement, making vaccination voluntary for service members. At first glance, this appears to be a narrow administrative change, framed in terms of personal autonomy and individual choice. In reality, it represents a broader shift in how risk is allocated—not just within the military, but across the public health landscape.

The implications of that shift extend well beyond military bases.

This Is Not Contained to the Military

The military is not an isolated population. Service members are stationed across the United States and deployed around the world. They live in close quarters, train in groups, travel frequently, and interact daily with civilian populations through healthcare systems, schools, transportation networks, and local communities.

That structure makes the military uniquely susceptible to rapid viral transmission. It also makes it a potential conduit for spreading infectious disease beyond its own ranks.

When vaccination rates decline in a population like this, the consequences are not confined to that population. Influenza does not remain on base. It moves outward—into surrounding communities, into hospitals, and into households.

This is particularly significant because influenza is not merely an individual health issue. It is a transmissible, seasonal virus that depends on population-level susceptibility to sustain itself. When more individuals are susceptible, transmission accelerates. When transmission accelerates in a highly mobile population, the geographic spread expands.

The result is not theoretical. It is predictable.

The Spillover Effect: From Bases to Communities

Military installations are embedded within civilian life. Service members and their families engage with local economies, public spaces, and healthcare providers. Civilian employees work on base. Contractors move in and out. Families attend local schools.

When influenza spreads more freely within the military, it does not stop at the perimeter.

It reaches elderly populations, immunocompromised individuals, children in schools and daycare settings, and local healthcare systems already managing seasonal demand. For vulnerable populations, influenza is not a minor illness. It can result in hospitalization, long-term complications, or death.

Historically, vaccination policies have been designed not only to protect the individual receiving the vaccine, but to reduce the likelihood of transmission to those who cannot fully protect themselves. When participation declines, that layer of protection weakens first for those who need it most.

This Is Not a Science-Driven Shift

It is important to separate policy from science.

There has been no new scientific development indicating that influenza is less contagious, less dangerous, or less responsive to vaccination. The underlying principles that have guided flu vaccination policy for decades remain unchanged. Vaccination reduces both the likelihood of infection and the severity of disease, and it plays a measurable role in reducing transmission across populations.

The rationale offered for eliminating the mandate centers on autonomy, personal choice, and the perceived overbreadth of prior policy. Those are policy considerations—not scientific conclusions.

Viruses do not respond to shifts in political or administrative philosophy. They respond to exposure, susceptibility, and opportunity. When susceptibility increases within a population, spread follows.

Why Vaccine Mandates Have Historically Been Necessary

Vaccine mandates have never existed simply to compel medical treatment. They exist because individual decision-making, standing alone, does not reliably produce population-level protection.

Vaccination operates on two levels simultaneously. It protects the individual from infection or severe disease, and it reduces the likelihood that the individual will transmit the disease to others. That second function is what makes vaccination policy distinct.

Without a mandate, participation becomes uneven. Immunity becomes fragmented. Viruses move through those gaps.

Mandates establish a uniform baseline of protection. They reduce variability, limit transmission chains, and create predictability for public health systems. They also prevent the well-known “free rider” problem, where individuals benefit from others’ vaccination without participating themselves—ultimately eroding overall protection.

In environments like the military, where close contact and mobility are unavoidable, mandates have historically been the most effective way to maintain that baseline.

Strong Vaccine Policy Is About System Stability

A robust vaccine policy does more than reduce infections—it stabilizes entire systems.

When vaccination rates are high, outbreaks are smaller and less frequent. Fewer people require medical care, and those who do are less likely to experience severe illness. That translates directly into reduced strain on emergency departments, hospitals, and healthcare providers.

Every flu season brings predictable pressure on the healthcare system. Increased infections lead to more emergency room visits, higher hospital admissions, and stretched resources. Vaccination reduces that burden and helps preserve capacity—not just for flu patients, but for everyone else needing care.

This is especially important in rural communities, where healthcare access is already limited. Hospitals operate with fewer resources, fewer providers, and less flexibility. Even a modest increase in cases can overwhelm the system, forcing patients to travel long distances and delaying care across the board.

Higher vaccination rates reduce the likelihood of those outcomes and help maintain access where it is already fragile.

Prevention vs. Response

Vaccine policy ultimately reflects a choice between prevention and response.

Prevention limits transmission before it begins. It protects vulnerable populations and reduces strain on healthcare systems. It is efficient, predictable, and far less costly.

Response occurs after outbreaks take hold. It requires treatment, hospitalization, and containment efforts. It is reactive, resource-intensive, and far less effective at minimizing harm.

When vaccination rates decline, systems are forced into response mode.

The military’s longstanding vaccination policy was built on prevention. Eliminating the mandate shifts that balance.

The Legal and Policy Shift

From a legal standpoint, this decision reflects a broader shift away from collective risk management toward individual autonomy. That trend has been developing across vaccine mandate litigation, administrative law challenges, and federal policy debates.

The military has traditionally prioritized collective necessity over individual preference. That is what made uniform vaccination policies both practical and legally defensible.

This change signals a departure from that framework.

It does not eliminate risk. It redistributes it—from institutions to individuals, and ultimately to the public.

The Bottom Line

The elimination of the flu vaccine mandate is not simply a military policy change. It is a shift in how infectious disease risk is managed in one of the most mobile populations in the country.

When vaccination rates decline in that population, the effects extend outward. Transmission increases, outbreaks become more likely, vulnerable populations face greater exposure, and healthcare systems absorb the consequences.

Encouraging widespread vaccination is not about eliminating individual choice. It is about recognizing that certain choices carry consequences beyond the individual.

Removing mandates does not remove risk. It increases the likelihood that it will surface elsewhere—less controlled, less predictable, and more costly to manage.

Subscribe now

Quick Summary

Talcum Powder (Johnson & Johnson and Others)

Talcum powder products, including those manufactured by Johnson & Johnson, have long been marketed for personal hygiene use. Plaintiffs allege that certain talc products were contaminated with asbestos and, when used over time, caused ovarian cancer and mesothelioma. Internal documents and expert testimony have been central to these claims. This remains one of the largest mass torts in the country, with tens of thousands of pending cases and multiple recent verdicts in the hundreds of millions to billions of dollars. Despite attempted bankruptcy strategies, litigation continues nationwide, with significant pressure on defendants to reach a global settlement.

Mesothelioma and Asbestos Exposure

Asbestos was widely used for decades in construction materials, insulation, and industrial products due to its heat-resistant properties. Exposure—often occupational or secondary—has been linked to mesothelioma, lung cancer, and other serious pulmonary diseases such as asbestosis. These diseases typically develop years or decades after exposure, making diagnosis and causation complex. Although asbestos litigation is a mature area of law, it remains highly active, with new claims filed regularly. Recent cases increasingly involve asbestos-contaminated consumer products, including talc. Courts across the country continue to see significant verdicts and settlements in favor of individuals suffering from these devastating illnesses.

Hernia Mesh (C.R. Bard, Ethicon, Covidien)

Hernia mesh devices are surgically implanted to support weakened or damaged tissue during hernia repair procedures. Manufacturers such as C. R. Bard, Ethicon, and Medtronic (Covidien) are defendants in thousands of lawsuits. Plaintiffs allege that defective mesh products can shrink, migrate, or erode, leading to chronic pain, infection, adhesions, bowel obstruction, and the need for revision surgery. These cases are consolidated in multiple federal MDLs and state court proceedings. While some settlements have occurred, litigation remains ongoing, with continued trials and negotiations shaping the future of the docket.

Paraquat Herbicide

Paraquat is a powerful herbicide used primarily in agricultural settings for weed control. Plaintiffs allege that prolonged exposure to paraquat is linked to the development of Parkinson’s disease, a progressive neurological disorder affecting movement and motor control. Many individuals bringing claims are farmers or agricultural workers who handled the chemical regularly. Litigation has grown rapidly and is centralized in federal court, where thousands of cases are proceeding through coordinated discovery. The parties are preparing for bellwether trials, which will serve as test cases and likely influence settlement discussions and overall valuation of claims moving forward.

AFFF / PFAS Firefighting Foam

Aqueous Film-Forming Foam (AFFF) has been widely used by military personnel, firefighters, and airport crews to combat fuel-based fires. The foam contains PFAS chemicals, often referred to as “forever chemicals” because they persist in the environment and the human body. Plaintiffs allege exposure to PFAS has caused various cancers and chronic health conditions, including kidney and testicular cancer. This litigation has become one of the largest environmental mass torts in the country, involving both personal injury and municipal water contamination claims. Significant settlements have already been reached in certain categories, while individual injury claims continue to move forward.

Hair Relaxer Litigation

Chemical hair relaxers are commonly used to straighten hair, particularly among women who use these products over long periods of time. Lawsuits allege that repeated exposure to certain chemicals in these products increases the risk of uterine cancer, ovarian cancer, and other hormone-related conditions. Scientific studies have drawn connections between endocrine-disrupting chemicals and these health outcomes. The litigation has expanded rapidly, with thousands of cases consolidated into a federal MDL. The cases are still in the early stages, with discovery ongoing and bellwether trials expected to play a critical role in determining the strength and value of claims.

Ozempic and GLP-1 Weight Loss Drugs

Medications such as Ozempic and similar GLP-1 receptor agonists are widely prescribed for diabetes management and weight loss. While these drugs have gained popularity, lawsuits allege that they can cause severe gastrointestinal injuries, including gastroparesis, stomach paralysis, and bowel obstruction. Some plaintiffs report long-term digestive complications even after discontinuing the medication. This is a rapidly developing pharmaceutical mass tort, with thousands of cases already filed. The litigation is in its early stages, with courts overseeing coordinated proceedings and the parties preparing for key rulings that will shape the trajectory of the cases.

Depo-Provera (Brain Tumor Claims)

Depo-Provera is an injectable contraceptive. Lawsuits allege that prolonged use of the drug is associated with the development of meningiomas, a type of brain tumor that can cause serious neurological symptoms. Plaintiffs claim that the risks were not adequately disclosed. This litigation has expanded quickly and is now centralized in federal court. With thousands of claims already filed, the case is moving at a faster pace than many traditional pharmaceutical mass torts, and early trial settings are anticipated, making it one of the most closely watched emerging dockets.

Bard PowerPort

The Bard PowerPort is an implanted catheter device used to deliver medications directly into the bloodstream, often for chemotherapy or long-term treatment. Lawsuits allege that the device can fracture or migrate, causing serious internal injuries, blood clots, infections, and the need for surgical removal. Manufactured by C. R. Bard, the product is the subject of a rapidly growing MDL. Plaintiffs claim the device was defectively designed and that safer alternatives were available. The litigation is currently in the coordinated discovery phase, with thousands of cases pending and expectations for future bellwether trials.

Social Media and Tech Addiction

Social media platforms operated by companies such as Meta Platforms and Alphabet Inc. are facing lawsuits alleging that their products are intentionally designed to maximize user engagement in ways that can harm minors. Claims focus on addiction, depression, anxiety, and self-harm linked to prolonged use. Plaintiffs argue that algorithms and platform design choices contributed to these outcomes. This is an emerging area of litigation, with cases consolidated in federal court and early trials beginning to test liability theories.

Camp Lejeune Water Contamination

For decades, individuals living and working at Camp Lejeune were exposed to contaminated drinking water containing toxic chemicals. These exposures have been linked to various cancers and serious health conditions. Under federal law, affected individuals and their families are now able to bring claims against the government. While this is not a traditional MDL, it is one of the largest coordinated compensation efforts in recent history, with ongoing settlement activity.

CPAP Device Recalls (Philips)

CPAP machines manufactured by Philips are used to treat sleep apnea and other breathing disorders. A large-scale recall was issued after it was discovered that internal foam components could degrade and release toxic particles. Plaintiffs allege that exposure has caused respiratory injuries and cancer. The litigation is centralized in federal court and remains active, with settlement discussions ongoing for certain categories of claims.

Paragard IUD

The Paragard intrauterine device is a hormone-free contraceptive used for long-term pregnancy prevention. Lawsuits allege that the device can break during removal, leaving fragments inside the body and requiring additional procedures. Plaintiffs report pain, complications, and potential fertility issues. The litigation is centralized in federal court and continues to move forward as courts address product design and warning claims.

Rideshare Sexual Assault (Uber and Lyft)

Rideshare companies such as Uber Technologies and Lyft provide transportation services used by millions. Lawsuits allege that these companies failed to implement adequate safety measures to prevent sexual assaults by drivers. Thousands of cases are pending, and the first bellwether trial has already taken place, marking a critical stage in determining liability and potential settlement value.

Roblox Child Exploitation Litigation

The platform operated by Roblox Corporation allows users—many of them minors—to interact in virtual environments. Lawsuits allege that the platform failed to protect children from grooming and exploitation. These cases are newly centralized in federal court and are in the early stages of litigation, with discovery underway and key legal issues yet to be decided.

Speak With an Attorney About Your Case

If you or a loved one has suffered from any of the injuries described above, you may be entitled to compensation. The process starts with a quick, confidential review of your situation.

Text or email me directly with:

• Your name

• The litigation that would apply to your or your loved one’s situation

• The injury or diagnosis

• Approximate dates of use and diagnosis

I will personally review your information and respond within the hour to let you know if you may qualify for a claim.

Text/Call: 215-326-9256
Email: dcarney@greenlegalteam.com

Subscribe now

The Conversation Is Focused on the Wrong Issue

The current discourse surrounding vaccine policy reform is built on a flawed premise. The suggestion that the system’s core problem lies in liability protections or the existence of the PREP Act reflects a misunderstanding of how vaccine injury claims actually function in practice. The PREP Act itself is not the issue. The issue is the compensation structure that accompanies it.

Under the current framework, individuals alleging injury from COVID vaccines are routed into a system that does not operate as a true compensation program. It is limited in scope, restrictive in eligibility, and lacks the procedural safeguards that define a functioning legal system. The result is not merely inefficiency—it is exclusion. Many individuals with legitimate claims are unable to recover at all, not because their claims lack merit, but because the system is not designed to accommodate them.

A meaningful reform effort would start by acknowledging this reality. The focus should not be on dismantling liability protections, but on ensuring that those protections are paired with a compensation system that works.

What the March 6, 2026 Letter Actually Seeks to Do

The March 6, 2026 letter proposes sweeping changes to the structure of vaccine regulation in the United States. While framed as an effort to improve safety and transparency, its substance reflects a broader attempt to reshape how vaccines are evaluated, recommended, and regulated across federal agencies.

Among its proposals are the elimination of routine vaccine recommendations in favor of individualized decision-making, the imposition of more burdensome clinical trial requirements, and structural changes affecting how agencies collect, analyze, and disseminate vaccine-related data. It also raises the issue of liability protections in a way that suggests dismantling existing frameworks rather than improving the systems that operate alongside them.

These proposals are not incremental. They represent a fundamental shift away from a centralized, science-driven approach to vaccine policy and toward a more fragmented and legally uncertain framework.

The Problem with “Shared Decision-Making” as Policy

One of the most consequential proposals in the current reform discussion is the move from routine vaccine recommendations to a model of “shared clinical decision-making.” While this concept may appear reasonable in isolation, its implications are significant.

Routine recommendations establish a clear standard of care. They provide consistency across providers, ensure uniform insurance coverage, and create a stable legal framework within which both physicians and patients operate. Shared decision-making, by contrast, removes that default. It shifts responsibility to individual providers and patients without providing a consistent baseline.

This shift introduces variability into medical practice, complicates reimbursement structures, and creates ambiguity in liability. From a legal perspective, it weakens the predictability that underpins both clinical decision-making and compensation systems. It is not a neutral change. It is a structural one, with consequences that extend well beyond individual patient interactions.

ACIP Is Not Just Advisory—It Is Foundational

The restructuring of ACIP must be understood in this context. ACIP is not simply an advisory body offering non-binding guidance. Its recommendations are embedded in federal law and have direct consequences for insurance coverage, public health policy, and liability protections.

When ACIP issues a recommendation, that recommendation determines what insurers must cover, what constitutes standard medical practice, and which vaccines fall within the Vaccine Injury Compensation Program. In effect, ACIP serves as the gateway through which vaccines enter the broader legal and regulatory framework.

Changes to ACIP, therefore, are not merely procedural. They affect the integrity of the entire system.

The Breakdown in Expertise and Process

The recent restructuring of ACIP raises serious concerns about both expertise and process. Historically, ACIP has been composed of individuals with specialized knowledge in immunization practices, vaccine safety, epidemiology, and clinical research. That expertise is not incidental; it is essential to the committee’s function.

The current composition reflects a departure from that model. While many of the appointed individuals are accomplished professionals, a significant number do not have meaningful experience in vaccines or immunization policy. This creates a disconnect between the committee’s mandate and its ability to fulfill that mandate effectively.

Equally concerning is the process by which these appointments were made. The longstanding procedures designed to ensure balance, transparency, and rigorous vetting were not followed. When both expertise and process are compromised, the legitimacy of the resulting recommendations is necessarily called into question.

The Real Difference: CICP vs. VICP

The most important issue in this entire debate is the distinction between the current compensation system and the one that should be in place.

The CICP does not function as a true compensation program. It does not allow recovery for pain and suffering or attorneys’ fees. It imposes caps on medical expenses and lost wages. It requires claims to be filed within one year of vaccination, a limitation that excludes many otherwise valid claims. Most critically, it lacks an independent adjudicatory structure. The same agency that administers the program effectively decides the outcome, and there is no meaningful right to appeal to an independent court.

The VICP operates in a fundamentally different way. It provides compensation for pain and suffering, lost wages, and both past and future medical expenses. It allows for recovery of attorneys’ fees, enabling individuals to pursue claims with proper representation. It provides a three-year statute of limitations, recognizing the realities of medical diagnosis and progression. Most importantly, it is adjudicated in an independent court system with special masters and a defined appellate process.

This is the difference between a system that exists in name and one that functions in practice.

What Real Reform Would Look Like

If the goal is to improve vaccine policy, the path forward is clear. Liability protections should remain in place to ensure continued vaccine development and distribution. At the same time, vaccines covered by those protections must be paired with a compensation system that provides meaningful recovery for those who are injured.

That means moving COVID vaccines into the VICP.

This approach preserves the stability of the system while addressing its most significant failure. It aligns legal protection with legal responsibility and ensures that individuals are not left without recourse.

Conclusion

The current debate over vaccine policy reform is not about safety in the way it is being presented. It is about structure, control, and the allocation of legal rights within the system. Efforts to redefine recommendation standards, restructure advisory bodies, and alter liability frameworks risk destabilizing a system that, while imperfect, has a clear and functional core.

The focus should not be on dismantling that system. It should be on fixing the part that does not work.

For those who represent injured individuals, the issue is not theoretical. It is practical and immediate. A system that fails to compensate those it was designed to protect is not a system in need of refinement. It is a system in need of correction.

Subscribe now

To understand why this matters, it helps to understand how vaccine policy is supposed to work in the United States. In a stable system, federal recommendations guide everything—from what pediatricians advise, to what insurance must cover, to what vaccines are readily available to families. (For a full breakdown, see How Vaccine Injury Compensation Works in the United States here) When that system functions properly, parents are not forced to navigate complex medical decisions alone. They rely on a consistent framework built on scientific review and uniform guidance.

That framework is now under pressure.

Recent political reporting suggests that vaccine policy has become a strategically avoided issue at the federal level. The issue is not that vaccines have been formally abandoned, but that they have become politically inconvenient. Messaging has grown quieter, priorities have shifted, and the visibility of routine vaccination guidance has diminished. That kind of shift does not produce immediate, dramatic effects—but it does change how information is received and acted upon.

At the same time, early signs of erosion in vaccination rates are beginning to emerge. Data summarized by the Center for Infectious Disease Research and Policy shows that while core childhood vaccines such as measles, polio, and varicella remain relatively high, others are declining. Influenza vaccination rates in young children have dropped meaningfully. More concerning, the hepatitis B birth dose—administered within hours of birth and widely viewed as a critical first layer of protection—has also declined. These are not isolated fluctuations. They are early signals that the system supporting routine vaccination is becoming less stable.

The consequences of even modest declines are already visible. Measles outbreaks have reappeared in areas where vaccination rates have dipped below herd immunity thresholds. The overwhelming majority of cases occur in unvaccinated individuals or those with unknown vaccination status. This is not a theoretical concern—it is a direct reflection of how sensitive the system is to small changes in uptake.

What Is Actually Driving the Decline in Vaccination Rates?

The recent dip in certain childhood vaccination rates is not the result of a single cause. It reflects a deeper shift: the erosion of clear, consistent, science-based decision-making in the public sphere. When vaccine guidance becomes less visible, less consistent, or appears to be influenced by political considerations, the downstream effect is predictable—parents hesitate.

For years, routine childhood vaccination operated within a stable and predictable structure. Federal recommendations were clear. Insurance coverage followed those recommendations. Pediatricians delivered consistent advice. That system did not require parents to independently evaluate complex scientific questions. It relied on institutional trust and uniform messaging.

That clarity is beginning to break down.

When public health messaging becomes fragmented or muted, parents are left to interpret risk and benefit on their own. In that environment, decision-making becomes less about established scientific consensus and more about uncertainty. Even parents who generally support vaccination may delay or decline certain vaccines because they no longer feel confident in the consistency of the information they are receiving.

This dynamic is especially pronounced with vaccines that require immediate or proactive decisions. The hepatitis B birth dose is a prime example. It must often be decided upon within hours of birth, before a relationship with a pediatrician is fully established. Without strong, consistent reinforcement of its importance, hesitation at that moment becomes more likely. Influenza vaccination presents a similar challenge, as it depends heavily on annual messaging and proactive participation.

This is not a collapse in confidence in vaccines. It is a breakdown in the clarity of the system that supports vaccine decision-making.

The State Response: New York Steps In

As federal messaging becomes less consistent, states are beginning to respond. Proposed legislation in New York is designed to preserve access to routine childhood vaccines regardless of changes at the federal level. The goal is not to mandate vaccination or resolve broader policy debates. It is to maintain the infrastructure that allows families to access vaccines easily and affordably.

This includes ensuring continued insurance coverage, maintaining distribution through pediatricians and pharmacies, and preventing cost barriers that could arise if federal recommendations are narrowed or removed. These are structural protections—designed to stabilize access even if the broader policy environment becomes uncertain.

This matters because vaccine uptake is not driven solely by belief. It is also driven by access. When vaccines are consistently covered, readily available, and integrated into routine care, uptake remains high. When those supports weaken, even populations that generally support vaccination can experience declines.

New York’s approach is an attempt to preserve that stability. By maintaining a consistent access framework, the state is trying to ensure that parents can continue to make decisions based on clear medical guidance rather than shifting policy signals.

For children, the implications are significant. Without these protections, vaccination could increasingly become dependent on geography—varying by state policy, insurance coverage, and local healthcare infrastructure. With them, the goal is to maintain a more uniform standard of access despite national uncertainty.

A Fragmented Future

Taken together, these developments point toward a broader transformation. Vaccine policy in the United States is becoming more decentralized. Federal messaging is less consistent. States are beginning to assert greater control over access and coverage. And families are navigating a more complex and less uniform decision-making environment.

This is not a system in collapse. It is a system in transition.

The concern is not that vaccines will disappear from American healthcare. It is that the consistency that once defined vaccine policy—clear recommendations, uniform coverage, and predictable access—may give way to a patchwork system. In that system, vaccination rates may remain high overall, but vary more significantly across states and communities.

For those trying to understand how this system works—and what protections exist when injuries occur—resources like What Is the Vaccine Injury Compensation Program (VICP)? provide important context. The legal framework surrounding vaccines has always been closely tied to how vaccines are recommended, administered, and accessed.

That is what makes this moment significant. The shift is not loud. It is not immediate. But it is measurable. And over time, it may determine whether access to vaccines—and the clarity surrounding their use—remains consistent across the country, or becomes something that depends on where you live.

Subscribe now

The Reality: Most of the Work Happens Before Filing

One of the biggest misconceptions about the VICP is that the case begins when the Petition is filed. In reality, a substantial portion of the legal and evidentiary work must be completed before the case ever reaches the Court. This includes drafting affidavits, analyzing the claim, and gathering all relevant medical records.

The Court expects counsel to submit a complete and well-developed case at filing, not a preliminary or incomplete one. This means obtaining records from every provider—primary care physicians, specialists, physical therapists, and even unrelated treatment sources—to give a full picture of the petitioner’s medical history. Without this foundation, the case is vulnerable to delays and early challenges.

Why Complete Medical Records Matter

The VICP is not limited to reviewing the injury itself. Instead, the Court evaluates the petitioner’s entire medical history to determine whether another condition could explain the symptoms. This is why even seemingly unrelated medical records must be collected and submitted.

If records are missing, the Court will require additional filings before the case can proceed. This can delay the case by months and weaken early positioning. Put simply, incomplete records signal an incomplete case—and that can affect both timing and outcome.

The Six-Month Rule Is Just the Starting Point

Under the VICP, a claim cannot be filed unless the injury has lasted at least six months and that duration is documented in the medical records. This requirement alone prevents many cases from being filed immediately after vaccination. It ensures that the injury is not temporary or self-resolving.

But the six-month rule is only the minimum threshold. From a strategic standpoint, the more important question is whether the injury has fully developed and whether the course of treatment is sufficiently clear to evaluate long-term impact.

Filing Too Early Can Reduce Case Value

Many petitioners understandably want to move quickly, but filing a case too early can be detrimental. At the early stages of an injury, treatment is often ongoing, and the full scope of the condition may not yet be known. Diagnostic testing may still be underway, and decisions about injections, therapy, or surgery may not yet have been made.

Because the VICP evaluates damages based on the severity, duration, and treatment of the injury, an underdeveloped record can make a serious injury appear less significant than it ultimately is. This can lead to lower evaluations, weaker settlement positions, and unnecessary disputes over the nature of the injury.

There Is No Immediate “Full Value” Settlement

Another common misunderstanding is that once a case is filed, it will quickly settle for its full value. That is simply not how the system operates. After filing, the Court conducts its own review, and the case is then evaluated by the Department of Health and Human Services and the U.S. Department of Justice.

Even in strong cases, this process takes time. Settlement discussions may take months or longer, and initial offers often do not reflect the full value of the claim. It typically requires continued development of the record, negotiation, and sometimes litigation to reach a fair resolution.

Timing and Leverage in the Real World

As cases progress, timing becomes an important factor in how they are resolved. Longer timelines can create pressure on petitioners, particularly when financial or medical burdens are ongoing. This dynamic can influence how settlement discussions unfold.

In practice, extended timelines may result in lower initial offers or more aggressive contesting of claims, even where the case is viable. Petitioners may feel pressure to resolve the case simply to move forward. That is why it is critical to evaluate offers against the full record and the likely value of the case—not just the length of time it has been pending.

The Current Backlog Is Making Things Slower

The timeline challenges are even more pronounced right now. As of March 3, 2026, Special Master Gowen retired, and that position has not yet been filled. This reduces the number of decision-makers available to handle an already significant caseload.

At the same time, the VICP continues to receive over 1,000 new filings per year, with 1,041 petitions filed in 2023, 1,185 in 2024, and 1,161 in 2025. With fewer Special Masters and sustained filing volume, delays in processing and decision-making are inevitable in the short term.

The Takeaway: Strong Cases Are Built, Not Rushed

The VICP is not a system where cases are filed and quickly resolved at full value. Instead, it is a deliberate process that requires careful preparation, strategic timing, and a complete evidentiary record. Filing too early or without proper development can have long-term consequences for the outcome of the case.

The strongest claims are those that are fully evaluated, thoroughly documented, and filed at the right time. While the process may take longer than expected, a well-prepared case is far more likely to achieve a fair and accurate result.

Many are asking what this means for vaccine safety, CDC recommendations, and COVID vaccine policy. The answer is straightforward: the system responsible for evaluating vaccines, issuing national guidance, and supporting vaccine injury compensation is no longer functioning as intended. And while attention remains focused on “vaccine manufacturer immunity,” the real issue is far more immediate—there is no stable framework to make or implement vaccine policy decisions.

If you missed the federal court decision that triggered this breakdown, it is explained here: Federal Judge Blocks Vaccine Schedule Changes

Subscribe now

The CDC’s Vaccine Advisory System Is No Longer Stable

The CDC’s Advisory Committee on Immunization Practices (ACIP) is the central authority for vaccine recommendations in the United States. It determines:

• which vaccines are recommended

• who should receive them

• whether insurance must cover them

That system is now destabilized.

A federal court blocked key actions taken by RFK Jr. and HHS, finding that the restructuring of the advisory process likely violated federal law and undermined the integrity of the system. As a result, ACIP’s ability to issue guidance on COVID-19 vaccines, influenza vaccines, and RSV vaccines is now uncertain.

At the same time, internal conflict has escalated, and Robert Malone stepped down from involvement in the advisory process, further highlighting instability.

The result is clear: the core mechanism that governs vaccine policy in the United States is no longer functioning predictably.

This Was a Policy Breakdown—Not a Scientific Shift

This disruption did not result from new data or evolving science. It was the product of deliberate policy decisions that altered the structure of vaccine oversight.

Many of these concerns were already developing, as discussed here.

Those actions included:

• removal of experienced vaccine advisors

• replacement with controversial or unconventional appointees

• rapid attempts to change vaccine recommendations

• and eventual court intervention blocking those changes

This is not how scientific reevaluation occurs. It is how institutional instability develops.

Vaccine Policy Is Now Being Influenced by Political Pressure

Scientific review requires transparency, data, and consistency. What is occurring instead is a pause—and in some cases a reversal—of vaccine policy activity that aligns with political considerations tied to voter sentiment.

Reporting indicates that senior officials have grown concerned that RFK Jr.’s vaccine positions are politically unfavorable ahead of the midterm elections, leading to internal pressure to slow or adjust policy changes. This reflects a shift away from science-driven decision-making and toward polling-driven strategy.

This distinction is critical.

Public health policy must be guided by scientific evaluation, even when conclusions evolve. When policy decisions are influenced by electoral considerations, the credibility and stability of the system are weakened.

Why This Disruption Has Immediate Consequences

The ACIP does not operate in isolation. Its decisions directly impact:

• national vaccine recommendations

• insurance coverage requirements

• vaccine availability and distribution

• clinical guidance for providers

Without a functioning advisory system, those decisions are delayed or unclear.

The consequences are already visible:

• uncertainty in vaccine recommendations

• delays in policy implementation

• inconsistent guidance across providers

• erosion of trust in vaccine oversight

This is not a theoretical concern. It is a present operational issue.

The Focus on “Manufacturer Immunity” Misses the Real Problem

At the same time this instability is unfolding, there is increasing attention on eliminating vaccine manufacturer immunity and dismantling the National Childhood Vaccine Injury Act.

That focus is misplaced.

The central issue is not whether manufacturers can be sued. The central issue is whether there is a functioning system to evaluate vaccines and compensate individuals who are injured.

The Vaccine Injury Compensation Program exists to provide that structure. It allows claims to be evaluated under a consistent standard and provides compensation without requiring proof of fault.

Removing that system would not improve accountability. It would eliminate the only reliable mechanism for compensation.

The COVID Vaccine Compensation Gap Remains Unresolved

This situation also highlights a critical failure: the lack of a meaningful compensation pathway for COVID-19 vaccine injuries.

The Secretary of Health and Human Services has the authority to:

• move COVID-19 vaccines into the Vaccine Injury Compensation Program

• expand eligibility for claims

• and provide access to the vaccine injury compensation fund

That authority has not been exercised.

As a result, individuals injured by COVID vaccines since 2020 remain outside the VICP system and lack meaningful access to compensation. This gap exists not because of manufacturer immunity, but because HHS has not taken action.

The System Is Fragmenting in Real Time

What is occurring now is not routine policy disagreement. It is fragmentation of the vaccine policy framework.

• the advisory system is unstable

• courts are intervening in policy decisions

• leadership actions are under scrutiny

• key participants are stepping away

This creates a system that is increasingly difficult to rely on for consistent, science-based decision-making.

The Bottom Line

The current CDC vaccine controversy is not about whether science should evolve. It should. It is about whether the process used to evaluate and implement that science remains intact.

Right now, that process is being influenced by political considerations, and vocal minorities that the current administration and Secretary Kennedy are loyal too, rather than a stable, evidence-driven science.

At the same time, proposals to eliminate vaccine manufacturer immunity would dismantle the compensation system that exists for vaccine injuries.

If these trends continue, the result will not be greater accountability or improved outcomes. It will be increased instability, reduced access to compensation, and a weakened public health system.

The answer is no. Repealing the Vaccine Injury Act would not help the vaccine injured—it would ensure they never receive meaningful compensation or even a full assessment of their injuries. The Vaccine Injury Compensation Program (VICP) exists because vaccine lawsuits fail under legal standards like Daubert. Without the VICP and the vaccine injury compensation fund, most vaccine injury claims would be dismissed before reaching a jury, leaving injured individuals without any viable path to recovery.

What the VSRF Actually Is—and What It Is Not

The Vaccine Safety Research Foundation (VSRF) presents itself as an accountability-driven organization focused on vaccine safety. In reality, it does not function as an advocacy group for the vaccine injured. It does not lobby Congress, propose legislation, or work within the Vaccine Injury Compensation Program to improve outcomes.

Instead, VSRF operates as a messaging platform targeting vaccine skeptics and anti-vaccine audiences. Its content reinforces distrust, amplifies perceived injustice, and drives engagement through emotionally charged narratives about vaccine manufacturer immunity and lack of liability. It does not propose workable reforms to the vaccine injury compensation fund or the National Childhood Vaccine Injury Act.

Rather than advancing solutions, it generates outrage and converts that outrage into petitions, audience growth, and financial contributions. That is not advocacy for the vaccine injured—it is narrative-driven fundraising.

The Truth About Vaccine Manufacturer Immunity

The claim that vaccine manufacturers are not accountable is one of the most persistent myths in the vaccine debate. In reality, manufacturers fund the Vaccine Injury Compensation Program through an excise tax on every dose administered.

This funding mechanism has created a multi-billion-dollar vaccine injury compensation fund that pays claims to individuals who prove that a vaccine caused their injury. The system ensures that compensation is available without requiring proof of fault, defect, or negligence.

In other words, vaccine manufacturer immunity does not eliminate accountability—it changes how accountability is delivered. Instead of unpredictable jury verdicts, compensation is provided through a structured system that guarantees payment when causation is established.

The real question is not whether manufacturers are accountable. It is whether civil litigation would do a better job.

Why Vaccine Lawsuits Fail Under Daubert

Civil litigation is not an alternative path to compensation. It is, in most cases, a dead end.

Under Daubert v. Merrell Dow Pharmaceuticals, Inc., courts require expert testimony to meet strict standards of scientific reliability before it can be presented to a jury. This is known as the Daubert standard, and it is the single biggest barrier to any vaccine lawsuit.

To survive a Daubert challenge, a plaintiff must show that the vaccine increased the risk of harm for the specific injury alleged. The only reliable way to prove that is through epidemiological evidence demonstrating a statistically significant association between the vaccine and injury and vaccines are clinically tested, followed for adverse events and have a positive effect on the human body usually. That’s not to say there are not risks associated with them or that injuries cannot happen from their administration - they can absolutely. But, they are rare and rare adverse events almost never prevail in the civil courts.

That evidence does not exist for most vaccine injuries.

Vaccine injuries are rare. The population sizes required to produce statistically meaningful epidemiology studies are often too small to generate reliable data. Without epidemiological support, expert opinions are routinely excluded under Daubert.

Once the expert is excluded, the case is dismissed. There is no jury. There is no trial. There is no compensation.

This is why the idea of suing vaccine manufacturers for damages is largely theoretical. A vaccine lawsuit cannot succeed if it cannot survive the admissibility stage. The presence of “deep pockets” does not matter if the case never reaches a jury.

Why the Vaccine Injury Compensation Program Exists

The National Childhood Vaccine Injury Act was enacted because civil litigation failed to compensate vaccine injuries. Congress recognized that traditional tort law imposed evidentiary burdens that could not be met in cases involving rare adverse events.

The Vaccine Injury Compensation Program solves that problem by lowering the burden of proof. Petitioners do not need to show defect, negligence, or increased risk. They only need to establish causation.

Equally important, the VICP does not require epidemiological studies to prove vaccine injury claims. Instead, it allows claims to proceed based on medical records, treating physician opinions, and scientifically plausible mechanisms.

This is why the VICP remains the only viable system for vaccine injury compensation. It is designed to succeed where civil litigation fails.

The Illusion of Vaccine Lawsuits and Jury Trials

Advocates for repealing vaccine manufacturer immunity often argue that individuals deserve their day in court. But a jury trial is only meaningful if a case can reach a jury.

Under the Daubert standard, most vaccine lawsuits cannot the high expert evidence threshold.

The right being invoked is not a practical one—it is theoretical. The Vaccine Injury Compensation Program replaces that illusion with an actual path to recovery. It allows claims to be heard, evaluated, and compensated in a way that civil litigation cannot. There is a specialized vaccine court, attorneys that represent the vaccine injured, and independent adjudicated decision from the court with the right to an appeal of any adverse decisions.

What Happens If the Vaccine Act Is Repealed

If the National Childhood Vaccine Injury Act were repealed, the consequences would be immediate. The vaccine injury compensation fund would disappear, and injured individuals would be forced into a civil litigation system that they cannot successfully navigate.

Read more about the analysis between civil court versus the VICP.

Cases would be dismissed at the expert admissibility stage. Years of litigation would produce no recovery.

This is not speculation. The Gardasil litigation and shingles vaccine litigation provide real-world examples of what happens when vaccine injury claims proceed through civil courts. Despite years of litigation and significant expense, those cases have struggled to produce meaningful compensation for plaintiffs.

That is what a vaccine lawsuit looks like in practice.

Repealing vaccine manufacturer immunity would not expand access to compensation. It would eliminate it.

Accountability Already Exists—Through the VICP

The current system holds manufacturers accountable through mandatory financial contributions and ensures that compensation is paid when causation is established. The vaccine injury compensation fund exists for one purpose: to compensate the vaccine injured.

Replacing that system with civil litigation would not improve accountability. It would remove the only system that consistently provides compensation.

Where Real Reform Should Happen

If the goal is to improve outcomes for vaccine injury claims, the focus should be on strengthening the Vaccine Injury Compensation Program. The Secretary of Health and Human Services has the authority to expand the Vaccine Injury Table, add injuries, and clarify compensation standards.

That authority also extends to COVID-19 vaccines. HHS has the power to move COVID-19 vaccines into the VICP and allow individuals injured since 2020 to access the vaccine injury compensation fund. Yet that has not happened. RFK Jr., despite having the authority to act, has failed to take meaningful steps in that direction. As a result, individuals with COVID vaccine injury claims remain without a viable path to compensation—not because of vaccine manufacturer immunity, but because HHS has failed to act.

Do you have a COVID-19 vaccine injury and want to push for compensation?

The Bottom Line

The push to eliminate vaccine manufacturer immunity is not a path to accountability—it is a path to fewer successful claims, more dismissed cases, and no compensation for the vaccine injured.

The Vaccine Injury Compensation Program is not perfect, but it is the only system that works. It allows vaccine injury claims to succeed in cases where civil litigation would fail under Daubert.

Abolishing that system would not empower the injured. It would leave them without recourse.

There is no fixed answer. Vaccine cases are highly fact-specific, and compensation depends on several categories of damages.

Every case includes compensation for pain and suffering. Some cases also include lost wages, medical expenses, and in more serious situations, future medical care.

Pain and suffering receives the most attention in case law not because it is the most important category, but because it is the only category present in every case. As a result, it provides the most consistent framework for evaluating value across different types of GBS claims. Vaccine injury cases are bifurcated, meaning that causation (did the vaccine cause GBS) must be determined before damages can be awarded.

To assess whether a vaccine caused GBS, click here.

Subscribe now

How Pain and Suffering Is Evaluated in GBS Cases

Pain and suffering is capped at $250,000 under the Vaccine Act, but within that cap there is no formula, only guidance from the Vaccine Court decisions. The Court evaluates severity, duration, and long-term impact, and then compares those facts to prior cases.

That comparison process is critical. GBS exists on a spectrum—from relatively mild cases with strong recovery to catastrophic cases involving respiratory failure, long-term disability, or death. Understanding where a case falls on that spectrum is what determines value.

The Floor: Strong Recovery, Limited Residual Symptoms

At the lower end of the range are cases where GBS is serious but ultimately resolves with relatively limited long-term impact.

These cases still involve real suffering. Individuals often experience rapid onset of neurological symptoms, including weakness, numbness, and difficulty walking. There may be a period of significant functional limitation, and in many instances, individuals seek emergency care or short-term hospitalization. However, these cases are defined by what happens after the acute phase.

In floor-level cases, recovery is steady and meaningful. The individual regains independence, returns to work, and resumes most daily activities. Residual symptoms may remain—such as intermittent numbness, tingling, or fatigue—but they are manageable and do not fundamentally alter the person’s lifestyle.

The Court has recognized that even these cases warrant substantial compensation because GBS is inherently serious and frightening. But where there is no prolonged hospitalization, no respiratory involvement, and no lasting functional impairment, pain and suffering awards tend to fall in the $130,000 to $150,000 range.

What distinguishes these cases is not the absence of suffering—it is the absence of long-term disruption.

Mid to Upper Range: Severe Acute Course With Lasting Effects

Most GBS cases fall into a middle-to-upper range where the illness is significantly more severe and the recovery is incomplete.

These cases typically involve a clear and dramatic progression. Symptoms begin with tingling or weakness and rapidly escalate to the point where the individual cannot walk, cannot perform basic activities, and requires hospitalization. Treatment often includes IVIG or plasmapheresis, and many individuals require extended inpatient care followed by weeks or months of rehabilitation.

What drives value in these cases is not just the acute illness, but the length and intensity of the recovery. Individuals are often discharged from the hospital but are far from recovered. They may require assistive devices such as walkers or braces. They may struggle with coordination, balance, and endurance. Even after formal therapy ends, symptoms frequently persist.

The case reflected in illustrates this category well. There, the individual experienced rapid onset of weakness and neurological symptoms within weeks of vaccination, followed by hospitalization, IVIG treatment, and an extended inpatient rehabilitation course. He was unable to walk, required significant assistance for daily activities, and underwent multiple transfers between facilities before gradually improving. Even after returning home, he continued to experience neuropathic pain, weakness, and coordination issues that affected his daily life and ability to work.

Similarly, in another case, the individual’s condition progressed to respiratory complications, prolonged hospitalization, and an extended recovery marked by persistent weakness and functional limitations. That case resulted in a pain and suffering award of $200,000, reflecting both the severity of the acute illness and the lasting impact of the condition .

These cases tend to fall in the $175,000 to $200,000 range, and what separates them from lower-end cases is clear: prolonged disability, aggressive treatment, and persistent symptoms that meaningfully affect daily life.

Upper Range With Future Care: When GBS Does Not Fully Resolve

At the highest end of non-death cases are those where GBS results in lasting, life-altering impairment.

In these cases, the individual does not return to a functional baseline. Instead, they may continue to experience significant weakness, impaired mobility, chronic fatigue, and neurological deficits that affect nearly every aspect of daily living. Walking may remain difficult or unsafe. Employment may no longer be possible. Independence may be limited.

What distinguishes these cases is the need for ongoing care.

Unlike moderate cases where treatment eventually ends, these cases often require long-term medical management. This is where future medical care becomes a critical component of compensation. A life care planner or nursing expert is typically retained to evaluate the individual’s condition, consult with treating providers, and develop a detailed plan outlining future needs. That plan may include ongoing therapy, medications, assistive devices, home modifications, and in some cases, in-home care.

The Vaccine Program is designed to cover these future costs, often through structured or annual payments.

In these cases, pain and suffering often approaches the $250,000 cap because of the severity and permanence of the condition. But the overall value of the case increases significantly because of the addition of future care costs.

The key distinction is that these cases are no longer defined by recovery—they are defined by permanence.

Death Cases: The Most Severe Outcomes

At the far end of the spectrum are cases where GBS results in death.

These cases often involve a rapid and devastating clinical course. Individuals may present with progressive weakness that quickly escalates to respiratory failure. Many require intubation, mechanical ventilation, and intensive care. Complications such as infections, autonomic instability, or cardiac events can follow.

The suffering in these cases is profound. Individuals often endure severe physical pain, total loss of independence, and the psychological distress associated with a rapidly deteriorating condition.

The case reflected in demonstrates this trajectory. There, the individual experienced rapid onset of weakness that progressed to quadriplegia and respiratory failure. She required intubation, tracheostomy, and feeding tube placement, along with aggressive inpatient care and rehabilitation. Despite these interventions, her condition continued to decline, leading to prolonged institutional care and ultimately death following complications related to her GBS.

In death cases, compensation includes both the individual’s pain and suffering prior to death and a statutory $250,000 death benefit. In one such case, the Court awarded $200,000 for pain and suffering along with the $250,000 death benefit, reflecting both the severity of the illness and the suffering endured before death .

These cases represent the most severe outcomes, where the illness not only disrupts life but ultimately ends it.

What Actually Increases the Value of a GBS Case

Across all categories, the same core factors drive value: the severity of the illness, the length of recovery, and the extent of lasting impact.

Pain and suffering provides the baseline because it exists in every case. From there, value increases when the evidence shows prolonged hospitalization, aggressive treatment, lasting symptoms, inability to return to baseline function, and, in the most serious cases, the need for ongoing care or the occurrence of death.

Lost wages and medical expenses can further increase value, but they are secondary to the overall clinical picture.

Final Thoughts: Understanding Where a Case Falls on the Spectrum

GBS cases are best understood as existing on a spectrum.

At one end are cases with strong recovery and limited long-term impact. At the other end are cases involving permanent disability or death. Most cases fall somewhere in between, where the illness is severe and recovery is incomplete.

The value of a case depends on where it falls along that spectrum.

Pain and suffering serves as the foundation because it reflects what every individual endures. Additional damages build on that foundation depending on how significantly the condition affects the person’s life.

Understanding that framework is the key to understanding how GBS cases are evaluated—and what they are worth.

Key Resources to Understand the Vaccine Court, How a Case Progresses, and GBS cases, see below:

Can Vaccines Cause GBS?

Understanding Vaccine Court

What is Vaccine Court?

Vaccine Program Explained

VICP Step by Step Guide

The broader medical consensus remains clear: vaccines are overwhelmingly safe and effective. At the same time, no medical intervention is entirely risk-free. In rare circumstances, immune stimulation—whether from infection or vaccination—can trigger an abnormal immune response that affects the nerves (Schonberger et al., 1979; Vellozzi et al., 2014).

From a legal standpoint, the question is not whether vaccines always cause GBS—they do not. The question is whether, in a specific case, it is more likely than not that the vaccine triggered the condition based on the medical evidence and timing.

Subscribe now

What Is Guillain-Barré Syndrome (GBS)?

Guillain-Barré Syndrome is a rare neurological disorder in which the body’s immune system mistakenly attacks the peripheral nervous system—the network of nerves that connects the brain and spinal cord to the muscles, skin, and internal organs (National Institute of Neurological Disorders and Stroke, 2023).

According to the NIH, the condition typically occurs when the immune system, which is designed to fight infections, becomes misdirected and begins damaging the protective covering of the nerves (myelin) or, in some cases, the nerves themselves. This damage disrupts the transmission of signals between the brain and the rest of the body, which is what leads to the hallmark symptoms of weakness and sensory changes.

GBS most commonly begins with tingling or “pins and needles” sensations in the feet or hands, followed by progressive muscle weakness that usually starts in the legs and moves upward. As the condition advances, individuals may experience difficulty walking, climbing stairs, or even standing. In more severe cases, the weakness can progress to near-total paralysis and may affect the muscles responsible for breathing, requiring ventilatory support (National Institute of Neurological Disorders and Stroke, 2023).

The progression of GBS is typically rapid, reaching its most severe point within two to four weeks after symptom onset. After this phase, patients enter a plateau period followed by gradual recovery. While many individuals recover fully or substantially over time, recovery can take months or even years, and some patients are left with lasting symptoms such as weakness, fatigue, numbness, or pain.

GBS is often preceded by an immune-triggering event. In many cases, that trigger is a bacterial or viral infection. However, the same immune activation process can, in rare instances, follow vaccination. The underlying biological concept is that the immune system, once activated, may mistakenly target components of the peripheral nerves due to similarities between foreign antigens and nerve tissue—a process commonly described in the medical literature as molecular mimicry (Willison et al., 2016).

What Vaccines Are Linked to Guillain-Barré Syndrome?

Certain vaccines have been studied more closely in connection with GBS. The most commonly discussed association is with the influenza vaccine, where epidemiological studies have identified a small increased risk in certain seasons, generally estimated at approximately one to two additional cases per million vaccinations (Vellozzi et al., 2014).

Other vaccines that have been examined in the medical literature include Tdap, pneumococcal (pneumonia), HPV, COVID-19, and hepatitis A and B vaccines. More rarely, vaccines such as varicella and MMR have also been evaluated in case reports and surveillance data. While the risk remains extremely low, the underlying biological mechanism is understood to involve immune activation and, in some cases, molecular mimicry (Willison et al., 2016).

GBS After a Vaccine: Can You File a Lawsuit?

If you develop GBS after a vaccine, you generally do not file a traditional lawsuit against a pharmaceutical company or vaccine administrator. Instead, claims are brought through the National Vaccine Injury Compensation Program, commonly referred to as Vaccine Court.

This system was created to provide compensation to individuals who experience vaccine-related injuries while maintaining the stability of the national vaccine supply. It operates as a no-fault system, meaning that a petitioner does not need to prove negligence. The focus is on causation—whether the vaccine caused the injury.

Timing of GBS After Vaccination: Why It Matters

Timing is one of the most important—and most contested—issues in GBS vaccine claims. Medically, GBS typically develops within days to several weeks following a triggering event, including infections or vaccinations (Sejvar et al., 2011).

In Vaccine Court, the commonly accepted timeframe for onset is approximately 3 to 42 days after vaccination. However, both the medical literature and case experience support a broader range. Onsets occurring as early as two days and as late as eight weeks post-vaccination can still be consistent with vaccine-related GBS, particularly when supported by a coherent clinical course and medical theory.

Because of this, the precise documentation of symptom onset in the medical records is critical. Small discrepancies in timing can become central issues in litigation.

How GBS Vaccine Claims Are Proven

GBS claims are driven by medical evidence rather than traditional fault-based litigation. A successful claim must demonstrate that the vaccination occurred, that symptoms followed within a medically appropriate timeframe, and that the condition is consistent with a diagnosis of GBS supported by a reliable medical theory of causation.

These cases often rely heavily on neurology evaluations, diagnostic testing, and expert medical opinion to connect the timing and mechanism of injury.

Compensation for GBS Vaccine Claims

Compensation in GBS cases depends on the severity of the condition and its long-term impact. The Vaccine Program allows recovery for several categories of damages, including:

• Pain and suffering (capped at $250,000)

• Past and future medical expenses

• Lost wages

• Future care needs, including life care planning in severe cases

The value of a claim is not determined by the diagnosis alone, but by how the condition affects the individual’s daily life over time.

How Much Is a GBS Case Worth?

There is no single value assigned to GBS cases because the condition varies significantly in severity.

In milder cases, individuals often require immediate hospitalization and treatment—typically with IVIG or plasmapheresis—followed by a strong recovery. However, even in these cases, patients may be left with residual symptoms such as numbness, weakness, or tingling in the extremities. These lingering effects can still support meaningful compensation.

More severe cases involve a very different trajectory. Individuals may experience ongoing paralysis, difficulty with balance and walking, and persistent neurological deficits that interfere with basic activities of daily living. In the most serious cases, long-term care planning becomes necessary. These cases typically result in substantially higher compensation due to the lasting and life-altering nature of the injury.

What Evidence Strengthens a GBS Claim?

The strength of a GBS claim is closely tied to the quality and consistency of the medical evidence. The most persuasive cases typically include:

• Detailed hospitalization records documenting acute onset and progression

• Neurology consultations confirming the diagnosis

• Diagnostic testing such as EMG or nerve conduction studies

• Evidence of prolonged rehabilitation, including physical and occupational therapy

• Ongoing follow-up care documenting persistent symptoms and limitations

Equally important is continuity of care. Consistent treatment after hospital discharge helps demonstrate that the condition resulted in lasting impairment rather than a transient illness.

Why GBS Vaccine Claims Are Often Challenged

Even well-supported GBS claims are frequently contested. One of the most common areas of dispute is the diagnosis itself. When diagnostic testing such as lumbar punctures or EMG studies is inconclusive or not strongly indicative of GBS, respondents often challenge whether the condition was accurately diagnosed.

Other common challenges include identifying alternative causes, such as recent infections, and disputing the timing of symptom onset. Because GBS can develop following a variety of triggers, distinguishing vaccine-related cases from other causes requires careful medical analysis.

How Long Do GBS Vaccine Cases Take?

GBS claims are medically complex and often take several years to resolve. Most cases fall within a range of two to four years, although some may take longer depending on the need for expert reports and the extent of the medical dispute. Therefore, the vaccine litigation process for a case to move through vaccine court can vary depending on the severity of the case and whether any elements of the claim are contested by the Department of HHS.

Do You Need a Lawyer for a GBS Vaccine Claim?

While individuals are permitted to file claims on their own, GBS cases involve complex medical and legal issues that typically require experienced representation. These cases depend on detailed medical analysis, expert support, and the ability to address challenges raised by the government.

Importantly, there is no upfront cost to the petitioner. Attorneys’ fees and costs are paid by the Vaccine Program, regardless of the outcome, provided the claim was brought in good faith and had reasonable basis. Even still, petitioners and their families do not pay for any legal fees and can take advantage of the vaccine lawyer’s expertise without paying a legal retainer or worrying that a large percentage of legal fees would be deducted from the settlement.

What To Do If You or a Loved One Developed GBS After a Vaccine

If you believe you developed GBS following vaccination, the most important step is to seek immediate medical care. Early diagnosis and treatment are critical for recovery. It is equally important to document symptoms carefully and obtain complete medical records. Speaking with an experienced vaccine injury attorney can help determine whether the facts of your case support a claim.

Final Thoughts: Risk, Reality, and Accountability

Vaccines are safe, and they are rigorously tested. The overwhelming weight of scientific evidence supports the conclusion that vaccines are safe and effective in preventing serious disease. That is not a controversial statement—it is a well-established fact.

But vaccines, like any pharmaceutical product, are not risk-free. There are risks. Sometimes those risks are mild and temporary. In rare cases, they can be significant. Guillain-Barré Syndrome is a severe autoimmune condition and is one of the most commonly recognized serious autoimmune conditions associated with vaccines.

The proper way to view vaccines is through a cost-benefit analysis. The benefits—preventing infection, reducing severe disease, and protecting public health—almost always outweigh the rare risks of adverse events. Vaccines save lives and prevent far more harm than they cause.

At the same time, when those rare adverse events do occur, the individuals affected should not bear that burden alone. The legal system, through the Vaccine Injury Compensation Program, exists to recognize that balance. It allows society to benefit from widespread vaccination while ensuring that those who experience rare but serious injuries are fairly compensated.

If you or a loved one has been diagnosed with Guillain-Barré Syndrome, it is critical to seek immediate medical attention, pursue rehabilitation aggressively, and continue treatment as recommended. It is also important to evaluate recent medical history, including infections, illnesses, vaccinations, and other potential triggers. In many cases, vaccines are not initially considered when identifying the cause of GBS, but they can be a contributing factor and should be carefully evaluated as part of that analysis.

Acknowledging both sides—safety and risk—is not contradictory. It is the most accurate and responsible way to understand vaccines.

Subscribe now

What Does “Vaccine Safety” Actually Mean?

In medicine, “safe” does not mean perfect—it means a product has been rigorously tested, approved based on a favorable risk-benefit profile, and continuously monitored after approval. Vaccines undergo extensive clinical trials before they are licensed, and their safety is tracked in real time through multiple surveillance systems once they are administered to the public (https://www.fda.gov/vaccines-blood-biologics/vaccines).

This is critical because no medication—not even common over-the-counter drugs—is entirely free of risk. Vaccines are no different. What distinguishes vaccines is the depth of scientific scrutiny applied before and after approval.

Scientific Evidence on Vaccine Safety

The scientific literature on vaccine safety is extensive, consistent, and spans decades.

Large systematic reviews examining vaccines used in the United States have found that the vast majority of adverse events are minor—such as soreness at the injection site or temporary fatigue—while serious adverse events are rare (https://pubmed.ncbi.nlm.nih.gov/25086160/). These findings apply across childhood vaccines, adult immunizations, and vaccines given during pregnancy.

Research has also thoroughly examined concerns about autism and vaccines, finding no causal association between vaccines and autism spectrum disorder (https://pubmed.ncbi.nlm.nih.gov/24814559/).

More recent studies evaluating newer vaccines, including COVID-19 vaccines, confirm the same conclusion: vaccines are safe and effective, with side effects that are generally mild and self-limited (https://pubmed.ncbi.nlm.nih.gov/38282394/).

Taken together, the scientific evidence consistently supports the safety of vaccines.

Risk vs. Benefit: The Most Important Question

The most important question in vaccine safety is not whether vaccines carry risk—they do—but whether the benefits outweigh those risks.

Every vaccine decision involves comparing:

• A very small risk of an adverse event

• Versus protection against serious infectious diseases such as influenza, measles, mumps, diphtheria, pertussis, and chickenpox (https://www.who.int/health-topics/vaccines-and-immunization)

But this analysis is often incomplete.

Vaccines do not just protect against infection. They also protect against the downstream consequences of infection—including autoimmune diseases triggered by illness.

Infections are well-established triggers for autoimmune conditions such as Guillain-Barré Syndrome (GBS), type 1 diabetes, and other immune-mediated disorders. In many cases, the infection itself carries a greater risk of triggering these conditions than the vaccine.

The real comparison is not “vaccine versus nothing.” It is:

• A controlled, predictable exposure with a very low risk

versus

• An uncontrolled infection with a higher risk of severe disease and autoimmune complications

That is the true risk-benefit framework.

Genetics, Autoimmune Disease, and Why Individuals Respond Differently

One of the most important realities in medicine is that individuals are biologically unique.

Each person has a different genetic makeup, which influences how their immune system responds to infections, vaccines, and environmental triggers. At present, we cannot predict with precision who will develop an autoimmune condition or what specific trigger will cause it.

For some individuals, a viral illness like influenza—or even a common cold—may trigger an autoimmune response such as Guillain-Barré Syndrome or diabetes. For others, it will not. In rare cases, a vaccine may be associated with an adverse immune response.

This variability does not mean vaccines are unsafe. It reflects the complexity of human biology and underscores why safety monitoring and compensation systems are necessary.

COVID-19 Vaccine Safety: Testing, Emergency Use, and Real-World Data

COVID-19 vaccines provide one of the clearest examples of how vaccine safety is evaluated.

Pre-Vaccination Testing (2020 Clinical Trials)

Before public rollout, COVID-19 vaccines underwent a complete testing process in 2020. No safety steps were skipped—phases were conducted in parallel to accelerate development during a global emergency (https://www.cdc.gov/vaccines/basics/test-approve.html).

Testing included:

• Preclinical studies in laboratory and animal models

• Phase 1 trials assessing safety and dosage

• Phase 2 trials expanding safety evaluation across populations

• Phase 3 trials involving tens of thousands of participants

The Pfizer-BioNTech Phase 3 trial, published in the New England Journal of Medicine, included over 43,000 participants and demonstrated a strong safety profile with no serious safety concerns prior to authorization (https://www.nejm.org/doi/full/10.1056/NEJMoa2034577).

Independent Data Safety Monitoring Boards reviewed the data throughout the trials, and the FDA required at least two months of follow-up data—consistent with established vaccine safety standards (https://www.fda.gov/media/142749/download).

Emergency Use Authorization (EUA): Why It Was Justified

COVID-19 vaccines were authorized under Emergency Use Authorization during one of the deadliest public health crises in modern history.

At the time:

• Hospitals were overwhelmed

• Mortality rates were significant

• There were limited treatment options

The decision to authorize vaccination was based on a clear scientific conclusion: the benefits outweighed the risks.

That conclusion proved correct. COVID-19 vaccines significantly reduced severe illness, hospitalization, and death, and played a central role in ending the pandemic phase (https://www.nejm.org/doi/full/10.1056/NEJMoa2034577).

Post-Authorization Safety Monitoring

After authorization, COVID-19 vaccines were monitored using the most comprehensive safety system ever implemented, including:

• VAERS (signal detection)

• v-safe (active monitoring)

• Vaccine Safety Datalink (real-time analysis)

• FDA BEST system (large-scale data analysis)

(https://www.cdc.gov/vaccine-safety-systems/index.html)

This monitoring confirmed:

• Most side effects were mild and short-lived

• Rare adverse events (e.g., myocarditis, TTS) were identified

• Risks were studied and incorporated into updated guidance

This is exactly how vaccine safety systems are designed to function.

Government Mistakes: Where Policy Fell Short

While the science behind COVID-19 vaccines was sound, government messaging and policy were not perfect.

First, officials overstated that vaccines would prevent transmission and fully stop infection. That was incorrect. The vaccines were designed to reduce severe disease—and they did so effectively—but they did not eliminate transmission.

Second, and more importantly, the government failed to provide an adequate compensation system. COVID-19 vaccines were placed in the Countermeasures Injury Compensation Program (CICP), which was never designed to handle large-scale claims or compensate pain and suffering (https://www.hrsa.gov/cicp).

This was a foreseeable and significant policy failure. If vaccination is promoted for the public good, there must also be a fair system to compensate those who experience rare adverse events. The only solution would have been to bolster the existing infrastructure of the Vaccine Injury Compensation Program and add COVID-19 vaccines in the VICP for compensation of any injuries associated.

Do Vaccine Injuries Occur? Yes—But They Are Rare

Serious vaccine injuries do occur, but they are rare. That reality is acknowledged through programs like the Vaccine Injury Compensation Program (VICP), which exists because even safe and beneficial vaccines can cause harm in a small number of individuals.

Understanding how these injuries can occur is important, because it frames the issue accurately and avoids oversimplification.

Vaccines are designed to stimulate the immune system—to teach the body how to recognize and fight a pathogen without causing the disease itself. In the vast majority of people, this process works exactly as intended, producing a controlled immune response that leads to protection. But in rare cases, that immune activation can lead to unintended effects.

One proposed mechanism is molecular mimicry, where components of the immune response resemble proteins in the body. In rare situations, this can lead the immune system to mistakenly target its own tissues, resulting in autoimmune conditions such as Guillain-Barré Syndrome. Importantly, this same mechanism is well-documented following natural infections—and often occurs more frequently after infection than after vaccination.

Another mechanism involves bystander activation, where immune signaling becomes broader than intended, activating additional immune pathways and contributing to inflammation or tissue injury. Again, this is not unique to vaccines—it reflects general immune system behavior.

Individual susceptibility also plays a critical role. Genetic predisposition, underlying immune dysregulation, or prior exposures may influence how a person responds to immune stimulation. At present, we do not have the ability to predict with precision who will experience an adverse immune response.

Certain vaccine-related injuries are better understood as localized inflammatory responses within specific tissues. Shoulder Injury Related to Vaccine Administration (SIRVA), for example, is increasingly understood as an inflammatory condition involving the shoulder structures—such as the bursa, tendons, or joint capsule—triggered by the introduction of vaccine antigen into or near these tissues. While injection location can be a factor, the underlying pathology is inflammatory in nature, and symptoms may develop even where administration appears otherwise appropriate.

It is also important to recognize that rare adverse events are often only identified after widespread use. Even large clinical trials involving tens of thousands of participants may not detect events that occur at very low rates. That is why post-authorization surveillance systems exist—to detect, study, and quantify these outcomes in real time.

For example, post-marketing surveillance of COVID-19 vaccines identified rare cases of myocarditis and pericarditis, which were then studied and incorporated into clinical guidance (https://www.cdc.gov/vaccine-safety-systems/index.html).

The key point is this: the existence of rare adverse events does not mean vaccines are unsafe. It reflects the complexity of the immune system and the reality that no medical intervention is entirely without risk.

Recognizing these mechanisms does not undermine vaccine safety—it strengthens the conversation by making it more accurate, more transparent, and more grounded in science.

Understanding VAERS: What It Can and Cannot Tell You

VAERS is often misunderstood.

It is a signal detection system—not proof of causation. Reports can be submitted by anyone and are used to identify patterns that require further scientific investigation (https://www.cdc.gov/vaccine-safety-systems/vaers/index.html).

Using VAERS alone to claim vaccines are unsafe reflects a misunderstanding of how vaccine safety monitoring works.

The Bottom Line: Are Vaccines Safe?

Vaccines are not risk-free. No medical intervention is.

But the evidence is clear: vaccines used in the United States are overwhelmingly safe, and their benefits far outweigh their risks. They protect against serious infectious diseases, reduce the risk of complications—including autoimmune conditions—and have been validated through decades of scientific research and real-world evidence. They reduce hospitalizations and lower healthcare costs as a result.

COVID-19 vaccines reinforced this framework in real time, demonstrating how rigorous testing, continuous monitoring, and transparent risk identification can coexist with clear and substantial public health benefits.

The better question is not whether vaccines are perfect—it is whether they are safe enough to justify their use.

Based on the science, the answer is yes.

Related Reading (Internal Links)

• What Is Vaccine Court? How the U.S. Vaccine Injury Compensation Program Works
  https://www.carneyvaccinelaw.com/p/what-is-vaccine-court-how-the-us

• Vaccine Injury Compensation: What You Need to Know About Filing a Claim
  https://www.carneyvaccinelaw.com/archive

• Recent Vaccine Policy and Legal Developments
  

Vaccine Injury: Facts Over Rhetoric

Separating fact from rhetoric in vaccine injury law, including how the Vaccine Injury Compensation Program works, vaccine public health policies and why COVID vaccine injuries remain uncompensated.

By David Carney

What was the lawsuit about?

At its core, the lawsuit challenged two intertwined actions taken by HHS earlier this year: (1) the restructuring of the childhood immunization schedule to remove or scale back several routinely recommended vaccines, and (2) the wholesale overhaul of the Advisory Committee on Immunization Practices (“ACIP”), the longstanding expert body that advises the CDC on vaccine recommendations.

The policy changes were substantial. The revised schedule reduced the number of vaccines universally recommended for children and shifted several long-standing recommendations—such as those for influenza, hepatitis A, hepatitis B, and others—into more limited or discretionary categories. These changes were not made through the traditional ACIP process, but instead followed Secretary Kennedy’s decision to remove all 17 members of the committee and replace them with new appointees, several of whom had publicly expressed skepticism toward certain vaccines.

Who challenged the policy?

The lawsuit was brought by a coalition of major medical organizations, led by the American Academy of Pediatrics, along with groups such as the American College of Physicians and the Infectious Diseases Society of America.

These organizations argued that the changes violated federal law—specifically the Administrative Procedure Act and the Federal Advisory Committee Act—by bypassing established scientific processes and improperly reconstituting a federal advisory body in a way that lacked balance, transparency, and independence.

What did the court decide?

The court agreed—at least at this preliminary stage.

In a detailed opinion, the judge granted a preliminary injunction, effectively freezing the new vaccine schedule and invalidating actions taken by the reconstituted ACIP. The court found that the government’s actions were likely “arbitrary and capricious,” a key legal standard under the Administrative Procedure Act, and further concluded that the restructuring of ACIP likely violated federal requirements governing advisory committees when it moved several vaccines to “shared clinical decision making.”

This ruling does not resolve the case on the merits, but it reflects the court’s conclusion that the plaintiffs are likely to succeed—and that allowing the changes to proceed would risk immediate and irreparable harm.

Why did the judge grant the injunction?

The judge’s reasoning focused heavily on process.

Federal agencies are not prohibited from changing policy—even dramatically—but they must do so through lawful procedures and reasoned decision-making. Here, the court found that the government departed from both. The abrupt removal of established recommendations, coupled with the replacement of an expert advisory body with individuals perceived as ideologically aligned, raised serious legal concerns about whether the decision-making process was grounded in science or driven by predetermined outcomes.

In short, the court was not evaluating whether the new vaccine schedule was correct—it was evaluating whether the government followed the law in creating it. And at this stage, the answer appears to be no.

What did the court say about ACIP?

The ruling also directly addressed the role of ACIP.

The court emphasized that ACIP is not a mere formality—it is a central pillar of the federal vaccine framework. Its recommendations drive insurance coverage, inform state vaccination policies, and guide clinical practice nationwide.

By dismantling and reconstituting the committee in a manner that likely violated federal law, the court concluded that any actions taken by that body—including votes affecting vaccine recommendations—could not stand. As a result, the court stayed the authority of the newly appointed ACIP members and invalidated the committee’s recent votes.

The ruling also halted upcoming ACIP activity, effectively putting the federal vaccine recommendation process in a temporary holding pattern.

Will HHS appeal—and does the White House’s political posture matter?

The more complicated question is not whether HHS can appeal—but whether it will, and how aggressively it chooses to do so in the current political climate.

From a purely legal standpoint, an appeal is the expected move. The Department of Justice routinely defends agency action, particularly where a federal court has enjoined a major policy initiative. The issues raised here—administrative authority, the scope of the Federal Advisory Committee Act, and the degree of deference owed to agency restructuring—are all questions that appellate courts regularly review. In that sense, filing a notice of appeal would be standard institutional practice.

But this case does not exist in a vacuum.

Recent reporting suggests that the White House has become increasingly cautious about vaccine policy as a political issue, particularly in advance of the midterm elections. Vaccine-related decisions—especially those affecting the childhood immunization schedule—carry a level of public visibility and controversy that extends far beyond typical administrative law disputes. As a result, there appears to be a shift toward limiting further disruption in this space, at least in the near term.

That dynamic creates tension within the government’s response. On one hand, declining to appeal could be viewed as acquiescing to a district court ruling that significantly restricts agency authority. On the other hand, pursuing an aggressive appellate strategy risks prolonging a highly visible legal fight over vaccines at a time when political advisors may prefer to de-escalate the issue.

There is also a practical consideration. Even if HHS appeals, the standard of review for a preliminary injunction is deferential to the district court’s factual findings. That means the government would need to show not only that it is likely to succeed on the merits, but that the lower court abused its discretion—a meaningful hurdle at this stage of the case. In other words, an appeal may be filed, but success is far from guaranteed in the short term.

The most likely outcome is a middle-ground approach: HHS files a notice of appeal to preserve its legal position, but does not seek expedited relief or an emergency stay that would immediately reinstate the policy changes. That would allow the administration to maintain its institutional posture while avoiding further escalation in the public arena.

Ultimately, the decision to appeal will reflect more than just legal strategy—it will reflect how the administration balances agency authority, judicial risk, and political optics. And in a case where all three are in play, the path forward is anything but straightforward.

Where does this leave vaccine policy going forward?

For now, the prior vaccine schedule remains in place, and the traditional framework governing vaccine recommendations is preserved—at least until further litigation or appellate review.

From a legal perspective, today’s decision reinforces a fundamental principle: agencies must follow the law, even when pursuing policy change. Courts are not arbiters of scientific truth, but they are gatekeepers of process. And when that process breaks down—particularly in areas as consequential as national vaccine policy—judicial intervention is not only possible, but inevitable.

At the same time, this case underscores a broader point that is often lost in public discourse. Vaccine policy in the United States is not static. It evolves. It should evolve. But that evolution must be grounded in transparent, evidence-based processes that maintain public trust. When those processes are bypassed, the result is not just legal vulnerability—it is systemic instability.

This litigation is far from over. The appellate courts—and potentially the Supreme Court—may ultimately define the boundaries of federal authority in this space. But for now, the message from the district court is clear: process matters, expertise matters, and the rule of law still governs even the most politically charged areas of public health.

Medical Literature Review

To fully understand the scientific and legal issues surrounding vaccines, autism, and neurological injuries, readers should review research and policy statements from leading public health and medical institutions. The Omnibus Autism Proceeding relied heavily on peer-reviewed literature and expert testimony drawn from many of these same sources.

Centers for Disease Control and Prevention (CDC)

The Centers for Disease Control and Prevention (CDC) has conducted and reviewed numerous epidemiological studies evaluating whether vaccines are associated with autism. These studies examine large populations of children and track vaccination history and developmental outcomes.

Examples include CDC-supported research analyzing hundreds of thousands of children across multiple countries. These studies consistently found no epidemiological association between the MMR vaccine and autism and no evidence linking thimerosal exposure to autism rates.

The CDC continues to monitor vaccine safety through surveillance systems such as:

• Vaccine Safety Datalink (VSD)

• Vaccine Adverse Event Reporting System (VAERS)

• Clinical Immunization Safety Assessment (CISA) Project

These programs collect and analyze data to detect potential vaccine-related adverse events and guide future research.

National Institutes of Health (NIH)

The National Institutes of Health (NIH) supports extensive research into the causes of autism spectrum disorder and neurological development.

NIH-funded studies have identified several potential contributors to autism, including:

• genetic susceptibility

• prenatal developmental factors

• environmental influences

• immune system dysfunction

• early neurological injury

The NIH has also funded research into autoimmune encephalitis and neuroinflammatory conditions, which can produce developmental regression and autism-like symptoms in children. This body of research highlights how immune-mediated brain inflammation may disrupt neural development.

National Academy of Medicine (Formerly Institute of Medicine)

The National Academy of Medicine (NAM)—formerly the Institute of Medicine—conducted some of the most comprehensive reviews of vaccine safety.

Two landmark reports evaluated the relationship between vaccines and autism:

• Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism (2001)

• Immunization Safety Review: Vaccines and Autism (2004)

These reports reviewed epidemiological studies, clinical data, and biological research. Both reports concluded that the evidence favors rejection of a causal relationship between vaccines and autism.

These findings played an important role in shaping the scientific framework discussed in the Vaccine Court’s autism test cases.

Peer-Reviewed Medical Journals

Much of the scientific evidence examined in the Omnibus Autism Proceeding came from peer-reviewed journals such as:

• The Lancet

• New England Journal of Medicine

• Pediatrics

• Journal of Autism and Developmental Disorders

• BMJ

• Journal of Child Psychology and Psychiatry

These journals publish rigorous scientific studies that undergo expert review before publication.

The Vaccine Court evaluated dozens of studies from these journals, including large epidemiological analyses involving hundreds of thousands of children, molecular virology research examining measles virus persistence, and toxicology studies examining mercury metabolism.

The Importance of Ongoing Scientific Research

The Omnibus Autism Proceeding reflected the best available scientific evidence at the time those cases were litigated. However, science continues to evolve as new data and research methods become available.

Continued research is essential to understanding rare neurological conditions that may follow vaccination, including:

• autoimmune encephalitis

• immune-mediated encephalopathy

• neuroinflammatory disorders

• developmental regression following neurological injury

Encouraging rigorous scientific research—while ensuring that individuals who suffer genuine vaccine-related neurological injuries receive fair compensation—is consistent with the goals of the Vaccine Injury Compensation Program.

Scientific inquiry, not speculation, remains the most reliable path toward understanding the complex causes of autism and other neurological conditions.

Autism Litigation Science Explained

The Omnibus Autism Proceeding involved one of the most extensive reviews of scientific literature ever conducted in vaccine litigation. The record contained hundreds of scientific articles addressing epidemiology, virology, toxicology, neurology, and immunology. The following section summarizes the principal medical literature discussed in the opinions, including the content of each article, the scientific positions advanced by the authors, and how the court ultimately treated each article in evaluating the competing causation theories.

Andrew Wakefield et al.

“Ileal-Lymphoid-Nodular Hyperplasia, Non-Specific Colitis, and Pervasive Developmental Disorder in Children” (Lancet, 1998)

Premise
This paper examined twelve children who presented with gastrointestinal symptoms and developmental disorders, including autism. The authors explored whether a relationship might exist between intestinal inflammation and developmental regression. Several parents reported that behavioral symptoms appeared after MMR vaccination.

Results
The researchers observed ileal lymphoid nodular hyperplasia and colitis in the children’s intestinal biopsies. The study documented gastrointestinal abnormalities but did not include a control group, statistical analysis, or epidemiological comparison.

Conclusions of the Authors
The authors suggested that a possible association between MMR vaccination, intestinal inflammation, and developmental regression warranted further investigation. They did not claim to prove causation.

Court’s Evaluation
The OAP decisions considered the article historically important but scientifically weak because it was a small uncontrolled case series incapable of establishing causation.

V. Uhlmann et al.

“Potential Viral Pathogenic Mechanism for New Variant Inflammatory Bowel Disease” (2002)

Premise
This molecular biology study attempted to determine whether measles virus RNA could be detected in intestinal tissue from children with developmental disorders and gastrointestinal disease.

Results
Using PCR testing, the researchers reported finding measles virus RNA in a high proportion of intestinal biopsy samples from affected children and in relatively few controls.

Conclusions of the Authors
The authors concluded that the results supported the possibility of a persistent measles infection contributing to inflammatory bowel disease in children with developmental disorders.

Court’s Evaluation
The OAP decisions treated this article as the central scientific support for the measles-persistence theory but ultimately rejected it due to methodological problems, lack of sequencing confirmation, and inability to replicate the findings.

Yasmin D’Souza, Eric Fombonne & Brian Ward

“No Evidence of Persisting Measles Virus in Peripheral Blood Mononuclear Cells From Children With Autism Spectrum Disorder” (2006)

Premise
This study tested whether measles virus RNA could be detected in blood cells of children with autism using PCR techniques.

Results
Researchers found no evidence of measles virus persistence in the blood samples of autistic children. The study also demonstrated that earlier PCR primers used in other studies could generate false positive signals.

Conclusions of the Authors
The authors concluded that their results did not support the hypothesis that persistent measles virus infection contributes to autism.

Court’s Evaluation
The OAP decisions treated this article as strong contrary evidence and as a methodological explanation for why earlier measles-detection studies may have produced false positives.

Y. D’Souza et al.

“No Evidence of Persisting Measles Virus in the Intestinal Tissues of Patients with Inflammatory Bowel Disease” (2007)

Premise
This follow-up study examined intestinal biopsy samples to determine whether measles virus RNA could be detected in bowel tissue.

Results
Using improved PCR techniques and sequencing confirmation, researchers found no evidence of persistent measles virus in intestinal tissues.

Conclusions of the Authors
The authors concluded that there was no molecular evidence supporting persistent measles virus infection in intestinal tissue.

Court’s Evaluation
Because the study examined the same tissue type used in earlier positive reports, the court considered it strong evidence undermining the measles persistence hypothesis.

Brent Taylor et al.

“Autism and Measles, Mumps, and Rubella Vaccine: No Epidemiological Evidence for a Causal Association” (1999)

Premise
This epidemiological study examined whether autism diagnoses increased after the introduction of the MMR vaccine in the United Kingdom.

Results
Researchers analyzed autism diagnoses and vaccination histories and found no temporal association between MMR vaccination and autism onset.

Conclusions of the Authors
The study concluded that epidemiological data did not support a causal relationship between the MMR vaccine and autism.

Court’s Evaluation
The court relied heavily on this study as early epidemiological evidence refuting the MMR-autism hypothesis.

Kreesten Madsen et al.

“A Population-Based Study of Measles, Mumps, and Rubella Vaccination and Autism” (New England Journal of Medicine, 2002)

Premise
This large Danish cohort study examined whether children who received MMR vaccination had a higher incidence of autism than unvaccinated children.

Results
The study followed more than 500,000 children and found no increased risk of autism among vaccinated children.

Conclusions of the Authors
The researchers concluded that MMR vaccination does not increase the risk of autism.

Court’s Evaluation
The OAP decisions treated this study as highly persuasive epidemiological evidence because of its large population size and rigorous methodology.

Liam Smeeth et al.

“MMR Vaccination and Pervasive Developmental Disorders: A Case-Control Study” (2004)

Premise
This case-control study compared vaccination histories of children with autism spectrum disorders and children without autism.

Results
The study found no increased odds of autism among children who had received the MMR vaccine.

Conclusions of the Authors
The authors concluded that MMR vaccination was not associated with pervasive developmental disorders.

Court’s Evaluation
The court treated this study as further epidemiological confirmation that MMR vaccination does not cause autism.

H. Honda et al.

“No Effect of MMR Withdrawal on the Incidence of Autism: A Total Population Study” (2005)

Premise
This ecological study examined autism incidence in Japan after the country discontinued use of the MMR vaccine.

Results
Autism diagnoses continued to increase even after MMR vaccination was discontinued.

Conclusions of the Authors
The authors concluded that withdrawal of MMR had no effect on autism rates.

Court’s Evaluation
The court considered this study powerful “natural experiment” evidence contradicting the claim that MMR causes autism.

Samuel Goth et al.

“Uncoupling of ATP-Mediated Calcium Signaling and Dysregulated Interleukin-6 Secretion in Dendritic Cells by Nanomolar Thimerosal”

Premise
This laboratory study examined how thimerosal exposure affects immune signaling in dendritic cells.

Results
The researchers observed changes in calcium signaling and cytokine secretion in cultured cells exposed to thimerosal.

Conclusions of the Authors
The study suggested that thimerosal could influence immune signaling pathways.

Court’s Evaluation
The court found the article limited because it involved in vitro cell experiments and did not demonstrate real-world neurological injury in humans.

Anshu Agrawal et al.

“Thimerosal Induces TH2 Responses via Influencing Cytokine Secretion by Human Dendritic Cells”

Premise
This study investigated whether thimerosal exposure alters immune system signaling in human dendritic cells.

Results
Researchers observed cytokine changes indicating a TH2-type immune response when cells were exposed to thimerosal.

Conclusions of the Authors
The authors concluded that thimerosal could influence cytokine signaling in immune cells.

Court’s Evaluation
The OAP decisions treated the study as insufficient to demonstrate vaccine-related immune injury because it involved laboratory conditions rather than real-world exposures.

A.S. Holmes et al.

“Reduced Levels of Mercury in First Baby Haircuts of Autistic Children”

Premise
This observational study tested whether mercury levels in hair samples differed between autistic children and controls.

Results
The authors reported lower mercury levels in hair samples from autistic children.

Conclusions of the Authors
They hypothesized that autistic children might have impaired mercury excretion.

Court’s Evaluation
The court found the study unreliable due to methodological flaws and questionable control data.

J.J. Bradstreet et al.

“A Case-Control Study of Mercury Burden in Children with Autistic Spectrum Disorders”

Premise
This study attempted to measure mercury burden in autistic children through chelation-challenge urine testing.

Results
Autistic children were reported to excrete higher levels of mercury following chelation therapy.

Conclusions of the Authors
The authors suggested the findings supported increased mercury burden in autism.

Court’s Evaluation
The court rejected the study due to flawed methodology, unreliable testing protocols, and weak statistical analysis.

Sarah Soden et al.

“24-Hour Provoked Urine Excretion Test for Heavy Metals in Children with Autism and Typically Developing Controls”

Premise
This pilot study examined whether autistic children retained higher levels of mercury using chelation-challenge testing.

Results
The study found no meaningful difference in mercury excretion between autistic children and controls.

Conclusions of the Authors
The authors concluded that the findings did not support mercury retention in autism.

Court’s Evaluation
The court treated the study as credible evidence contradicting the mercury-retention hypothesis.

E. Fombonne & S. Chakrabarti

“No Evidence for a New Variant of Measles-Mumps-Rubella-Induced Autism” (Pediatrics, 2001)

Premise
This article addressed a central claim that emerged after Wakefield’s work: that even if MMR did not cause autism generally, it might cause a “new variant” marked by regression and gastrointestinal symptoms. The study was an epidemiologic/phenotype analysis of autistic children in the United Kingdom designed to determine whether the introduction of MMR was associated with a change in the frequency or pattern of regressive autism.

Results
The authors found no increase in the proportion of regressive autism after the introduction of MMR. The rate of regression remained stable over time. The article therefore did not support the claim that MMR created a new subtype of autism.

Conclusions of the Authors
The authors concluded that there was no evidence for a new variant of autism induced by MMR vaccination.

Court’s Evaluation
The OAP decisions treated this study as especially important because it directly tested the “new variant” theory rather than autism generally. The courts relied on it as affirmative evidence that regressive autism was not meaningfully altered by the advent of MMR.

Brent Taylor et al.

“Measles, Mumps, and Rubella Vaccination and Bowel Problems or Developmental Regression in Children with Autism: Population Study” (BMJ, 2002)

Premise
This epidemiological study tested the refined Wakefield theory that MMR might be associated specifically with bowel problems or developmental regression within autism, rather than with autism as a whole. The study looked at autistic children and examined whether bowel symptoms or regression correlated with MMR exposure or timing.

Results
The study found no association between MMR vaccination and bowel problems, and no association between MMR vaccination and developmental regression. It also found that the proportion of regressive autism within autism cases did not rise after the introduction of MMR.

Conclusions of the Authors
The authors concluded that the data did not support a causal association between MMR and either bowel problems or developmental regression in children with autism.

Court’s Evaluation
The special masters treated Taylor 2002 as one of the strongest studies against petitioners’ narrower theory. It was particularly valuable because it directly addressed the regression/GI hypothesis rather than only autism in the aggregate.

J. Richler et al.

“Is There a ‘Regressive Phenotype’ of Autism Spectrum Disorder Associated with the Measles-Mumps-Rubella Vaccine? A CPEA Study” (Journal of Autism and Developmental Disorders, 2006)

Premise
This study was designed specifically to determine whether regressive autism is a distinct phenotype and, if so, whether it is associated with the timing of MMR vaccination. The study compared autistic children with regression to autistic children without regression and evaluated developmental patterns and vaccine timing.

Results
The researchers found some group differences between children with and without regression, but no evidence that those differences were associated with MMR timing. The data did not show that regression clustered around MMR exposure.

Conclusions of the Authors
The authors concluded that the evidence did not support a regressive phenotype associated with MMR vaccination.

Court’s Evaluation
The OAP courts considered Richler one of the most important studies on regression because it asked the exact question petitioners were pressing. The courts relied on it heavily in rejecting the argument that MMR could still cause a narrow subgroup of “regressive” autism even if it did not cause autism generally.

T. Uchiyama et al.

“MMR-Vaccine and Regression in Autism Spectrum Disorders: Negative Results Presented from Japan” (Journal of Autism and Developmental Disorders, 2007)

Premise
This Japanese study tested whether children with autism who received MMR had a higher rate of regression than children with autism who did not receive MMR. It was aimed directly at the claim that MMR causes regressive autism.

Results
The study found no increased regression rate among Japanese autistic children who had received MMR compared with those who had not. The regression rates were not higher in the exposed group.

Conclusions of the Authors
The authors concluded that their findings disconfirmed the hypothesis that MMR vaccination causes regression in autism spectrum disorders.

Court’s Evaluation
The OAP opinions repeatedly cited Uchiyama as direct evidence against the regression theory. The special masters treated it as especially probative because it specifically addressed the very subgroup petitioners insisted had been missed in broader epidemiologic studies.

Liam Smeeth et al.

“MMR Vaccination and Pervasive Developmental Disorders: A Case-Control Study” (Lancet, 2004)

Premise
This case-control epidemiology study examined whether children with pervasive developmental disorders differed from controls in their rates or timing of MMR vaccination.

Results
The study found no increased odds of pervasive developmental disorders among children who received MMR. The vaccination histories of the autism cases and controls did not support a causal link.

Conclusions of the Authors
The authors concluded that MMR vaccination was not associated with pervasive developmental disorders.

Court’s Evaluation
The special masters treated this as another competent epidemiologic study that failed to show an association. It strengthened the courts’ view that negative results were appearing across different study designs, not only in cohort analyses.

S. DeWilde et al.

“Do Children Who Become Autistic Consult More Often After MMR Vaccination?” (British Journal of General Practice, 2001)

Premise
This study asked whether children later diagnosed with autism had an increase in doctor consultations shortly after MMR vaccination, which might be expected if the vaccine precipitated noticeable behavioral or medical decline.

Results
The researchers found no increased consultation rate in the autism group compared with controls during the six months following MMR vaccination.

Conclusions of the Authors
The authors concluded that the data did not support the idea of a post-MMR behavioral decline detectable in routine medical consultations.

Court’s Evaluation
The courts treated this as one more epidemiologic study cutting against the MMR theory. Although not as central as Taylor or Madsen, it helped show the absence of any medical-utilization signal after vaccination.

Larry Dales et al.

“Time Trends in Autism and in MMR Immunization Coverage in California” (JAMA, 2001)

Premise
This ecological study examined whether autism rates in California moved in a way that corresponded to changes in MMR immunization coverage.

Results
The authors found no correlation between increasing autism diagnoses and shifts in the age or coverage of MMR vaccination. The epidemiologic trends did not track one another in a way consistent with causation.

Conclusions of the Authors
The authors concluded that the time trends did not support a causal relationship between MMR coverage and autism rates.

Court’s Evaluation
The OAP decisions cited this article as part of the larger body of ecological evidence showing that autism trends did not align with MMR policy or uptake in the way petitioners’ theory would predict.

Eric Fombonne

“Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links with Immunizations” (Pediatrics, 2006)

Premise
This Canadian epidemiology study examined autism prevalence and potential links with immunizations, including whether rates differed after first and second MMR doses.

Results
The study found no increased autism risk after the second MMR dose and no epidemiologic pattern supporting a vaccine-autism relationship.

Conclusions of the Authors
The authors concluded that the data did not support a causal link between immunization and pervasive developmental disorders.

Court’s Evaluation
The special masters treated this article as another competent study from a different setting showing the same negative pattern. It reinforced the point that the negative epidemiology was international and consistent.

H. Honda et al.

“No Effect of MMR Withdrawal on the Incidence of Autism: A Total Population Study” (Journal of Child Psychology and Psychiatry, 2005)

Premise
This ecological Japanese study asked what happened to autism incidence after MMR was withdrawn. It functioned as a natural experiment: if MMR caused autism, autism incidence should have declined after the vaccine’s removal.

Results
Autism rates continued to rise in birth cohorts after MMR was no longer administered. There was no drop in incidence during the period of non-use.

Conclusions of the Authors
The authors concluded that MMR was unlikely to cause a substantial proportion of autism cases.

Court’s Evaluation
The OAP courts gave Honda substantial weight. They repeatedly pointed to it as easy-to-understand evidence that autism trends did not respond to MMR withdrawal in the way a causal theory would predict.

Hviid et al.

“Association Between Thimerosal-Containing Vaccines and Autism” (JAMA, 2003)

Premise
This Danish cohort study evaluated whether children exposed to thimerosal-containing vaccines had a higher incidence of autism than children who were not exposed.

Results
The study found no increased risk of autism associated with thimerosal exposure. The comparison between exposed and unexposed groups did not reveal a meaningful association.

Conclusions of the Authors
The authors concluded that their results did not support a relationship between thimerosal-containing vaccines and autism.

Court’s Evaluation
The thimerosal test-case opinions treated Hviid as one of the principal epidemiologic studies against petitioners’ theory. Petitioners’ expert Dr. Greenland argued that the confidence intervals did not rule out a tiny risk in a subgroup, but the courts still regarded Hviid as strong evidence against a general association.

K.M. Madsen et al.

“Thimerosal and the Occurrence of Autism: Negative Ecological Evidence From Danish Population-Based Data” (Pediatrics, 2003)

Premise
This ecological study examined what happened to autism rates in Denmark after thimerosal was removed from vaccines.

Results
Autism rates continued to increase even after thimerosal was discontinued. The expected decline did not occur.

Conclusions of the Authors
The authors concluded that the data did not support a causal correlation between thimerosal in vaccines and autism incidence.

Court’s Evaluation
The courts treated Madsen as one of the key ecological studies undermining the thimerosal hypothesis. Petitioners argued that ecological studies could miss a very small subgroup effect, but the special masters found the continued increase after thimerosal removal to be inconsistent with petitioners’ broader claim.

T. Verstraeten et al.

“Safety of Thimerosal-Containing Vaccines: A Two-Phased Study of Computerized Health Maintenance Organization Databases” (Pediatrics, 2003)

Premise
This study examined large HMO databases in the United States to determine whether different levels of thimerosal exposure were associated with neurodevelopmental outcomes, including autism.

Results
The study found no clear association between thimerosal exposure and autism. Petitioners pointed to language in the article suggesting that some questions remained unresolved, but the overall results did not show a persuasive autism signal.

Conclusions of the Authors
The authors did not conclude that thimerosal caused autism; rather, the study did not confirm a causal association and was part of the broader body of literature finding no clear link.

Court’s Evaluation
The thimerosal decisions treated Verstraeten as part of the consistent negative epidemiology. Petitioners’ expert emphasized its cautionary wording, but the courts viewed the article in the context of the larger literature, which overwhelmingly pointed the same way.

P. Stehr-Green et al.

“Autism and Thimerosal-Containing Vaccines: Lack of Consistent Evidence for an Association” (American Journal of Preventive Medicine, 2003)

Premise
This ecological study compared autism trends in California, Denmark, and Sweden, including settings where thimerosal had been discontinued.

Results
The study found increasing autism rates despite differences in thimerosal exposure and despite thimerosal removal in Denmark and Sweden.

Conclusions of the Authors
The authors concluded that there was no consistent evidence for an association between thimerosal-containing vaccines and autism.

Court’s Evaluation
The OAP special masters treated this article as another important ecological study showing that autism trends did not follow thimerosal exposure patterns. It reinforced the broader point that the epidemiology was remarkably consistent.

N. Andrews et al.

“Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association” (Pediatrics, 2004)

Premise
This retrospective U.K. cohort study examined infant thimerosal exposure and later developmental disorders, including autism-related outcomes.

Results
The study found no relationship between thimerosal dose and autism. It also looked at a large population that included low-birth-weight infants.

Conclusions of the Authors
The authors concluded that the data did not support a causal association between thimerosal exposure and developmental disorders.

Court’s Evaluation
The courts treated Andrews as a substantial cohort study that directly contradicted petitioners’ theory. Petitioners argued subgroup effects could still be missed, but the special masters regarded the article as strong contrary evidence.

Jon Heron et al.

“Thimerosal Exposure in Infants and Developmental Disorders: A Prospective Cohort Study in the United Kingdom Does Not Support a Causal Association” (Pediatrics, 2004)

Premise
This prospective cohort study followed approximately 13,000 British children from birth to school age and assessed whether early thimerosal exposure was associated with developmental problems.

Results
The study did not use autism as a formal endpoint, but it did evaluate special educational needs and found no association between thimerosal exposure and those outcomes.

Conclusions of the Authors
The authors concluded that the study did not support a causal relationship between thimerosal exposure and developmental disorders.

Court’s Evaluation
The special masters acknowledged that Heron did not specifically use autism as an endpoint, but they still regarded it as relevant because autistic children often require special educational services. It was treated as additional evidence against a thimerosal-developmental injury theory.

Eric Fombonne et al.

“Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links with Immunizations” (Pediatrics, 2006)

Premise
This study examined autism prevalence in Montreal and changes in immunization practices, including changes involving thimerosal and MMR scheduling.

Results
The researchers found no correlation between autism prevalence and changes in immunization exposures.

Conclusions of the Authors
The authors concluded that the data did not support a link between immunizations and pervasive developmental disorders.

Court’s Evaluation
The OAP thimerosal cases treated this as one of the important international epidemiologic studies showing no relationship between changing vaccine exposures and autism prevalence.

Robert Schechter & Judith Grether

“Continuing Increases in Autism Reported to California’s Developmental Services System: Mercury in Retrograde” (Archives of General Psychiatry, 2008)

Premise
This ecological study examined California autism-service data after the phase-out of thimerosal from childhood vaccines. The theory tested was simple: if thimerosal were a major cause of autism, cases should fall after its removal.

Results
The number of autistic children reported to the California developmental services system continued to climb during the years when a decline would have been expected if thimerosal were causal.

Conclusions of the Authors
The authors concluded that the results were inconsistent with the hypothesis that thimerosal had been a primary cause of autism in California.

Court’s Evaluation
The thimerosal special masters cited Schechter and Grether as one of the clearest ecological refutations of petitioners’ overall theory. The study was treated as strong evidence that autism trends did not respond to thimerosal removal.

Hershel Jick & James A. Kaye

“Autism and DPT Vaccination in the United Kingdom” (New England Journal of Medicine letter, 2004)

Premise
This was a short report, published as a letter, comparing autistic children and controls in the United Kingdom to see whether there was any difference in exposure to thimerosal-containing DPT vaccination.

Results
The study found no significant difference between autistic children and controls with respect to thimerosal exposure.

Conclusions of the Authors
The authors commented that the findings provided further support for the view that exposure to mercury in vaccines was not the cause of the rising incidence of autism.

Court’s Evaluation
The special masters treated the results as generally consistent with the other negative studies, but they gave the article diminished weight because it was published only as a short letter rather than a full article and because the published note disclosed consultancy work for a vaccine manufacturer’s counsel. Thus, the study was not rejected on its face, but was considered less weighty than the other epidemiologic articles.

William W. Thompson et al.

“Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years” (New England Journal of Medicine, 2007)

Premise
This U.S. study examined whether early thimerosal exposure was associated with later neuropsychological deficits in children aged seven to ten years. It did not use autism as a formal endpoint, but it included speech, language, and intellectual-function measures relevant to autism-like concerns.

Results
The study generally found no association between early thimerosal exposure and adverse neuropsychological outcomes.

Conclusions of the Authors
The authors concluded that the results did not support an association between thimerosal exposure and deficits in neuropsychological functioning.

Court’s Evaluation
The OAP thimerosal decisions treated Thompson as relevant supportive evidence against petitioners’ theory, even though autism itself was not a formal endpoint. The courts viewed it as another indication that thimerosal exposure was not producing the kind of neurological deficits petitioners posited.

A. Hviid, K.M. Madsen, Stehr-Green, Andrews, Verstraeten, Heron, Fombonne, Schechter, Jick, and Thompson — Collective Court Treatment

Across the thimerosal test cases, the courts repeatedly emphasized not merely that one or two studies were negative, but that numerous research groups in several countries, using several different study designs, all failed to find evidence that thimerosal-containing vaccines are associated with autism. The courts specifically summarized these studies as part of a unified epidemiologic record pointing in the same direction. Petitioners’ expert Dr. Greenland argued that the studies could not exclude a tiny, rare subgroup of “clearly regressive autism,” but he also conceded that the studies had not proved petitioners’ theory and that he had no autism expertise of his own. The special masters accepted that epidemiology can never rule out every hypothetical sliver of possibility, but concluded that the actual evidence overwhelmingly weighed against petitioners’ claims.

Geier & Geier

“A Comparative Evaluation of the Effects of MMR Immunization and Mercury Doses from Thimerosal-Containing Childhood Vaccines on the Population Prevalence of Autism” and “Pediatric MMR Vaccination Safety”

Premise
These studies were among the few publications cited by petitioners as suggesting a positive association between vaccines and autism.

Results
They purported to identify relationships between vaccine exposure and autism prevalence.

Conclusions of the Authors
The authors advanced conclusions supportive of vaccine-autism causation.

Court’s Evaluation
The OAP decisions gave these studies essentially no evidentiary weight. The special masters described them as methodologically deficient and noted that they had been heavily criticized by reviewers, by petitioners’ own epidemiology expert, and by other courts. In the thimerosal decisions especially, the Geier articles were treated as too unreliable to assist petitioners.

Hansen et al.

“Regression in Autism: Prevalence and Associated Factors in the CHARGE Study” (Ambulatory Pediatrics, 2008)

Premise
This study examined the prevalence of regression in children with autism and how rates varied depending on the definition of regression used.

Results
When regression was defined as loss of both social skills and language, 15% of children were classified as regressed. When regression was defined more broadly as loss of either language or social skills, an additional 26% were captured, for a total of 41%.

Conclusions of the Authors
The study showed that regression is a significant and variably defined phenomenon within autism, depending on the criteria used.

Court’s Evaluation
The thimerosal and MMR opinions used Hansen not to support petitioners’ theory, but to show that regression is not rare, novel, or necessarily a distinct vaccine-linked phenotype. It helped the courts explain why regression, by itself, did not prove a different cause.

Final Analysis

Once the additional studies are included, the pattern becomes even clearer. The OAP courts were not choosing between one positive study and one negative study. They were faced with a broad scientific record in which numerous epidemiologic studies from multiple countries, using cohort, case-control, ecologic, and subgroup analyses, repeatedly failed to show that MMR or thimerosal-containing vaccines caused autism, regressive autism, bowel-associated autism, or any new vaccine-linked autism phenotype. The special masters acknowledged that epidemiology cannot mathematically eliminate every theoretical possibility, especially a tiny hypothetical subgroup. But they held that the literature actually before them did not support such a subgroup and, taken as a whole, weighed strongly against the petitioners’ theories.

Case Law Analysis: How the Vaccine Court Addressed Autism Claims

While the medical literature formed the scientific foundation of the Omnibus Autism Proceeding, the Vaccine Injury Compensation Program ultimately had to answer a legal question: whether the available scientific evidence demonstrated, by a preponderance of the evidence, that vaccines can cause autism. To address that question, the Court selected a series of **test cases—Cedillo, Hazlehurst, Snyder, King, Dwyer, and Mead—**to examine the competing medical theories and the extensive scientific record developed by both parties. These cases allowed the Court to evaluate expert testimony, analyze hundreds of peer-reviewed studies, and determine whether petitioners had presented a reliable medical theory causally linking vaccination to autism. The decisions that followed did not simply reject individual claims; they created a detailed legal framework explaining how courts evaluate complex medical evidence, how scientific literature is weighed under the Vaccine Act, and why the evidence presented in the autism test cases ultimately failed to establish vaccine causation under the governing legal standard.

Cedillo v. Secretary of Health and Human Services

(Special Master Decision 2009; aff’d, 89 Fed. Cl. 158 (2009); aff’d, 617 F.3d 1328 (Fed. Cir. 2010))

Cedillo was one of the lead test cases in the Omnibus Autism Proceeding, a coordinated set of Vaccine Program cases designed to evaluate whether childhood vaccines can cause autism. Petitioners alleged that Michelle Cedillo developed autism after receiving the MMR vaccine along with thimerosal-containing vaccines. Petitioners advanced a multi-step medical theory: thimerosal exposure allegedly impaired Michelle’s immune system; the MMR vaccine then introduced measles virus that persisted in her body; that persistent infection caused gastrointestinal disease; and the virus ultimately affected the brain and caused autism.

The Special Master evaluated extensive expert testimony and a large body of scientific literature addressing mercury toxicity, immune dysfunction, measles virus persistence, and epidemiology of autism and vaccination. Petitioners relied heavily on studies suggesting persistent measles infection, particularly the Uhlmann PCR study, as well as toxicology literature concerning thimerosal. Respondent countered with numerous epidemiological studies finding no association between MMR vaccination and autism and with molecular studies—such as research by D’Souza and Afzal—that failed to replicate claims of measles virus persistence.

The Special Master concluded that petitioners failed to demonstrate that vaccines can cause autism or that vaccines caused Michelle Cedillo’s condition. He found the measles persistence evidence unreliable due to methodological problems and lack of replication and concluded that the epidemiological literature consistently showed no causal association between MMR vaccination and autism.

Petitioners sought review in the Court of Federal Claims, arguing that the Special Master misinterpreted the scientific literature and improperly discounted their experts. The court affirmed, holding that the Special Master carefully evaluated the evidence and reasonably rejected petitioners’ causation theory.

Petitioners then appealed to the Federal Circuit, which again affirmed. The appellate court held that the Special Master’s evaluation of the scientific evidence and expert testimony was entitled to substantial deference and was well supported by the record. The Federal Circuit concluded that the evidence did not establish that vaccines caused Michelle Cedillo’s autism, leaving the denial of compensation intact.

Dwyer v. Secretary of Health and Human Services

(Special Master Decision, 2010 – Omnibus Autism Proceeding Theory 2 Test Case)

Dwyer was one of the three “Theory 2” test cases in the Omnibus Autism Proceeding (OAP), addressing the claim that thimerosal-containing vaccines (“TCVs”)—specifically the ethylmercury preservative used in certain childhood vaccines—can cause autism spectrum disorders (“ASDs”). Petitioners Timothy and Maria Dwyer alleged that their son, Colin Dwyer, developed autism due to exposure to mercury contained in thimerosal-containing vaccines administered during infancy.

Petitioners advanced a multi-part medical theory built largely on expert testimony from Drs. Aposhian, Deth, and Kinsbourne. They argued that ethylmercury exposure from vaccines produced metabolic disruption, oxidative stress, and neuroinflammation in susceptible children. According to petitioners, these biochemical effects interfered with neuronal signaling and ultimately produced the behavioral and developmental symptoms of autism. Petitioners further asserted that a subgroup of children—described as having “clearly regressive autism”—might possess a genetic hypersensitivity to mercury, rendering them uniquely vulnerable to vaccine-related neurotoxicity.

The government presented extensive expert testimony from epidemiologists, neurologists, toxicologists, and autism researchers who argued that petitioners’ hypotheses were biologically implausible and inconsistent with the known effects of mercury on the brain. Respondent emphasized that epidemiological studies examining populations exposed to thimerosal-containing vaccines had consistently failed to show any association with autism. Respondent’s experts also explained that the biochemical mechanisms proposed by petitioners did not resemble known manifestations of mercury toxicity and were unsupported by reliable experimental evidence.

After reviewing a voluminous record that included expert testimony, scientific literature, and extensive medical research, Special Master Denise Vowell concluded that petitioners failed to establish by a preponderance of the evidence that thimerosal-containing vaccines can cause autism or that they caused Colin Dwyer’s condition. The decision found petitioners’ causation theories scientifically unreliable and unsupported by the broader body of medical literature. Accordingly, the Special Master denied compensation under the Vaccine Act.

Hazlehurst v. Secretary of Health and Human Services

(Special Master Decision, 2009; aff’d, 88 Fed. Cl. 473 (2009); aff’d, 604 F.3d 1343 (Fed. Cir. 2010))

Hazlehurst was one of the three Theory 1 test cases in the Omnibus Autism Proceeding (OAP), addressing the claim that autism can result from a combination of the MMR vaccine and thimerosal-containing vaccines. Petitioners Rolf and Angela Hazlehurst alleged that their son, Yates Hazlehurst, developed regressive autism following his receipt of routine childhood vaccines, including the MMR vaccine administered shortly before his first birthday. Prior to vaccination, Yates reportedly developed normally; however, within months of receiving the MMR vaccine he exhibited behavioral regression, loss of speech, hyperactivity, and gastrointestinal symptoms.

Petitioners advanced a theory that the measles component of the MMR vaccine caused immune dysfunction that prevented clearance of the measles virus. According to this hypothesis, persistent measles infection in the gastrointestinal tract led to chronic inflammation that spread to the brain and ultimately produced neurological injury manifesting as autism. Petitioners’ experts relied heavily on studies reporting the detection of measles virus in intestinal tissue of autistic children, including research associated with Andrew Wakefield and testing performed by the Unigenetics laboratory. Respondent challenged these studies and presented expert testimony explaining that the measles persistence hypothesis lacked biological plausibility and that the laboratory testing methods underlying the purported findings were unreliable.

The Special Master concluded that petitioners failed to establish a reliable medical theory linking the MMR vaccine to autism. Central to the ruling was the determination that the measles persistence evidence—described as the “linchpin” of petitioners’ theory—was scientifically unreliable because the underlying studies were methodologically flawed and had not been replicated by independent laboratories. The Special Master further found that epidemiological studies consistently showed no association between MMR vaccination and autism. Accordingly, the Special Master held that petitioners failed to satisfy the first two prongs of the Althen causation test and denied compensation.

Petitioners sought review in the Court of Federal Claims, arguing that the Special Master improperly relied on evidence discrediting the Unigenetics laboratory and failed to consider evidence supporting measles persistence. The court rejected these arguments and affirmed the Special Master’s decision, holding that the evaluation of scientific evidence and expert testimony was reasonable and supported by the record. The court also agreed that petitioners had not established a reliable medical theory linking vaccination to autism and therefore failed to meet their burden under the Vaccine Act.

Snyder v. Secretary of Health and Human Services

(Special Master Decision, 2009; aff’d, 88 Fed. Cl. 706 (2009))

Snyder was the third “Theory 1” test case in the Omnibus Autism Proceeding (“OAP”), which examined the claim that autism can result from the combined effects of thimerosal-containing vaccines (“TCVs”) and the measles component of the MMR vaccine. Petitioners Kathryn and Joseph Snyder alleged that their son, Colten Snyder, developed a pervasive developmental disorder (“PDD”), a condition within the autism spectrum, after receiving routine childhood vaccinations including MMR at fifteen months of age. Petitioners advanced a multi-step biological theory: that ethylmercury contained in TCVs suppresses immune function; that the measles component of the MMR vaccine further impairs immune response; that the combined immune suppression allows the attenuated measles virus to persist in the body; and that persistent measles infection ultimately reaches the brain and causes neurological injury manifesting as autism.

The Special Master reviewed an extensive evidentiary record consisting of expert testimony across multiple scientific disciplines, including virology, immunology, neurology, toxicology, epidemiology, and gastroenterology, along with hundreds of medical journal articles and laboratory studies. Petitioners relied heavily on expert opinions proposing immune dysregulation and measles virus persistence, while respondent presented epidemiological research showing no association between vaccines and autism and expert testimony explaining that autism is strongly genetic and typically arises from prenatal neurodevelopmental abnormalities. The court also evaluated laboratory testing allegedly detecting measles virus in biological samples, ultimately finding significant methodological problems and reliability concerns with those results.

After weighing the scientific evidence and expert testimony, the Special Master concluded that petitioners failed to establish by a preponderance of the evidence that vaccines can cause autism or that they caused Colten Snyder’s condition. The decision found petitioners’ theories speculative, unsupported by reliable medical research, and inconsistent with the broader body of scientific literature. The Court of Federal Claims later affirmed the decision, holding that the Special Master’s evaluation of the scientific evidence and credibility determinations were well supported by the record and entitled to deference.

King v. Secretary of Health and Human Services

(Special Master Decision, 2010)

King was one of the three “Theory 2” test cases in the Omnibus Autism Proceeding addressing the claim that thimerosal-containing vaccines alone can cause autism. Petitioners alleged that Jordan King developed autism spectrum disorder following exposure to pediatric vaccines that contained thimerosal, a mercury-based preservative. Petitioners advanced a biological theory that ethylmercury from vaccines accumulates in the brain as inorganic mercury, triggering oxidative stress, neuroinflammation, and disruptions in neuronal signaling that ultimately lead to autistic regression. Petitioners relied on toxicology literature concerning mercury metabolism and cellular studies suggesting that thimerosal can affect immune or neurological function.

Respondent challenged the biological plausibility of this theory and presented extensive expert testimony from toxicologists, neurologists, epidemiologists, and autism researchers. Respondent’s experts emphasized that mercury poisoning produces clinical symptoms different from autism and that epidemiological studies examining large populations had consistently failed to show any association between thimerosal exposure and autism. Respondent also argued that the petitioners’ reliance on biochemical hypotheses lacked reliable experimental support.

After evaluating the expert testimony and the scientific literature, the Special Master concluded that petitioners failed to demonstrate a reliable medical theory connecting thimerosal exposure to autism. The decision held that the proposed biological mechanisms were speculative and unsupported by the broader scientific evidence. Because petitioners failed to establish general causation under the Vaccine Act, the claim for compensation was denied.

Mead v. Secretary of Health and Human Services

(Special Master Decision, 2010)

Mead was another test case in the Omnibus Autism Proceeding addressing the theory that thimerosal-containing vaccines can cause regressive autism. Petitioners George and Victoria Mead alleged that their son William developed regressive autism after receiving routine childhood vaccinations containing thimerosal. Petitioners’ theory proposed that ethylmercury from vaccines accumulated in the brain as inorganic mercury, creating oxidative stress and neuroinflammation that disrupted neuronal signaling. Petitioners further argued that this neuroinflammatory process caused the developmental regression characteristic of certain autism cases.

Petitioners relied on expert testimony and various biochemical and toxicological studies addressing mercury metabolism, oxidative stress, and glutathione depletion. They also argued that epidemiological studies examining autism generally failed to detect an association because they did not isolate a specific subgroup of “clearly regressive” autism cases. Respondent countered with expert testimony from neurologists, epidemiologists, toxicologists, and autism researchers who argued that autism arises primarily from prenatal neurodevelopmental abnormalities and genetic influences. Respondent also relied on numerous epidemiological studies demonstrating no association between thimerosal-containing vaccines and autism.

After reviewing extensive scientific literature and expert testimony, the Special Master concluded that petitioners failed to establish a scientifically reliable medical theory linking thimerosal exposure to autism. The court found petitioners’ hypotheses biologically implausible and inconsistent with the weight of the epidemiological evidence. Because petitioners failed to establish both general and specific causation, the claim for compensation was dismissed.

Encephalitis Induced Autism

Autoimmune Encephalitis, Developmental Regression, and Autism-Like Outcomes

One important neurological condition—autoimmune encephalitis (AE)—demonstrates why some children who appear to develop autism after a period of normal development may actually be experiencing a distinct brain injury rather than idiopathic autism. Autoimmune encephalitis is a group of disorders in which the immune system mistakenly attacks brain tissue, producing inflammation of the central nervous system and a wide range of neurological and psychiatric symptoms. These symptoms frequently include seizures, behavioral changes, cognitive impairment, language loss, and developmental regression. (PubMed)

A growing body of medical literature has documented that AE can produce autism spectrum disorder (ASD) or autism-like features, particularly when the condition occurs in early childhood. A 2021 review examining the relationship between autoimmune encephalitis and autism concluded that AE may either act as a causative neurological event leading to ASD-type symptoms or produce clinical features that closely mimic autism, resulting in misdiagnosis. (PMC)

This relationship is especially relevant in cases of autistic regression, where a previously healthy toddler loses language, social engagement, and developmental milestones. Research has documented that inflammatory brain diseases—including autoimmune encephalitis and viral encephalitis—can precipitate such regression, producing symptoms identical to those seen in autism spectrum disorders. (Thinking Autism Taking Action)

Clinically, AE often presents with sudden developmental regression, behavioral abnormalities, language loss, and neurological symptoms that overlap with core autism features. Because the immune-mediated inflammation directly affects brain function, the resulting developmental delays may persist even after the acute illness resolves. (Psych Central)

This distinction has important implications for vaccine injury law. Encephalitis and encephalopathy are compensable neurological injuries under the Vaccine Injury Compensation Program (VICP) when they occur following vaccination within the appropriate medical timeframe. If a toddler develops autoimmune encephalitis and subsequently demonstrates developmental regression or autism-like symptoms, the compensable injury is the brain inflammation itself, not autism as an independent diagnosis.

Understanding this medical pathway is critical because it illustrates how a neurological injury recognized by the Vaccine Program—autoimmune encephalitis—can lead to long-term developmental outcomes that resemble autism. The literature therefore highlights an important clinical reality: some cases labeled as autism may actually represent the neurological consequences of immune-mediated brain injury.

Legal Analysis on Autism Claims

Legal Analysis: What the Vaccine Court Actually Decided About Vaccines and Autism

For more than two decades, courts and scientists have examined whether childhood vaccines—particularly the measles-mumps-rubella (MMR) vaccine and vaccines that once contained thimerosal—can cause autism. Thousands of petitions raising that claim were filed in the National Vaccine Injury Compensation Program (VICP). Because of the volume and the complexity of the scientific issues, the Court consolidated many of those cases into the Omnibus Autism Proceeding (OAP) and selected several test cases—Cedillo, Hazlehurst, Snyder, King, Dwyer, and Mead—to evaluate the competing medical theories and scientific evidence.

From a legal standpoint, the question before the Court was not whether science had reached absolute certainty. The Vaccine Program does not require scientific certainty. Instead, the legal standard is preponderance of the evidence—whether a causal connection is more likely than not (greater than 50%). The special masters reviewed an enormous scientific record, including hundreds of peer-reviewed articles, epidemiological studies, toxicology research, molecular biology studies, and expert testimony from leading physicians and scientists across multiple disciplines. After evaluating that evidence, the Court concluded that the available medical literature did not establish that vaccines cause autism by a preponderance of the evidence.

That conclusion is frequently misunderstood. The Court did not hold that autism can never follow vaccination, nor did it say that science has answered every question about autism. Rather, the Court determined that the scientific record—particularly the large epidemiological studies examining hundreds of thousands of children—does not demonstrate that vaccines themselves are a direct cause of autism.

Modern medical research consistently describes autism as a multifactorial neurodevelopmental condition. Studies cited in the OAP and subsequent research identify several contributing influences, including:

• Genetic factors and inherited susceptibility

• Prenatal neurological development abnormalities

• Environmental influences during pregnancy or early development

• Immune dysregulation and neuroinflammation in some cases

• Perinatal or early childhood neurological injury

Because vaccines are administered during infancy and early childhood—precisely when developmental milestones are rapidly emerging—it is understandable that parents may associate the timing of vaccination with the onset of behavioral or developmental changes. But temporal association alone does not establish causation. When millions of children receive vaccines during the same developmental window in which autism symptoms typically emerge, coincidental timing is inevitable. The Vaccine Court concluded that this coincidence does not constitute proof that vaccines are the cause of autism.

At the same time, the medical literature recognizes that neurological injuries following vaccination can occur, and those injuries are compensable under the Vaccine Injury Compensation Program. One such condition is autoimmune encephalitis (AE)—an immune-mediated inflammation of the brain that can produce seizures, behavioral disturbances, language loss, cognitive impairment, and developmental regression. In young children, the long-term neurological consequences of encephalitis can include persistent developmental delay and autism-like symptoms.

This distinction is critically important. In cases where a child develops autoimmune encephalitis following vaccination and later manifests autism-spectrum symptoms, the causal pathway is not “vaccine causes autism.” Instead, the medically recognized pathway is:

Vaccine → Autoimmune Encephalitis → Neurological Injury → Autism-like Developmental Sequelae

The compensable injury in that scenario is the brain inflammation itself, which is a recognized neurological injury under the Vaccine Program. The later developmental condition—whether diagnosed as autism spectrum disorder, developmental delay, or cognitive impairment—is part of the sequelae of the encephalitic injury.

In other words:

• Vaccine → Autism was the theory tested in the Omnibus Autism Proceeding and was not proven by a preponderance of the evidence.

• Vaccine → Autoimmune Encephalitis → Autism-like outcomes is a medically plausible pathway recognized in neurological literature and consistent with injuries compensable under the Vaccine Program.

For families navigating the Vaccine Program, that distinction matters. The presence of an autism diagnosis should not be treated as an automatic exclusion from compensation when the evidence shows that a vaccine caused a neurological injury—such as encephalitis—that later resulted in developmental regression or autism-spectrum symptoms.

Finally, an important lesson from the Omnibus Autism Proceeding is that science is not static. Medical understanding evolves, and legal analysis must evolve with it. The OAP decisions reflect the best available evidence at the time those cases were litigated. As research advances, our understanding of neurological injury, immune-mediated brain disorders, and developmental outcomes will continue to develop. Rather than prematurely assigning blame without reliable scientific proof, the better path forward is continued rigorous research. Rare conditions such as autoimmune encephalitis and other immune-mediated neurological injuries deserve further study so that the scientific community can better understand their causes, mechanisms, and long-term outcomes. Encouraging that research—while fairly compensating those who suffer genuine vaccine-related neurological injuries—is the responsible and scientifically grounded approach.

Shoulder Injury Related to Vaccine Administration (SIRVA)

Shoulder Injury Related to Vaccine Administration occurs when a vaccine is injected too high or too deep into the shoulder, causing inflammation of the shoulder joint, bursae, or rotator cuff tendons. Symptoms typically develop within hours or days and include persistent shoulder pain, reduced range of motion, weakness, and difficulty lifting the arm. Diagnosis is based on clinical history, physical examination, and imaging such as MRI or ultrasound showing bursitis, tendonitis, or adhesive capsulitis. Treatment often includes anti-inflammatory medications, corticosteroid injections, and structured physical therapy. Some cases require arthroscopic surgery. Prognosis varies, but many patients improve with appropriate orthopedic treatment over several months.

Guillain-Barré Syndrome (GBS)

Guillain-Barré Syndrome is an acute autoimmune neuropathy in which the immune system attacks peripheral nerves. Symptoms often begin with tingling or numbness in the feet or hands and progress to muscle weakness that may ascend through the limbs. In severe cases, respiratory muscles can be affected. Variants include acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and acute motor sensory axonal neuropathy (AMSAN). Diagnosis typically involves neurological examination, nerve conduction studies, and cerebrospinal fluid analysis. Treatment generally includes intravenous immunoglobulin or plasma exchange. Many patients recover gradually over months, though some experience long-term weakness or fatigue.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune neurological disorder in which the immune system attacks the myelin sheath surrounding peripheral nerves. The condition typically develops gradually over weeks to months and causes progressive muscle weakness, numbness, tingling, and loss of reflexes in the arms and legs. Many patients experience difficulty walking, impaired balance, and fatigue due to nerve damage. Diagnosis often involves neurological examination, nerve conduction studies demonstrating demyelination, and cerebrospinal fluid analysis showing elevated protein levels. Treatment commonly includes immune-modulating therapies such as intravenous immunoglobulin (IVIG), corticosteroids, or plasma exchange. Some patients require long-term immunosuppressive therapy. Prognosis varies, but many individuals experience improvement with treatment, although CIDP can follow a chronic or relapsing course requiring ongoing neurological care.

Transverse Myelitis

Transverse myelitis is an inflammatory disorder affecting the spinal cord that disrupts communication between the brain and the body. Symptoms often develop rapidly over hours or days and may include limb weakness, numbness or abnormal sensations, back pain, and problems with bladder or bowel control. The inflammation damages nerve fibers responsible for movement and sensory signaling below the level of the spinal cord injury. Diagnosis typically involves MRI imaging of the spinal cord, neurological examination, and cerebrospinal fluid analysis obtained through lumbar puncture. Treatment usually includes high-dose corticosteroids to reduce inflammation and plasma exchange for severe cases. Rehabilitation therapy is often required to restore mobility and function. Recovery varies widely; some patients regain normal neurological function while others experience persistent weakness or sensory deficits.

Acute Disseminated Encephalomyelitis (ADEM)

Acute Disseminated Encephalomyelitis (ADEM) is an immune-mediated inflammatory disease affecting the brain and spinal cord. It typically occurs suddenly and can cause symptoms such as headache, fever, confusion, seizures, weakness, vision changes, and coordination difficulties. MRI imaging often reveals widespread inflammatory lesions in the white matter of the brain. Diagnosis involves neurological examination, brain imaging, and cerebrospinal fluid testing to evaluate central nervous system inflammation. Treatment usually includes high-dose corticosteroids to suppress immune activity, with intravenous immunoglobulin or plasma exchange used in severe cases. Many patients experience significant recovery over several weeks or months, although some may have persistent neurological symptoms depending on the severity of the inflammatory episode.

Neuromyelitis Optica (NMO)

Neuromyelitis Optica is a rare autoimmune disorder that primarily affects the optic nerves and spinal cord. The disease occurs when antibodies attack a protein called aquaporin-4, which is found on cells in the central nervous system. Patients commonly experience episodes of optic neuritis causing vision loss or eye pain, along with spinal cord inflammation that leads to weakness, numbness, and bladder dysfunction. Diagnosis typically involves MRI imaging and blood tests detecting aquaporin-4 antibodies. Treatment focuses on controlling immune system activity through corticosteroids, plasma exchange, and long-term immunosuppressive medications to reduce relapse risk. Without treatment, recurrent attacks can lead to permanent neurological disability, but modern therapies have improved outcomes for many patients.

MOG Antibody Disease (MOGAD)

Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) is an autoimmune neurological disorder in which antibodies attack proteins involved in the protective myelin coating of nerve cells in the central nervous system. The condition can cause optic neuritis, transverse myelitis, or brain inflammation resembling acute disseminated encephalomyelitis. Symptoms may include vision loss, limb weakness, sensory disturbances, headaches, and neurological deficits depending on the affected region of the brain or spinal cord. Diagnosis involves MRI imaging and blood testing for antibodies targeting myelin oligodendrocyte glycoprotein. Treatment often includes corticosteroids during acute attacks and immunosuppressive therapies to reduce relapse risk. Many patients recover well from individual attacks, although recurrent episodes can occur.

Optic Neuritis

Optic neuritis is inflammation of the optic nerve that interferes with visual signals traveling from the eye to the brain. Patients often develop sudden vision loss in one eye, pain with eye movement, blurred vision, and difficulty distinguishing colors. The condition may occur alone or as part of other neurological diseases affecting the central nervous system. Diagnosis typically involves ophthalmologic examination, MRI imaging of the optic nerve and brain, and visual evoked potential testing to assess nerve conduction. Treatment commonly includes corticosteroids to reduce inflammation and accelerate visual recovery. Vision frequently improves over several weeks, although some patients experience lasting visual impairment depending on the extent of nerve damage.

Encephalitis

Encephalitis refers to inflammation of the brain caused by infections, autoimmune reactions, or other inflammatory processes. Symptoms may include fever, headache, confusion, seizures, behavioral changes, and neurological deficits such as weakness or difficulty speaking. Because the brain controls many bodily functions, inflammation can produce a wide range of neurological symptoms. Diagnosis typically involves MRI imaging of the brain, electroencephalography (EEG), and cerebrospinal fluid analysis obtained through lumbar puncture to identify infection or immune activity. Treatment depends on the underlying cause and may include antiviral medications, corticosteroids, immunotherapy, and supportive care. Prognosis varies widely; some individuals recover fully while others may develop long-term neurological complications.

Small Fiber Neuropathy (SFN)

Small Fiber Neuropathy is a neurological disorder affecting the small sensory nerve fibers responsible for transmitting pain and temperature signals. Patients commonly experience burning pain, tingling, numbness, and heightened sensitivity to touch, often beginning in the feet or hands and spreading in a “stocking-glove” distribution. Some individuals also develop autonomic symptoms such as abnormal sweating, gastrointestinal disturbances, dizziness when standing, or changes in heart rate. Diagnosis typically involves neurological examination, quantitative sensory testing, and skin biopsy measuring intraepidermal nerve fiber density. Treatment focuses on managing neuropathic pain with medications such as gabapentin, duloxetine, or pregabalin while addressing underlying causes when identified. Prognosis varies; symptoms may stabilize, improve with treatment, or persist chronically depending on disease severity.

Vasculitis

Vasculitis refers to a group of disorders characterized by inflammation of blood vessels. When blood vessel walls become inflamed, they may narrow, weaken, or become damaged, reducing blood flow to tissues and organs. Symptoms vary depending on the organs involved but may include fatigue, fever, skin rash, joint pain, nerve symptoms, or organ dysfunction. Diagnosis typically involves blood tests for inflammatory markers, imaging studies, and sometimes tissue biopsy to confirm vascular inflammation. Treatment usually includes corticosteroids and immunosuppressive medications designed to reduce immune system activity. Prognosis varies widely depending on the specific type of vasculitis and the severity of organ involvement.

Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia is an autoimmune disorder in which the immune system mistakenly attacks and destroys platelets, the blood components responsible for clotting. Reduced platelet counts can lead to symptoms such as easy bruising, petechiae (small red or purple skin spots), frequent nosebleeds, bleeding gums, or prolonged bleeding after minor injuries. Some individuals experience fatigue due to the underlying immune activity. Diagnosis typically involves blood tests showing low platelet levels and exclusion of other causes of thrombocytopenia. In certain cases, bone marrow evaluation may be performed. Treatment may include corticosteroids, intravenous immunoglobulin (IVIG), medications that stimulate platelet production, or immunosuppressive therapies. Many patients respond well to treatment, though some develop chronic ITP requiring ongoing monitoring.

Parsonage-Turner Syndrome (Brachial Neuritis)

Parsonage-Turner Syndrome, also known as brachial neuritis, is a neurological disorder involving inflammation of the brachial plexus, a network of nerves controlling shoulder and arm movement. The condition usually begins with sudden severe shoulder pain followed by muscle weakness, loss of range of motion, and muscle wasting in the affected arm. Patients may have difficulty lifting objects or moving the shoulder normally. Diagnosis often involves neurological examination, electromyography (EMG), and imaging studies to rule out structural nerve injury. Treatment typically includes pain management, physical therapy, and sometimes corticosteroids to reduce inflammation. Recovery often occurs gradually over months to years, although some patients experience lingering weakness or reduced shoulder function.

Complex Regional Pain Syndrome (CRPS)

Complex Regional Pain Syndrome is a chronic pain condition that usually develops after injury or trauma affecting a limb. The disorder involves abnormal responses in the nervous system that amplify pain signals. Patients often experience severe burning pain, swelling, changes in skin temperature or color, hypersensitivity to touch, and reduced range of motion in the affected limb. Diagnosis is primarily clinical and based on characteristic symptoms and physical examination, although imaging or nerve tests may help exclude other conditions. Treatment often involves a multidisciplinary approach including physical therapy, medications for nerve pain, nerve blocks, and psychological support. Early intervention improves outcomes, though some individuals experience persistent chronic pain.

Polyneuritis Cranialis

Polyneuritis Cranialis is a rare neurological condition involving inflammation of multiple cranial nerves, which control functions such as facial movement, vision, swallowing, and hearing. Symptoms vary depending on which cranial nerves are affected but may include facial weakness, double vision, difficulty swallowing, hearing disturbances, or abnormal facial sensations. Because several cranial nerves may be involved simultaneously, patients may develop complex neurological symptoms affecting multiple head and neck functions. Diagnosis typically involves neurological examination, MRI imaging of the brain and cranial nerves, and sometimes cerebrospinal fluid testing. Treatment often includes corticosteroids or immunotherapy when autoimmune inflammation is suspected. Prognosis depends on the underlying cause, but many patients experience gradual improvement with treatment.

Myasthenia Gravis

Myasthenia Gravis is a chronic autoimmune neuromuscular disorder that interferes with communication between nerves and muscles. The immune system produces antibodies that block or destroy acetylcholine receptors at the neuromuscular junction, leading to muscle weakness that worsens with activity and improves with rest. Common symptoms include drooping eyelids, double vision, difficulty speaking or swallowing, and weakness in the arms, legs, or neck. Diagnosis typically involves antibody blood tests, electromyography studies, and imaging of the thymus gland. Treatment may include medications that improve nerve–muscle signaling, immunosuppressive therapy, thymectomy in certain cases, and supportive care. With appropriate treatment, many patients achieve good symptom control, though the condition often requires long-term management.

Dermatomyositis

Dermatomyositis is an autoimmune inflammatory disease affecting skeletal muscles and the skin. The condition causes progressive muscle weakness, particularly in the shoulders, hips, and neck, making tasks such as climbing stairs or lifting objects difficult. Patients also develop distinctive skin findings, including a purplish rash around the eyes and red patches on the knuckles, elbows, or knees. Diagnosis typically involves blood tests detecting muscle inflammation, electromyography, MRI imaging of affected muscles, and sometimes muscle or skin biopsy. Treatment commonly includes corticosteroids and immunosuppressive medications to reduce immune system activity. Physical therapy is often recommended to maintain strength and mobility. Prognosis varies, but many patients experience improvement with treatment.

Autoimmune Hepatitis

Autoimmune Hepatitis is a chronic inflammatory liver disease in which the immune system mistakenly attacks liver cells. Patients may experience fatigue, abdominal discomfort, joint pain, jaundice, or elevated liver enzymes detected during routine blood tests. Diagnosis usually involves liver function testing, detection of autoimmune antibodies, and sometimes liver biopsy to confirm inflammation and rule out other liver diseases. Treatment generally includes corticosteroids and immunosuppressive medications such as azathioprine to reduce immune-mediated liver damage. With appropriate treatment, many patients achieve long-term disease control, although some require lifelong therapy to prevent relapse and preserve liver function.

Autoimmune Hemolytic Anemia

Autoimmune Hemolytic Anemia is a condition in which the immune system destroys red blood cells faster than the body can replace them. This leads to anemia and symptoms such as fatigue, weakness, shortness of breath, pale skin, dizziness, and jaundice. Diagnosis typically involves blood tests demonstrating anemia and the presence of antibodies attacking red blood cells, commonly detected through the direct antiglobulin (Coombs) test. Treatment often includes corticosteroids to suppress immune activity, along with immunosuppressive medications or other therapies when needed. Many patients respond well to treatment, although some cases may become chronic and require ongoing medical management.

Aplastic Anemia

Aplastic Anemia is a rare but serious condition in which the bone marrow fails to produce sufficient numbers of blood cells, including red blood cells, white blood cells, and platelets. Patients may develop fatigue, frequent infections, easy bruising, or prolonged bleeding due to the lack of normal blood cell production. Diagnosis typically involves blood tests showing reduced cell counts and bone marrow biopsy demonstrating decreased bone marrow activity. Treatment may include immunosuppressive therapy, blood transfusions, medications that stimulate bone marrow function, or bone marrow transplantation in severe cases. Prognosis varies depending on disease severity and treatment response.

Granulomatosis with Polyangiitis

Granulomatosis with Polyangiitis is a rare autoimmune disease characterized by inflammation of small and medium-sized blood vessels, particularly affecting the respiratory tract and kidneys. Symptoms may include sinus inflammation, nasal congestion, cough, shortness of breath, fatigue, joint pain, and kidney dysfunction. Diagnosis typically involves blood tests detecting antineutrophil cytoplasmic antibodies (ANCA), imaging studies, and tissue biopsy demonstrating vasculitis and granulomatous inflammation. Treatment generally includes corticosteroids and immunosuppressive medications such as cyclophosphamide or rituximab to control immune activity. Early treatment improves outcomes, although the disease can follow a relapsing course requiring long-term monitoring.

Polyarteritis Nodosa

Polyarteritis Nodosa is a systemic vasculitis that causes inflammation of medium-sized arteries throughout the body. The disease can affect multiple organs including the skin, nerves, gastrointestinal tract, and kidneys. Symptoms may include fever, fatigue, muscle and joint pain, abdominal pain, skin lesions, and neurological deficits caused by reduced blood flow to tissues. Diagnosis often involves blood tests, imaging studies of affected blood vessels, and sometimes tissue biopsy showing arterial inflammation. Treatment usually includes corticosteroids and immunosuppressive medications to control inflammation and prevent organ damage. With treatment, many patients achieve disease control, although complications may occur without prompt therapy.

Henoch-Schönlein Purpura (IgA Vasculitis)

Henoch-Schönlein Purpura, also known as IgA vasculitis, is an immune-mediated condition that causes inflammation of small blood vessels. It most commonly affects children but can occur in adults. Patients typically develop a characteristic purplish rash on the lower legs and buttocks, along with joint pain, abdominal pain, and kidney involvement. Diagnosis is often based on clinical features and laboratory tests, with skin biopsy sometimes confirming IgA immune complex deposition in blood vessels. Treatment is generally supportive, though corticosteroids may be used for severe symptoms. Many patients recover completely, although kidney involvement requires monitoring.

Narcolepsy

Narcolepsy is a chronic neurological sleep disorder that affects the brain’s ability to regulate sleep-wake cycles. Individuals with narcolepsy often experience excessive daytime sleepiness, sudden episodes of falling asleep, and disrupted nighttime sleep. Some patients develop cataplexy, a sudden loss of muscle tone triggered by strong emotions such as laughter or surprise. Other symptoms may include sleep paralysis and vivid dream-like hallucinations when falling asleep or waking. Diagnosis commonly involves overnight sleep studies such as polysomnography followed by a multiple sleep latency test that measures how quickly a person enters REM sleep. Treatment focuses on managing symptoms through medications that promote wakefulness, regulate sleep cycles, and control cataplexy. Although narcolepsy is typically lifelong, many patients maintain normal daily functioning with appropriate treatment.

Uveitis

Uveitis refers to inflammation of the uvea, the middle layer of the eye that includes the iris, ciliary body, and choroid. This inflammation can disrupt normal eye function and lead to symptoms such as eye redness, pain, blurred vision, light sensitivity, and floaters. Uveitis may occur suddenly or develop gradually and can affect one or both eyes. Diagnosis typically involves ophthalmologic examination using slit-lamp microscopy, imaging tests, and laboratory evaluation to identify potential autoimmune or infectious causes. Treatment often includes corticosteroid eye drops, oral medications, or immunosuppressive therapy depending on the severity and underlying cause. With prompt treatment many cases resolve, although untreated inflammation can lead to complications affecting vision.

Pemphigus

Pemphigus is a rare autoimmune blistering disease that affects the skin and mucous membranes. The immune system produces antibodies that disrupt the connections between skin cells, leading to fragile blisters and painful sores on the skin or inside the mouth. These lesions can rupture easily and leave areas of raw skin that may become infected. Diagnosis typically involves skin biopsy and immunofluorescence testing to detect antibodies targeting proteins responsible for cell adhesion in the skin. Treatment generally includes corticosteroids and immunosuppressive medications to reduce immune system activity and prevent blister formation. With modern therapies many patients achieve disease control, though long-term treatment and monitoring are often required.

Linear IgA Bullous Dermatosis

Linear IgA Bullous Dermatosis is an autoimmune blistering skin disorder caused by the deposition of IgA antibodies along the basement membrane of the skin. Patients develop tense blisters, itching, and ring-shaped skin lesions that may appear on the trunk, limbs, or face. The condition can occur in both children and adults, sometimes following infections or medication exposure. Diagnosis typically involves skin biopsy with direct immunofluorescence testing showing a linear pattern of IgA antibody deposition. Treatment commonly includes medications such as dapsone, corticosteroids, or other immunosuppressive agents to reduce inflammation and blister formation. Many patients respond well to treatment, although relapses can occur.

Postural Orthostatic Tachycardia Syndrome (POTS)

Postural Orthostatic Tachycardia Syndrome is a disorder of the autonomic nervous system that affects the body’s ability to regulate heart rate and blood flow when standing. Patients typically experience a rapid increase in heart rate upon standing, accompanied by dizziness, lightheadedness, fatigue, brain fog, palpitations, and sometimes fainting. Symptoms occur because blood circulation fails to adjust properly to upright posture. Diagnosis commonly involves tilt-table testing and monitoring heart rate changes after standing. Treatment often includes increased hydration and salt intake, medications to regulate heart rate or blood pressure, and structured exercise programs designed to improve cardiovascular conditioning. Many patients experience improvement over time, although symptoms can persist for years in some individuals.

Acute Panautonomic Neuropathy

Acute Panautonomic Neuropathy is a rare neurological disorder affecting the autonomic nervous system, which controls involuntary bodily functions such as heart rate, blood pressure, digestion, and sweating. The condition often develops rapidly and can cause severe dizziness when standing, abnormal heart rate, gastrointestinal dysfunction, urinary retention, and impaired temperature regulation. Because the autonomic nervous system regulates many essential processes, symptoms may involve multiple organ systems. Diagnosis typically includes autonomic function testing, neurological examination, and evaluation for underlying autoimmune or infectious triggers. Treatment focuses primarily on supportive care and management of symptoms, including medications to stabilize blood pressure or heart rate. Recovery varies widely; some patients improve gradually over months while others experience persistent autonomic dysfunction.

Yes—but vaccine injury claims must first be filed through the Vaccine Injury Compensation Program (VICP) rather than through traditional civil lawsuits against pharmaceutical companies. The VICP, often referred to as “vaccine court,” allows individuals to seek compensation if they can demonstrate that a vaccine more likely than not caused their injury. Individuals can reject the vaccine court decision and sue the vaccine manufacturer directly for a manufacturing defect or failure to warn defect.

Introduction

If someone believes they were injured by a vaccine, the first question they often ask is simple: can you sue for vaccine injury?

At first glance, suing a pharmaceutical company may seem like the most logical path. In most product liability cases, injured individuals pursue compensation directly from manufacturers in civil court.

But vaccine injury cases are different. In practice, traditional lawsuits against vaccine manufacturers are rarely the most effective way to obtain compensation. The legal framework governing vaccines was specifically designed to address the unique scientific and evidentiary challenges involved in proving vaccine injury claims.

Lawyers representing injured individuals routinely evaluate where a case has the best chance of success. In the vaccine context, decades of legal experience have shown that the most realistic path to justice and compensation is not traditional product liability litigation—it is the Vaccine Injury Compensation Program (VICP).

Rather than filing lawsuits in state or federal courts, most vaccine injury claims proceed through this specialized federal system, often referred to as “vaccine court.” Created by Congress in 1986, the VICP was designed to resolve vaccine injury claims under a more flexible evidentiary standard while maintaining a stable national vaccine supply.

Understanding how this system works—and why it often provides a more practical path to compensation than traditional lawsuits—is essential for anyone navigating vaccine injury claims in the United States.

Why Vaccine Lawsuits Work Differently

Vaccines occupy a unique place in American law and public health policy.

Unlike most pharmaceutical products, vaccines are administered to millions of healthy individuals, including infants and children, to prevent infectious diseases. Because vaccines are recommended as part of national immunization programs, Congress concluded that traditional product liability litigation was not the most efficient system for resolving vaccine injury claims.

During the early 1980s, vaccine manufacturers faced increasing litigation related to vaccines—particularly the DTP vaccine. As lawsuits increased, the number of companies producing vaccines declined dramatically.

By the mid-1980s, the number of vaccine manufacturers in the United States had fallen from 18 companies to just four. Policymakers became concerned that continued litigation could destabilize the vaccine market and threaten the nation’s ability to produce essential vaccines.

Congress responded by creating a new legal framework designed to accomplish two goals:

1. Maintain a stable vaccine supply.

2. Ensure that individuals who experience rare vaccine injuries can receive compensation.

The result was the National Childhood Vaccine Injury Act of 1986.

The National Childhood Vaccine Injury Act

The National Childhood Vaccine Injury Act established the Vaccine Injury Compensation Program (VICP).

Under this law, individuals who believe they were injured by certain vaccines may file claims in the U.S. Court of Federal Claims, where cases are decided by judicial officers known as Special Masters.

The program operates as a no-fault compensation system, meaning petitioners do not need to prove negligence, defective design, or wrongdoing by vaccine manufacturers.

Instead, the central legal question is:

Did the vaccine more likely than not cause the injury?

This lower evidentiary standard reflects Congress’s recognition that traditional tort litigation would make compensation extremely difficult in many vaccine injury cases. Vaccines work by stimulating the immune system, and in rare cases that immune response may become abnormal in certain individuals. Proving product defect in such circumstances would often be extraordinarily difficult.

The VICP was therefore designed to focus on causation rather than fault.

The Vaccine Injury Compensation Program

The Vaccine Injury Compensation Program functions as a specialized legal system dedicated to resolving vaccine injury claims.

When a claim is filed, the Department of Health and Human Services reviews the medical evidence to determine whether the government will concede causation or contest the claim.

If a petitioner successfully proves that a vaccine caused their injury, compensation may include:

• reimbursement for past and future medical expenses

• compensation for lost wages or reduced earning capacity

• pain and suffering damages

• compensation for future care needs

• attorney’s fees and litigation costs

Compensation is paid from the Vaccine Injury Compensation Trust Fund, which is funded through an excise tax on each covered vaccine dose.

Since its creation, the program has awarded billions of dollars in compensation to individuals and families who proved vaccine injuries. See here for how the Vaccine Injury Program works.

What the Supreme Court Said in Bruesewitz v. Wyeth

In 2011, the U.S. Supreme Court addressed vaccine liability in the case Bruesewitz v. Wyeth.

The Court held that the Vaccine Act largely preempts design defect lawsuits against vaccine manufacturers for vaccines covered under the VICP. In practical terms, individuals generally cannot sue vaccine manufacturers claiming that a vaccine should have been designed differently.

However, the Court did not eliminate all potential lawsuits.

Claims involving manufacturing defects or failure to warn may still be pursued under certain circumstances. Even in those cases, the claimant must first file a petition in the Vaccine Injury Compensation Program before pursuing civil litigation.

The decision reinforced Congress’s intent that vaccine injury claims should primarily be resolved through the specialized compensation system created by the Vaccine Act.

When Lawsuits Are Still Possible

Although the Vaccine Injury Compensation Program handles most vaccine injury claims, civil litigation can still occur in certain circumstances.

After filing a petition in vaccine court, petitioners may choose to opt out after 240 days and pursue some claims in civil court.

Civil lawsuits may also arise in cases involving:

• manufacturing defects

• failure to warn claims

• vaccines not covered under the Vaccine Injury Compensation Program

One notable example involves COVID-19 vaccines, which currently fall under a different federal compensation program.

Why Vaccine Court Exists

The Vaccine Injury Compensation Program reflects an important public policy principle.

Vaccines are one of the most effective tools for preventing infectious diseases, but no medical intervention is completely risk-free. Congress recognized that if society encourages widespread vaccination for the public good, individuals who experience rare vaccine injuries should not bear the consequences alone.

The VICP was created to provide a fair compensation system while protecting the stability of the national vaccine supply.

In many cases, this framework actually makes compensation more accessible than traditional pharmaceutical litigation. Petitioners do not need to prove negligence or defective design—they only need to demonstrate that the vaccine more likely than not caused the injury.

For many injured individuals, that legal structure offers a far more practical path to compensation than attempting to sue pharmaceutical companies directly.

Frequently Asked Questions

Can you sue Pfizer for vaccine injury?

Most vaccine injury claims (except Covid-19 vaccine) must first be filed through the Vaccine Injury Compensation Program (VICP) rather than through traditional lawsuits against pharmaceutical companies. Pfizer Covid-19 vaccine injury claims can only be filed in the CICP, not the VICP

Can you sue for COVID vaccine injury?

COVID-19 vaccine injury claims currently fall under the Countermeasures Injury Compensation Program (CICP) created under the PREP Act, which operates differently from the VICP.

What is vaccine court?

“Vaccine court” is the informal name used to describe the Vaccine Injury Compensation Program, which operates within the U.S. Court of Federal Claims and is presided over by Special Masters.

How do vaccine injury claims work?

A vaccine injury claim begins when a petitioner files a petition in the U.S. Court of Federal Claims. The Department of Health and Human Services evaluates the medical evidence and determines whether compensation should be awarded. The burden of proof is lower than in civil court and the directive of the Vaccine Act is to compensate the vaccine injured.

Definition

Vaccine court is the informal name for the National Vaccine Injury Compensation Program (VICP), a federal legal system created by Congress to resolve vaccine injury claims in the United States. Cases are heard in the U.S. Court of Federal Claims and decided by judicial officers known as Special Masters, who determine whether a vaccine caused an injury and whether compensation should be awarded.

Key Facts About Vaccine Court

• Created by the National Childhood Vaccine Injury Act of 1986
• Claims are filed in the U.S. Court of Federal Claims
• Cases are decided by Special Masters within the Office of Special Masters
• Petitioners must prove causation by a preponderance of the evidence
• Most vaccine injury claims must go through the program before civil lawsuits can be filed

Why Vaccine Court Exists

Congress created the Vaccine Injury Compensation Program during the 1980s after rising product liability lawsuits threatened the stability of the national vaccine supply. Large jury verdicts involving childhood vaccines led some manufacturers to consider leaving the vaccine market altogether.

To address this risk, Congress enacted the National Childhood Vaccine Injury Act, establishing a system that would both protect the nation’s vaccine supply and compensate individuals who suffer rare vaccine-related injuries.

Rather than requiring injured individuals to prove negligence by vaccine manufacturers, the program created a no-fault compensation system focused on whether the vaccine caused the injury. This approach was intended to allow legitimate claims to be evaluated more efficiently while preserving widespread access to vaccines.

Who Decides Cases in Vaccine Court

Vaccine injury claims are decided by Special Masters within the Office of Special Masters at the U.S. Court of Federal Claims.

Special Masters exclusively handle vaccine injury cases. They do not preside over other types of federal litigation. Unlike medical experts, Special Masters do not have scientific or medical backgrounds. They are attorneys appointed by the Court of Federal Claims who come from legal careers that may include service with the Department of Justice, representation of vaccine-injured petitioners, or private legal practice.

Because vaccine injury litigation often involves complex medical and scientific evidence, Special Masters regularly review detailed medical records, expert reports, and scientific literature when evaluating claims.

Unlike traditional civil litigation, vaccine injury cases are decided without a jury, and the proceedings focus heavily on medical causation rather than product liability or negligence.

How Vaccine Court Differs from Civil Lawsuits

Vaccine court differs significantly from traditional civil litigation against pharmaceutical companies.

In most situations, individuals who believe they were injured by a vaccine must first file a claim through the Vaccine Injury Compensation Program before pursuing a civil lawsuit. This requirement ensures that vaccine injury claims are evaluated within a specialized legal system designed to address complex medical questions.

Additionally, the Supreme Court’s decision in Bruesewitz v. Wyeth (2011) significantly limited certain product liability claims against vaccine manufacturers by holding that the Vaccine Act preempts most design defect lawsuits involving covered vaccines.

As a result, vaccine injury claims are typically resolved within the VICP rather than through traditional state or federal courts.

How Vaccine Court Fits into the Vaccine Compensation System

The Vaccine Injury Compensation Program is funded through a federal excise tax on each covered vaccine dose, which is deposited into the Vaccine Injury Compensation Trust Fund. This means compensation awards are paid from the trust fund rather than directly from vaccine manufacturers.

The program reflects a policy tradeoff created by Congress: in exchange for reduced litigation risk, vaccine manufacturers participate in a system where individuals injured by vaccines can seek compensation through a specialized legal process.

For a complete explanation of how the system works, including how claims are proven and what compensation can be awarded, see here

Why Vaccine Court Matters

Vaccines are one of the most important public health tools ever developed. They prevent disease outbreaks, reduce hospitalizations, and protect vulnerable populations such as infants, elderly individuals, and people with compromised immune systems.

At the same time, Congress recognized that no medical intervention is completely without risk. Although serious vaccine injuries are rare, the Vaccine Injury Compensation Program exists to ensure that individuals who experience those injuries have access to a fair system of compensation.

By providing a specialized forum for resolving vaccine injury claims, vaccine court helps maintain both public confidence in vaccination programs and fairness for the small number of individuals who suffer vaccine-related injuries.

Frequently Asked Questions About Vaccine Court

Is vaccine court a real court?

Yes. Vaccine injury claims are filed in the U.S. Court of Federal Claims and decided by Special Masters within the Office of Special Masters.

What is the Vaccine Injury Compensation Program?

The Vaccine Injury Compensation Program is a federal no-fault system created by Congress to compensate individuals who experience rare vaccine-related injuries.

Who decides vaccine court cases?

Cases are decided by Special Masters, attorneys appointed by the U.S. Court of Federal Claims who exclusively handle vaccine injury claims.

What must a petitioner prove in vaccine court?

Petitioners must show by a preponderance of the evidence that it is more likely than not that the vaccine caused the injury.

Can you sue vaccine manufacturers instead of going to vaccine court?

In most situations, individuals must first file a claim through the Vaccine Injury Compensation Program before pursuing civil litigation.

The Existence of the Vaccine Injury Compensation Program

One of the most important facts mentioned during the interview is that the United States operates a federal vaccine injury compensation system.

The National Vaccine Injury Compensation Program (VICP) was created by Congress in 1986 through the National Childhood Vaccine Injury Act. The program allows individuals who believe they were injured by certain vaccines to file claims in the U.S. Court of Federal Claims, where cases are decided by judicial officers known as Special Masters within the Office of Special Masters.

The VICP functions as a no-fault vaccine injury compensation system. Rather than requiring injured individuals to prove negligence or wrongdoing by a vaccine manufacturer or healthcare provider, the program evaluates whether the evidence shows that the vaccine more likely than not caused the injury. If causation is established, the program may award compensation for medical expenses, lost wages, pain and suffering, and other damages.

Since the program began operating in 1988, billions of dollars have been paid to individuals and families through the Vaccine Injury Compensation Program.

Despite this, most Americans have never heard of the VICP or understand how vaccine injury claims are handled in the United States. Public awareness of the program remains surprisingly low. The Department of Health and Human Services and the broader medical community have historically done very little to educate the public about the existence of the program or how individuals can access it.

As a result, much of the public education about vaccine injury compensation actually comes from attorneys who practice in vaccine court and represent injured petitioners.

That lack of public awareness is a legitimate issue.

The Supreme Court Limited Certain Vaccine Lawsuits

The interview also correctly references the Supreme Court’s decision in Bruesewitz v. Wyeth (2011).

In that case, the Supreme Court held that the National Childhood Vaccine Injury Act largely preempts design defect lawsuits against vaccine manufacturers for vaccines covered under the Vaccine Injury Compensation Program. In practical terms, the Court concluded that Congress intended the VICP to serve as the primary forum for resolving vaccine injury claims rather than traditional product liability litigation.

However, the decision did not eliminate all potential lawsuits against vaccine manufacturers. Claims based on manufacturing defects or failure to warn may still be brought under certain circumstances.

Importantly, the Vaccine Act requires that a vaccine injury claim first proceed through the Vaccine Injury Compensation Program before a claimant may pursue civil litigation. After filing a claim in vaccine court, a petitioner may choose to opt out of the VICP after 240 days and pursue a traditional civil lawsuit, particularly if the claim involves allegations of manufacturing defects or inadequate warnings.

This legal structure is unusual, but it was created for a specific reason: to maintain a stable vaccine supply while still providing a forum for injured individuals to seek compensation.

The VICP removes one of the most difficult hurdles present in traditional pharmaceutical litigation. Petitioners in vaccine court do not need to prove that the vaccine was defectively designed. Instead, they must demonstrate that the vaccine caused their injury.

In traditional product liability litigation, proving that a pharmaceutical product was defectively designed can be extraordinarily difficult. Vaccines are typically effective and safe for the overwhelming majority of individuals. Demonstrating that a vaccine was defective in a very small number of cases can therefore be a substantial evidentiary challenge.

The VICP was designed to lower that burden and provide a more accessible path to compensation for legitimate vaccine injuries.

Pharmaceutical Companies Do Have Significant Political Influence

Another point raised in the interview is the influence of pharmaceutical companies in the political process.

Like many large industries, pharmaceutical companies engage in lobbying and political advocacy. This is a common feature of modern regulatory systems and occurs across a wide range of sectors, including technology, energy, healthcare, and finance.

Large corporations often lobby Congress and federal agencies in order to influence policy decisions that affect their industries. While this dynamic can raise important questions about regulatory capture and industry influence, it is not unique to vaccines or the pharmaceutical industry.

At the same time, it is important to recognize that the structure created by the National Childhood Vaccine Injury Act reflects a negotiated policy framework that many stakeholders—including those who represent vaccine-injured individuals—continue to support.

Attorneys who represent injured petitioners in vaccine court, many of whom are members of the Vaccine Injured Petitioners Bar Association (VIP Bar), have historically supported the existence of the Vaccine Injury Compensation Program. The VICP provides a specialized forum where injured individuals can seek compensation without needing to prove manufacturer negligence or product defect.

The program is funded through an excise tax on each covered vaccine dose, which is deposited into the Vaccine Injury Compensation Trust Fund. That trust fund currently contains billions of dollars dedicated specifically to compensating individuals who can prove that a vaccine caused their injury.

For many practitioners who work in this field, the goal is not to dismantle the Vaccine Injury Compensation Program or create broad new avenues to sue manufacturers. If the objective is to ensure that injured individuals receive compensation, the VICP often provides a more efficient and realistic path to recovery than traditional pharmaceutical litigation.

As a result, many attorneys who represent vaccine-injured petitioners focus their efforts on preserving and improving the VICP rather than eliminating it.

Transparency From Public Health Agencies Matters

The Rogan interview also emphasizes the importance of transparency from public health agencies such as the Centers for Disease Control and Prevention and the Food and Drug Administration.

On this point, many people across the political spectrum agree. Transparency about regulatory decisions, safety monitoring, and scientific evidence is essential for maintaining public trust in vaccines and public health institutions.

At the same time, it is important to distinguish between calls for transparency and allegations that the underlying data itself is fraudulent or compromised. There is no credible evidence that vaccine safety data produced by agencies such as the CDC, FDA, or National Institutes of Health is systematically falsified, manipulated, or fraudulent.

Vaccines undergo extensive clinical testing, regulatory review, and post-licensure safety monitoring through systems such as the Vaccine Adverse Event Reporting System (VAERS) and other federal surveillance programs. These systems are designed to detect rare adverse events and continuously evaluate vaccine safety in the population.

Calls for transparency and accountability in public health policy are legitimate and important. However, where the Rogan interview begins to go off course is in how these legitimate concerns are used to support much broader claims about vaccine safety that are not supported by the scientific evidence.

Criticism of regulatory decisions should not automatically be conflated with claims that the entire system of vaccine safety monitoring is fundamentally corrupt or fraudulent.

Maintaining that distinction is essential for having a serious and productive public conversation about vaccines, vaccine policy, and vaccine injury compensation.

Unpacking the False Rhetoric from the Joe Rogan - Aaron Siri Podcast

Claim: “Vaccines Are the Only Product You Cannot Sue Over”

The framing used in the Rogan interview suggests that the inability to sue vaccine manufacturers in traditional product liability litigation represents a denial of justice. But this argument misunderstands the fundamental purpose of injury litigation.

The purpose of a product liability lawsuit is ultimately to obtain compensation for an alleged injury. Whether that compensation comes through a jury verdict or through a statutory compensation system does not change the underlying objective: providing financial recovery for individuals who can demonstrate that a product caused harm.

Congress recognized this when it created the Vaccine Injury Compensation Program in 1986. Rather than forcing injured individuals to navigate complex pharmaceutical litigation, Congress created a specialized compensation system with a lower evidentiary burden. Petitioners in vaccine court do not need to prove that a vaccine was defectively designed or manufactured. Instead, they must demonstrate that it is more likely than not that the vaccine caused the injury.

This distinction is important because many vaccine injuries do not arise from defective products in the traditional sense. Vaccines are designed to stimulate the immune system. In rare cases, an individual’s immune response may become abnormal or dysregulated, leading to neurological or autoimmune complications. In those situations, the vaccine itself may function exactly as intended while still triggering an adverse outcome in a susceptible individual.

Traditional product liability law is poorly suited to address these kinds of cases because it focuses on whether a product was defectively designed or manufactured. The Vaccine Injury Compensation Program instead focuses on the central question that matters most to injured individuals: did the vaccine cause the injury?

By removing the need to prove defect and replacing it with a causation-based standard, Congress created a system that can actually make compensation more accessible rather than less.

The debate therefore should not be framed around whether injured individuals can sue vaccine manufacturers. The more relevant question is whether individuals who experience rare vaccine injuries have access to a compensation system that is fair, efficient, and capable of evaluating complex medical evidence.

That is precisely the role the Vaccine Injury Compensation Program was designed to serve.

Claim: “The Vaccine Act Was Passed Because Vaccines Were Causing So Much Harm”

Another assertion made during the interview is that the National Childhood Vaccine Injury Act of 1986 was passed because vaccines were causing widespread harm.

The historical record shows something very different.

The Vaccine Act was enacted during the early 1980s after a surge in product liability litigation created a liability crisis for vaccine manufacturers. As lawsuits increased, the number of companies willing to manufacture vaccines declined sharply. By the mid-1980s, the number of vaccine manufacturers in the United States had fallen dramatically—from approximately 18 companies to only four producing vaccines for the U.S. market.

Congress became concerned that continued litigation could destabilize the national vaccine supply and potentially lead to shortages of essential vaccines used in childhood immunization programs. Historical analyses of the period confirm that policymakers feared the United States might lose the capacity to produce certain vaccines entirely if manufacturers continued to exit the market due to liability exposure. (See Institute of Medicine, Adverse Effects of Vaccines: Evidence and Causality; JAMA Pediatrics, historical review of the Vaccine Injury Compensation Program.)

The Vaccine Act was therefore designed to solve two problems simultaneously.

First, it created a federal compensation system for individuals who experience rare vaccine injuries. Second, it stabilized the vaccine market by reducing the unpredictability and cost of traditional product liability litigation.

The structure of the law reflects a negotiated policy compromise. Vaccine manufacturers agreed to fund a compensation system through a federal excise tax on each covered vaccine dose, which is deposited into the Vaccine Injury Compensation Trust Fund. In exchange, most vaccine injury claims would first proceed through the Vaccine Injury Compensation Program rather than through traditional civil litigation.

Importantly, the creation of the VICP was not based on a conclusion that vaccines were causing widespread harm. Rather, it reflected a practical recognition by Congress, attorneys representing injured individuals, and vaccine manufacturers that traditional civil litigation was poorly suited to resolving vaccine injury claims.

In many vaccine injury cases, the injury alleged is not the result of a defective product in the conventional sense. Vaccines function by stimulating the immune system. In rare cases, that immune response may become abnormal or dysregulated in a particular individual. Proving in civil court that a vaccine increased the risk of a specific injury would often require large epidemiological studies or scientific evidence that simply does not exist for extremely rare conditions.

Congress recognized that attempting to prove these cases under traditional tort standards would often be impossible. The problem would become even more difficult after the Supreme Court’s Daubert v. Merrell Dow Pharmaceuticals (1993) decision, which significantly tightened the evidentiary standards governing expert testimony in civil litigation.

The Vaccine Injury Compensation Program was therefore designed as a more flexible and scientifically informed forum where claims could be evaluated using a lower evidentiary standard focused on causation rather than product defect.

In short, the Vaccine Act was not passed because vaccines were causing widespread harm. It was passed because policymakers recognized that the existing tort system could neither reliably compensate injured individuals nor preserve the stability of the national vaccine supply.

The VICP was created to accomplish both goals.

Claim: “Vaccines Are Not Tested Like Other Medical Products”

The interview also suggested that vaccines are uniquely unsafe because they are not tested with long-term placebo-controlled trials. This claim misunderstands how vaccine development and clinical trials work in modern medicine.

Vaccines undergo a rigorous, multi-stage scientific process that typically takes 10–15 years from early research to regulatory approval. In the United States, vaccine development and licensure are overseen by the Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER), which regulates vaccines and other biological products. Each stage of development is designed to evaluate safety, effectiveness, and manufacturing quality before a vaccine can be licensed for public use. (FDA, Vaccine Development – 101; CDC, Ensuring the Safety of Vaccines in the United States).

How Vaccine Development and Clinical Trials Work

Vaccine development typically proceeds through several stages.

1. Preclinical research

Before a vaccine is ever tested in humans, it undergoes extensive laboratory and animal testing. During this stage, researchers evaluate the biological mechanism of the vaccine candidate and determine whether it produces the desired immune response. Scientists also study potential toxicity, dosing levels, and how the immune system responds to the vaccine antigen.

Preclinical research often involves cell culture experiments and animal models to identify potential safety concerns before human trials begin. These studies help determine whether a vaccine candidate is likely to be safe enough to move into human testing and whether it generates an immune response capable of protecting against disease. (World Health Organization, Vaccine Safety Basics; Plotkin, Orenstein & Offit, Vaccines, 7th ed.).

2. Phase I clinical trials

If preclinical research shows promising results, the vaccine candidate moves into Phase I clinical trials, the first stage of testing in humans.

Phase I trials typically involve 20 to 100 healthy volunteers. The primary goal at this stage is to evaluate safety and determine appropriate dosing. Researchers carefully monitor participants for side effects and collect preliminary data about the immune response produced by the vaccine.

Because vaccines are given to healthy individuals—often including children—safety monitoring during Phase I trials is particularly rigorous. Investigators track both short-term reactions, such as fever or soreness at the injection site, and early indicators of immune response. (FDA Center for Biologics Evaluation and Research; National Institute of Allergy and Infectious Diseases).

3. Phase II clinical trials

Phase II trials expand the study population to several hundred participants and continue evaluating safety while refining dosing schedules and assessing immune responses across different age groups.

At this stage, researchers determine the optimal number of doses, spacing between doses, and whether the vaccine produces a consistent immune response across populations that will eventually receive the vaccine. These trials also provide additional safety data and help identify less common side effects. (CDC, Vaccine Testing and the Approval Process; WHO Vaccine Development Guidelines).

4. Phase III clinical trials

Phase III clinical trials are the largest and most comprehensive stage of vaccine testing before regulatory approval. These studies typically involve thousands to tens of thousands of participants across multiple clinical sites.

Participants are divided into groups that receive either the vaccine candidate or a control intervention. Researchers then monitor participants over time to determine how well the vaccine prevents disease and to identify rare adverse events that may occur.

Because rare side effects may only appear when a vaccine is administered to large numbers of people, Phase III trials are critical for establishing a vaccine’s safety profile. For many vaccines, these trials involve tens of thousands of participants followed over extended periods before regulators review the data.

After reviewing Phase III results, the FDA evaluates the vaccine’s safety, effectiveness, manufacturing processes, and quality control systems before granting licensure. (FDA, Vaccine Development and Approval Process; Institute of Medicine, Adverse Effects of Vaccines: Evidence and Causality).

Why Placebo-Controlled Trials Are Not Always Used in Vaccine Research

The interview also implied that vaccines are unsafe because many vaccine trials do not use inert placebo controls. This claim overlooks an important ethical principle in medical research.

Placebo-controlled trials are commonly used when no effective treatment or preventive measure already exists. However, once an effective vaccine has been developed to prevent a serious disease, withholding that protection from study participants by giving them an inert placebo may expose them to unnecessary risk.

For this reason, many vaccine trials compare new vaccines to existing licensed vaccines rather than inert placebos. This approach, known as an active comparator trial, allows researchers to evaluate the safety and effectiveness of the new vaccine while still providing participants with protection against the disease.

This practice is consistent with internationally recognized ethical standards for human research. The Declaration of Helsinki, which governs medical research involving human subjects, states that placebo-controlled trials should not be used when doing so would deny participants access to an effective intervention. (World Medical Association, Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects).

Regulatory agencies such as the FDA and the World Health Organization recognize that vaccine trials may appropriately use active comparators when an effective vaccine already exists. This approach ensures that new vaccines can be evaluated safely and ethically while maintaining scientific rigor. (WHO, Guidelines on Clinical Evaluation of Vaccines).

Post-Licensure Safety Monitoring

Safety evaluation does not end when a vaccine is approved.

After licensure, vaccines continue to be monitored through multiple surveillance systems that track safety across millions of doses administered. In the United States, these systems include:

• the Vaccine Adverse Event Reporting System (VAERS)

• the Vaccine Safety Datalink (VSD)

• the Clinical Immunization Safety Assessment (CISA) Network

These systems allow researchers and public health agencies to detect extremely rare adverse events that may not appear during clinical trials and to continuously evaluate vaccine safety in the population. (CDC, Vaccine Safety Monitoring Systems).

Together, the processes of preclinical research, phased clinical trials, regulatory review, and ongoing safety monitoring form the foundation of modern vaccine safety evaluation.

Claim: “Measles Was Not a Serious Public Health Threat”

The interview also suggested that measles deaths were minimal prior to vaccination and therefore the disease was not a significant public health concern.

This framing relies on a selective interpretation of the historical record.

While it is true that measles mortality declined significantly in the United States during the early 20th century due to improvements in sanitation, nutrition, and medical care, measles remained a major public health problem before the introduction of the measles vaccine in 1963.

According to the Centers for Disease Control and Prevention (CDC), before vaccination became widespread in the United States, measles infected approximately 3 to 4 million Americans each year. Of those infections, roughly 48,000 people were hospitalized annually, about 1,000 individuals developed encephalitis (brain inflammation), and 400 to 500 people died each year (CDC, History of Measles in the United States).

These numbers illustrate why focusing solely on mortality can be misleading. Even when death rates declined, measles continued to cause large numbers of hospitalizations and serious complications, particularly among young children.

Measles and Neurological Complications

One of the most serious complications associated with measles infection is measles encephalitis, an inflammatory condition affecting the brain. Encephalitis can result in permanent neurological damage, including cognitive impairment, seizures, hearing loss, and developmental disabilities.

Another rare but devastating complication is subacute sclerosing panencephalitis (SSPE), a progressive neurological disorder caused by persistent measles virus infection in the brain. SSPE typically develops years after the initial measles infection and is almost always fatal (National Institute of Neurological Disorders and Stroke, Subacute Sclerosing Panencephalitis Information Page; World Health Organization, Measles Fact Sheet).

Research has also shown that measles infection can produce what scientists call “immune amnesia.” This occurs when the virus damages immune memory cells, weakening the body’s ability to fight other infections for months or even years after recovery. A 2019 study published in Science found that measles infection can significantly reduce preexisting immune protection against other pathogens (Mina et al., Science, 2019).

Measles Outbreaks Today

Despite the availability of a highly effective vaccine, measles outbreaks still occur when vaccination coverage declines. In the United States, most recent outbreaks have been linked to clusters of unvaccinated individuals, often in communities with low vaccination rates or among international travelers who introduce the virus into susceptible populations (CDC, Measles Cases and Outbreaks).

Globally, measles remains a significant public health concern. The World Health Organization estimates that measles caused approximately 136,000 deaths worldwide in 2022, primarily among unvaccinated children (World Health Organization, Measles Fact Sheet).

These statistics highlight the central point often lost in debates about measles: vaccination dramatically reduced the number of infections, hospitalizations, and severe complications associated with the disease.

The fact that measles deaths declined before the vaccine was introduced does not mean the disease was harmless. Rather, it reflects broader improvements in living conditions and medical care that reduced mortality from many infectious diseases during the same period.

Vaccination ultimately addressed a different problem—preventing the millions of infections and serious complications that continued to occur each year.

Claim: “There Are No Studies Showing Vaccines Do Not Cause Autism”

The interview repeatedly asserted that there are no studies showing that vaccines do not cause autism. This claim misrepresents both the scientific literature and the legal history of autism-related vaccine litigation.

Multiple large epidemiological studies involving hundreds of thousands to millions of children have examined potential links between vaccines and autism spectrum disorders. These studies have consistently found no causal relationship between vaccines and autism. Research conducted in multiple countries—including Denmark, Sweden, the United States, and Japan—has repeatedly examined vaccination status and autism diagnoses across large populations without finding evidence that vaccines increase the risk of autism. (See, e.g., Hviid et al., Annals of Internal Medicine, 2019; Taylor et al., Vaccine, 2014).

Autism Claims Were Extensively Litigated in Vaccine Court

Claims that vaccines cause autism were litigated extensively within the Vaccine Injury Compensation Program, particularly through the Autism Omnibus Proceeding. Beginning in the early 2000s, thousands of petitions were filed in vaccine court alleging that vaccines—most prominently the measles, mumps, and rubella (MMR) vaccine or vaccines containing the preservative thimerosal—caused autism.

To address these claims efficiently, the Court of Federal Claims consolidated several representative cases and conducted lengthy evidentiary hearings involving expert testimony, epidemiological studies, and scientific literature. After reviewing the evidence, the Special Masters issued detailed decisions rejecting the theory that vaccines cause autism.

The court ultimately concluded that the evidence presented did not establish a causal link between vaccines and autism. As a result, the test cases in the Autism Omnibus Proceeding were denied. While individual claims can still be brought under different factual circumstances, the litigation established that, based on the available evidence, a direct causal connection between vaccines and autism had not been demonstrated within the Vaccine Injury Compensation Program.

The Role of the Wakefield Study

One of the most widely cited pieces of evidence used to support the claim that vaccines cause autism was a 1998 study published in The Lancet by British physician Andrew Wakefield. The study suggested a potential connection between the MMR vaccine and autism.

However, subsequent investigations revealed serious problems with the study. In 2011, an investigation published in the British Medical Journal concluded that Wakefield had manipulated patient data and misrepresented clinical findings in the research (Godlee, Smith & Marcovitch, BMJ, 2011).

The investigation found that several of the children described in the study had medical histories that were altered or inaccurately reported in order to support the hypothesis linking the MMR vaccine to autism. Additional conflicts of interest were also uncovered, including undisclosed financial arrangements related to litigation against vaccine manufacturers.

As a result of these findings, The Lancet fully retracted the Wakefield paper, and Wakefield lost his medical license in the United Kingdom. The study is now widely regarded as one of the most prominent examples of scientific misconduct in modern medical research.

What the Scientific Literature Actually Shows

The claim that there are “no studies showing vaccines do not cause autism” is also misleading from a scientific perspective.

In epidemiology, researchers typically examine whether exposure to a factor increases the risk of a particular condition. When large, well-designed studies repeatedly fail to find an increased risk, the scientific conclusion is that no causal relationship has been demonstrated.

Numerous population-based studies have examined whether vaccines increase the risk of autism. These studies include large cohort analyses involving hundreds of thousands—and in some cases over one million—children. The consistent finding across this research is that vaccination does not increase the risk of autism spectrum disorder.

In other words, the available scientific evidence does not support the claim that vaccines cause autism.

A More Nuanced Issue: Vaccine-Associated Encephalitis

While the direct vaccine–autism theory has not been supported by the evidence, there is credible medical literature showing that vaccines can, in extremely rare cases, cause encephalitis, which is inflammation of the brain.

Both the MMR vaccine and certain other vaccines have been associated with rare instances of encephalitis. Encephalitis can cause neurological injury, including cognitive and developmental impairments. In some cases, children who suffer encephalitis may later develop symptoms consistent with autism spectrum disorders.

The Vaccine Injury Compensation Program recognizes this possibility. Claims involving vaccine-related encephalitis are routinely evaluated and, when causation is established, compensated through the program.

This distinction is important. While vaccine court has rejected the theory that vaccines directly cause autism, it does recognize that vaccine-induced neurological injuries such as encephalitis can lead to long-term neurological impairment, which in some cases may present with autism-like symptoms.

The Current Scientific Consensus

The broader scientific consensus remains that vaccines have not been shown to increase the risk of autism. Claims to the contrary generally rely on misinterpretations of the literature or on studies that have been discredited.

That does not mean the science surrounding autism is complete. Autism spectrum disorder is a complex condition that likely involves multiple genetic and environmental factors. Continued research is needed to better understand the causes of autism and how best to support individuals and families affected by it.

But the assertion that there are no studies examining vaccines and autism—or that vaccines have been shown to increase the risk of autism—is not supported by the scientific evidence currently available.

Why the Rogan–Siri Narrative Ultimately Harms the Vaccine Injury Compensation Program

The irony of much of the Rogan–Siri conversation is that while it raises concerns about vaccine injuries and pharmaceutical accountability, the narrative presented ultimately undermines the very system designed to help individuals who believe they were injured by vaccines.

The Vaccine Injury Compensation Program exists precisely because Congress recognized two realities. First, vaccines are one of the most important public health tools ever developed. Second, like any medical intervention administered to millions of people, rare adverse events can occur. The Vaccine Act created a framework intended to balance those two realities by ensuring that individuals who experience rare vaccine-related injuries have access to a fair compensation system.

When discussions about vaccine law become dominated by sensational claims—such as the idea that vaccines are uniquely shielded from accountability or that the compensation system exists to hide vaccine injuries—it erodes public understanding of how the system actually works.

In reality, the Vaccine Injury Compensation Program was designed to make compensation more accessible, not less. Petitioners in vaccine court are not required to prove negligence, product defect, or wrongdoing by vaccine manufacturers. Instead, they must demonstrate that it is more likely than not that the vaccine caused the injury, a significantly lower evidentiary burden than what is required in traditional pharmaceutical litigation.

For many injured individuals, this framework offers a far more realistic path to compensation than attempting to litigate complex pharmaceutical product liability cases in state or federal court.

Unfortunately, narratives that portray the Vaccine Act as a system designed to shield pharmaceutical companies from accountability can discourage injured individuals from pursuing claims through the very program that exists to help them.

A Missing Piece in the Conversation: COVID Vaccines and the VICP

Perhaps the most important issue that received little attention in the Rogan interview is that COVID-19 vaccines are not currently covered by the Vaccine Injury Compensation Program.

Instead, injuries related to COVID vaccines fall under the Public Readiness and Emergency Preparedness Act (PREP Act), which places those claims within the Countermeasures Injury Compensation Program (CICP).

The CICP operates very differently from the VICP. It provides significantly more limited compensation, offers little opportunity for judicial review, and historically has compensated very few claims.

As a result, individuals who believe they were injured by COVID vaccines face a far more difficult path to obtaining compensation than individuals injured by vaccines covered under the VICP.

A Practical Solution Exists

If the goal is truly to help individuals who believe they were injured by vaccines, one of the most meaningful reforms available would be to move COVID vaccines into the Vaccine Injury Compensation Program.

The Secretary of Health and Human Services has the authority to add vaccines to the Vaccine Injury Table and bring them within the VICP framework.

Interestingly, Aaron Siri has served as legal counsel to Health and Human Services Secretary Robert F. Kennedy Jr.

If the focus of the Rogan discussion is genuinely on improving accountability and helping vaccine-injured individuals, advocating for the inclusion of COVID vaccines within the VICP would be a far more constructive step than promoting narratives that undermine public confidence in the existing compensation system.

The Conversation We Should Be Having

Public debates about vaccines often become polarized, with discussions drifting into ideology rather than focusing on practical policy solutions.

But the question that should be at the center of the conversation is simple:

If society encourages vaccination for the public good, how do we ensure that the small number of individuals who experience vaccine injuries are treated fairly?

The Vaccine Injury Compensation Program was created to answer that question.

Strengthening the program—and ensuring that it covers the vaccines people receive—would do far more to support injured individuals than rhetoric that misrepresents how vaccine law actually works.

Why Accuracy Matters

Public conversations about vaccines often become polarized and ideological. But vaccine injury compensation is not a partisan issue, and it should not be reduced to sensational talking points designed to generate clicks or controversy.

Suggesting on a major public platform that vaccines are unsafe because they are not properly tested is a serious claim. It is also critically incorrect. Vaccines undergo extensive clinical testing, regulatory review, and ongoing safety monitoring before and after they are introduced into the public health system. These safeguards exist precisely because vaccines are administered to large populations, including children.

At the same time, acknowledging that vaccines are overwhelmingly safe does not mean ignoring the reality that rare adverse events can occur. That recognition is exactly why Congress created the Vaccine Injury Compensation Program.

The VICP represents a unique legal framework designed to balance two important goals: maintaining a stable and reliable vaccine supply while ensuring that individuals who experience rare vaccine-related injuries have access to a meaningful compensation system.

When discussions about vaccine law become dominated by sensational rhetoric or misleading claims, it undermines public understanding of both vaccine safety and the legal protections that exist for those who are injured. That confusion can discourage people from pursuing legitimate claims through the system designed to help them.

Accuracy and truth matter—particularly when the topic is public health.

Educating the public about the safety and effectiveness of vaccines must go hand in hand with educating them about the legal safeguards in place when rare injuries occur. Setting the record straight ultimately benefits everyone: the public, the legal system, and most importantly, the individuals and families who rely on the Vaccine Injury Compensation Program when rare vaccine injuries occur.

This system is called the National Vaccine Injury Compensation Program (VICP)—often referred to as “vaccine court.”

Congress created the program in the 1980s after concerns arose that lawsuits against vaccine manufacturers could threaten the stability of the national vaccine supply. The result was a system designed to balance two important goals:

1. Protect the public by maintaining a stable vaccine supply, and

2. Provide compensation to individuals who suffer rare vaccine-related injuries.

Today, the Vaccine Injury Compensation Program (VICP) remains the primary legal pathway for resolving vaccine injury claims in the United States.

The Law That Created Vaccine Court

The Vaccine Injury Compensation Program was created by the National Childhood Vaccine Injury Act of 1986, which amended the Public Health Service Act and established a new framework for resolving vaccine injury claims in the United States.

The statute establishing the program can be found here:

National Childhood Vaccine Injury Act (Public Health Service Act §§ 300aa-1 through 300aa-34) https://www.hrsa.gov/sites/default/files/hrsa/vicp/title-xxi-phs-vaccines-1517.pdf

Congress enacted the Vaccine Act during a period of growing litigation against vaccine manufacturers in the early 1980s. Large product liability verdicts, particularly involving the DPT vaccine, created significant uncertainty in the vaccine market. Several manufacturers considered leaving the market altogether, raising concerns that the nation’s vaccine supply—and routine childhood immunization programs—could be jeopardized.

The Vaccine Act was designed to solve two problems at once. First, it created a remedial vaccine injury compensation program for individuals who experience rare but serious vaccine injuries. Second, it provided liability protections for vaccine manufacturers and administrators to help ensure that vaccines remained widely available.

Under this framework, individuals who believe they were injured by a covered vaccine may file a petition in the National Vaccine Injury Compensation Program (VICP) rather than pursuing traditional civil litigation. The program operates as a no-fault vaccine injury compensation system, meaning petitioners do not need to prove negligence, product defect, or wrongdoing by a manufacturer. Instead, the central question is whether the vaccine caused or contributed to the injury.

Congress intentionally established a lower evidentiary burden than traditional civil courts to help ensure that individuals with plausible vaccine injury claims could receive compensation more efficiently. The goal was not to determine whether vaccines are generally safe or unsafe, nor to serve as a forum for resolving broader scientific debates about vaccine safety.

Rather, the VICP was created as a remedial compensation system—one designed to provide relatively quick and generous compensation when causation can be established, while preserving public confidence in vaccination programs.

The tradeoff created by the Vaccine Act was clear: in exchange for reduced litigation risk, vaccine manufacturers and administrators agreed to participate in a system where individuals injured by recommended vaccines could seek compensation through a specialized legal process. Vaccines recommended for routine use in children are therefore generally covered by the program.

This framework reflects an important public health principle: vaccination benefits society as a whole, but when rare injuries occur, those individuals should not bear the cost alone.

What Is the Vaccine Injury Compensation Program?

The Vaccine Injury Compensation Program (VICP) is a federal program that resolves vaccine injury claims through a specialized legal process administered by the U.S. Court of Federal Claims.

Rather than being handled in traditional civil courts, vaccine injury cases are heard by judicial officers known as Special Masters within the court’s Office of Special Masters.

These officials focus exclusively on vaccine injury litigation and routinely evaluate complex medical records, expert testimony, and scientific evidence.

The program is funded through a federal excise tax on each covered vaccine dose, which is deposited into the Vaccine Injury Compensation Trust Fund. This funding mechanism means that compensation awards do not come from general taxpayer revenue but from the vaccine program itself.

Several government entities participate in the Vaccine Injury Compensation Program and play distinct roles in the adjudication process.

Petitioner

The injured individual—or, in cases involving minors or deceased individuals, a parent, guardian, or estate representative—who files the vaccine injury claim.

Petitioners are typically represented by attorneys experienced in Vaccine Act litigation. Many of these attorneys are members of the Vaccine Injured Petitioners Bar Association, a professional organization composed of lawyers who regularly represent petitioners in vaccine court proceedings.

Department of Health and Human Services (HHS)
The Department of Health and Human Services administers the Vaccine Injury Compensation Program and conducts the initial medical review of each petition. Medical experts within HHS evaluate the petitioner’s medical records and scientific evidence to determine whether the government will concede that the vaccine caused the injury or contest the claim. HHS also maintains and updates the Vaccine Injury Table, which lists injuries that are presumed to be caused by certain vaccines if they occur within specified time frames. The department determines which vaccines are covered under the program and which injuries qualify for table presumptions. For example, HHS has thus far declined to add COVID-19 vaccines to the Vaccine Injury Table, meaning those injuries currently fall outside the VICP and instead are addressed through a different federal compensation program.

Department of Justice (DOJ)
Attorneys from the Department of Justice represent the Secretary of Health and Human Services in vaccine court proceedings. In this role, DOJ attorneys serve as the legal adversaries to petitioners’ counsel. They evaluate the medical evidence, negotiate settlements when appropriate, and litigate contested claims before the Office of Special Masters. The DOJ is also responsible for processing compensation awards once a case is resolved.

Special Masters
Special Masters are the judicial officers who preside over vaccine injury cases and ultimately determine whether compensation should be awarded. They are not traditional federal or state judges; rather, they are appointed by the U.S. Court of Federal Claims to serve renewable four-year terms. Special Masters conduct hearings, review expert reports, evaluate medical records, and issue written decisions resolving vaccine injury claims. Their decisions can be appealed to judges of the U.S. Court of Federal Claims, who serve as the appellate authority within the vaccine program. Unlike traditional civil litigation, vaccine injury claims are decided without a jury, and the proceedings are designed to focus heavily on medical evidence and expert testimony.

Together, these participants form the structure of the Vaccine Injury Compensation Program, a system intended to provide a specialized forum for resolving vaccine injury claims while maintaining the stability of the national vaccination program.

What Counts as a Vaccine Injury?

Table Injuries

Within the Vaccine Injury Compensation Program, some injuries are recognized on what is known as the Vaccine Injury Table. These are injuries for which the scientific evidence linking a specific vaccine to a specific condition is strong enough that the government has made a policy determination to presume causation when certain criteria are met.

In practical terms, a Table injury exists when three elements are satisfied:

1. A covered vaccine was administered.

2. The petitioner developed a specific injury listed on the Vaccine Injury Table.

3. The symptoms began within a defined time period after vaccination.

When these criteria are met, the law presumes that the vaccine caused the injury, unless the government can demonstrate that another factor caused the condition. This presumption significantly reduces the evidentiary burden placed on petitioners.

A commonly cited example involves Guillain-Barré Syndrome (GBS). GBS is recognized as a Table injury only in connection with the influenza vaccine, and only when the onset of symptoms occurs between 3 and 42 days after vaccination. If those conditions are satisfied, causation is presumed.

Although the Vaccine Injury Table exists to simplify certain claims, it is relatively limited in scope. Only a small number of injuries currently qualify for the presumption of causation, and in practice two of the most frequently litigated Table injury claims are:

• Shoulder Injury Related to Vaccine Administration (SIRVA)
• Guillain-Barré Syndrome following influenza vaccination

Because these cases involve injuries that have already been recognized by the Vaccine Injury Table, they are typically handled through a specialized division of vaccine court known as the Special Processing Unit (SPU). The SPU operates under the direction of the Chief Special Master and a team of staff attorneys who focus on resolving these cases more efficiently, often through streamlined proceedings and settlements.

Off-Table Injuries (Causation-in-Fact)

While Table injuries receive the most public attention, the majority of vaccine injury cases are actually off-table claims.

An off-table injury is any condition that does not appear on the Vaccine Injury Table. In these cases, petitioners must prove that the vaccine caused their injury through a legal framework known as causation-in-fact.

These cases are typically assigned to the remaining Special Masters within the Office of Special Masters and are evaluated under the legal standard established by the Federal Circuit in Althen v. Secretary of Health and Human Services.

Under Althen, petitioners must establish three elements to prove causation:

1. A medically plausible theory of causation
The petitioner must present a scientifically credible explanation for how the vaccine could cause the type of injury alleged. This does not require definitive scientific proof but must be grounded in sound medical reasoning.

2. A logical sequence of cause and effect
The petitioner must show that the facts of the case support the theory that the vaccine caused the injury in that specific individual. This often involves medical records documenting symptoms, physician observations, and expert testimony connecting the theory to the patient’s clinical course.

3. A proximate temporal relationship between vaccination and injury
The onset of symptoms must occur within a timeframe that is medically consistent with the proposed mechanism of injury. Timing alone is not enough to prove causation, but an appropriate temporal relationship is a necessary component of the analysis.

Together, these three elements form the foundation of causation-in-fact analysis in vaccine court.

Off-Table Vaccine Injuries

Off-table cases often involve complex neurological, autoimmune, or inflammatory conditions where medical experts must explain how an immune response triggered by vaccination could lead to the injury.

Some of the more commonly litigated off-table claims include:

Neurological and demyelinating disorders

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Guillain-Barré Syndrome variants (AIDP, AMAN, AMSAN)
• Transverse Myelitis
• Acute Disseminated Encephalomyelitis (ADEM)
• Neuromyelitis Optica
• MOG Antibody Disease (MOGAD)
• Optic Neuritis
• Encephalitis

Peripheral nerve and autonomic disorders

• Small Fiber Neuropathy (SFN)
• Postural Orthostatic Tachycardia Syndrome (POTS)
• Acute Panautonomic Neuropathy
• Parsonage-Turner Syndrome (Brachial Neuritis)
• Polyneuritis Cranialis

Autoimmune and inflammatory disorders

• Myasthenia Gravis
• Dermatomyositis
• Autoimmune Hepatitis
• Autoimmune Hemolytic Anemia
• Aplastic Anemia
• Granulomatosis with Polyangiitis
• Polyarteritis Nodosa
• Henoch-Schönlein Purpura
• Vasculitis

Other immune-mediated conditions

• Immune Thrombocytopenia (ITP)
• Narcolepsy
• Uveitis
• Pemphigus
• Linear IgA Bullous Dermatosis
• Complex Regional Pain Syndrome (CRPS)

These cases frequently require detailed medical expert reports and scientific literature to explain the potential immune-mediated mechanisms linking vaccination to the injury.

Why the Distinction Matters

The distinction between Table injuries and off-table causation-in-fact cases reflects the structure Congress created when it enacted the Vaccine Act.

Table injuries allow the program to quickly compensate individuals with well-recognized vaccine reactions, while off-table cases ensure that individuals with less commonly recognized conditions still have an opportunity to establish causation through medical evidence.

Together, these two pathways allow the Vaccine Injury Compensation Program to function as a remedial compensation system that addresses plausible vaccine injuries while maintaining the stability of the national vaccination program.

What Are the Most Common Vaccine Injuries?

Vaccines are among the most carefully studied medical products in modern medicine and remain overwhelmingly safe. However, as Congress recognized when it enacted the Vaccine Act, rare adverse reactions can occur. These reactions form the basis of vaccine injury claims brought in the Vaccine Injury Compensation Program.

Among the most commonly litigated vaccine injury claims are Shoulder Injury Related to Vaccine Administration (SIRVA) and Guillain-Barré Syndrome (GBS) following influenza vaccination. SIRVA occurs when a vaccine is administered too high in the shoulder joint, causing inflammation or injury to structures such as the bursa, rotator cuff tendons, or surrounding tissues. Guillain-Barré Syndrome is a neurological disorder in which the immune system attacks peripheral nerves, potentially leading to weakness, paralysis, and other neurological complications.

Many vaccine injury claims are also brought as off-table injuries, meaning the condition does not appear on the Vaccine Injury Table and causation must be proven through medical evidence and expert testimony. Some of the most frequently litigated off-table vaccine injury claims include immune thrombocytopenia (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), and brachial neuritis (Parsonage-Turner syndrome).

These cases often involve complex neurological or immune-mediated mechanisms and typically require expert testimony explaining how an immune response triggered by vaccination could plausibly lead to the injury.

How Vaccine Injury Claims Are Proven

Vaccine injury claims are decided using a legal standard known as preponderance of the evidence. This standard is lower than the burden typically required in traditional civil litigation and reflects Congress’s intent that the Vaccine Injury Compensation Program function as a remedial compensation system rather than a fault-based lawsuit.

Under this standard, the petitioner must demonstrate that it is more likely than not that the vaccine caused or significantly contributed to the injury. Petitioners are not required to prove causation with absolute scientific certainty or establish negligence by a vaccine manufacturer or administrator. Instead, the Special Master evaluates whether the totality of the evidence supports a plausible causal relationship between the vaccination and the injury.

Evidence in vaccine injury cases usually includes:

• medical records, including vaccination documentation and records showing the onset and progression of symptoms
• witness affidavits, often from the petitioner or family members describing the timing and development of symptoms
• treating physician opinions, which may document early suspicion of a vaccine-related injury
• expert medical reports from qualified specialists such as neurologists, rheumatologists, orthopedic surgeons, and immunologists
• scientific and medical literature discussing potential biological mechanisms linking vaccination to the injury
• temporal evidence, showing that symptoms began within a medically reasonable timeframe after vaccination

Special Masters review all submitted evidence—including expert testimony, medical literature, and factual records—to determine whether the petitioner has established a logical and medically plausible causal connection between the vaccine and the injury.

What Compensation Can Be Awarded?

If a petitioner successfully proves a vaccine injury claim, the Vaccine Injury Compensation Program (VICP) may award several categories of compensation designed to address both the economic and non-economic impact of the injury. The purpose of the program is to place the injured individual as close as possible to the financial position they would have been in had the injury not occurred.

1. Past and Future Medical Expenses
The program may reimburse medical expenses related to the vaccine injury that were not covered by health insurance. This can include hospitalizations, physician visits, surgeries, rehabilitation services, medications, diagnostic testing, assistive devices, and other treatment-related costs necessary to manage the injury both now and in the future.

2. Lost Wages and Loss of Earning Capacity
Petitioners may receive compensation for income lost as a result of the injury. This includes both past wages lost while the injured individual was unable to work and future income losses if the injury limits the individual’s ability to return to their previous occupation or maintain full-time employment.

3. Pain and Suffering
The program allows compensation for pain and suffering, which includes physical pain, emotional distress, and diminished quality of life resulting from the injury. Under the Vaccine Act, these damages are capped at $250,000.

4. Future Care Costs
In cases involving permanent or long-term injuries, compensation may include funding for future medical care and life-care needs. These damages are often calculated using detailed life-care plans prepared by medical or nursing experts that outline expected future treatments, therapies, medications, and supportive services.

5. Death Benefit
If a vaccine injury results in death, the program may award a death benefit to surviving family members.

6. Attorney’s Fees and Costs
The Vaccine Act also allows attorney’s fees and litigation costs to be paid separately by the program, provided the claim was filed in good faith and supported by a reasonable basis. This provision ensures that individuals can pursue legitimate claims without bearing the financial burden of legal representation.

How Long Vaccine Injury Cases Take

The timeline for resolving a vaccine injury claim varies significantly depending on the complexity of the case, the type of injury alleged, and whether the government concedes or contests causation. While some claims resolve relatively quickly through settlement, others—particularly complex neurological or autoimmune cases—can take several years to reach a final decision.

The process generally unfolds in several stages.

1. Medical Treatment and Documentation of the Injury
Before a case can be filed, the injured individual must typically experience symptoms of the alleged vaccine injury for at least six months. This requirement is part of the Vaccine Act’s statutory severity requirement, which ensures that only injuries causing significant or lasting harm are eligible for compensation. An exception exists when the injury results in surgery requiring hospitalization, in which case a claim may be filed sooner.

2. Collection of Medical Records
Prior to filing the claim, attorneys must obtain and review extensive medical records documenting the petitioner’s medical history, vaccination records, and treatment following the injury. These records often include years of pre-vaccination medical history, vaccination documentation, diagnostic testing, physician notes, and specialist evaluations.

3. Filing the Petition in the U.S. Court of Federal Claims
Once the records have been collected and reviewed, a petition is filed with the U.S. Court of Federal Claims, initiating the case within the Vaccine Injury Compensation Program.

4. Court Review of the Petition and Medical Records
After filing, the court conducts an initial review to ensure that the petition and supporting medical records are complete and sufficient to begin litigation. If additional documentation is required, the court may order the petitioner to supplement the record.

5. Review by the Department of Health and Human Services (HHS)
The medical records are then reviewed by physicians and legal staff within the Department of Health and Human Services (HHS). HHS evaluates the evidence and determines its preliminary position on the case. At this stage, the government may:

• Concede causation, acknowledging that the vaccine caused the injury;

• Enter settlement discussions, even if causation is disputed; or

• Contest the merits of the claim.

6. Damages Negotiations or Settlement Discussions
If HHS concedes causation, the case proceeds directly to damages negotiations, where the parties evaluate compensation for medical expenses, lost wages, pain and suffering, and future care needs. When cases settle, damages discussions follow a similar process, although the government may not formally concede causation.

7. Expert Reports in Contested Cases
If the government contests the claim, the case enters a more complex litigation phase. Both parties typically retain medical experts to analyze the medical records and relevant scientific literature. Expert reports in vaccine court cases are often detailed and extensive, addressing immunology, neurology, epidemiology, and other medical specialties. This phase can take a prolonged period of time due to the depth of analysis involved.

8. Briefing or Evidentiary Hearing
After expert reports are submitted, the case may proceed in one of several ways. The parties may reach a settlement after reviewing the expert evidence, or they may submit legal briefing on the causation issues for the Special Master to decide. In some cases, the Office of Special Masters may schedule a trial (evidentiary hearing) where experts testify and are cross-examined.

9. Decision by the Office of Special Masters
Once briefing is completed or a hearing has occurred, the Special Master issues a written decision on causation. Depending on the complexity of the case and the court’s docket, obtaining a final decision can take anywhere from six months to several years, with some contested cases taking three to four years or more before a final ruling is issued.

Because of these multiple stages—medical review, expert analysis, and legal briefing—the timeline for vaccine injury litigation can vary widely. However, the structure of the program is designed to ensure that claims are evaluated carefully and based on thorough medical and scientific evidence.

Why Civil Lawsuits for Vaccine Injuries Are Rare

Under the National Childhood Vaccine Injury Act of 1986, individuals who believe they were injured by a covered vaccine are generally required to first file a claim through the Vaccine Injury Compensation Program (VICP) before pursuing a traditional civil lawsuit. This requirement is often referred to as the “exhaustion” requirement, meaning a claimant must first attempt to resolve the claim through the Vaccine Program before filing a case in civil court.

The Vaccine Act also limits certain types of product liability claims against vaccine manufacturers, particularly claims based on allegations that a vaccine’s design is defective. These protections were intended to reduce the risk that extensive litigation or large jury verdicts could discourage manufacturers from producing vaccines or threaten the stability of the national vaccine supply.

Can you sue a vaccine manufacturer?

The scope of these protections was further clarified by the United States Supreme Court in Bruesewitz v. Wyeth (2011). In that case, the Court held that the Vaccine Act preempts most design defect claims against vaccine manufacturers for injuries caused by vaccines covered under the program. In practical terms, the decision significantly limits the ability of individuals to pursue civil lawsuits alleging that a vaccine should have been designed differently or made safer.

As a result of the Vaccine Act and the Bruesewitz decision, most vaccine injury claims must be pursued through the VICP rather than through traditional product liability litigation. Congress designed this structure to ensure that vaccine injury claims are evaluated within a specialized system capable of addressing complex medical and scientific evidence while still providing a pathway for compensation.

Why Vaccine Injury Compensation Matters

Vaccines have transformed modern medicine by dramatically reducing the spread of infectious diseases that once caused widespread illness and death. Routine vaccination programs protect not only the individuals receiving vaccines but also the broader community, particularly infants, elderly individuals, and people with compromised immune systems who may be more vulnerable to severe infections.

At the same time, Congress recognized that no medical intervention is completely without risk. Although serious vaccine injuries are rare, the Vaccine Act acknowledges that when such injuries occur, the individuals affected should not bear the consequences alone.

The Vaccine Injury Compensation Program was designed to uphold this principle by creating a system that compensates individuals who experience rare vaccine-related injuries while preserving the stability of the national vaccination program. By providing a fair, specialized, and more accessible compensation process, the VICP helps maintain public trust in vaccines and ensures that the small number of individuals injured by vaccines receive meaningful support.

How Many Vaccine Injury Claims Are Filed Each Year?

The number of vaccine injury claims filed each year varies depending on vaccination patterns, public awareness of the Vaccine Injury Compensation Program, and which vaccines are covered by the program. Since the program began operating in 1988, thousands of petitions have been filed in the U.S. Court of Federal Claims seeking compensation for alleged vaccine-related injuries.

According to statistics published by the Health Resources and Services Administration (HRSA), which administers the Vaccine Injury Compensation Program, the number of petitions filed in recent fiscal years includes:

• FY 2016 – 1,120 petitions filed

• FY 2017 – 1,243 petitions filed

• FY 2018 – 1,238 petitions filed

• FY 2019 – 1,282 petitions filed

• FY 2020 – 1,192 petitions filed

• FY 2021 – 2,057 petitions filed

• FY 2022 – 1,029 petitions filed

• FY 2023 – 1,167 petitions filed

• FY 2024 – 1,185 petitions filed

• FY 2025 – 1,300 petitions filed

• FY 2026 – 330 petitions filed as of March 1, 2026

The vaccines most frequently involved in Vaccine Injury Compensation Program claims are influenza vaccines and Tdap vaccines. This is primarily because they are among the most widely administered vaccines in the United States, not because they are inherently unsafe.

Influenza vaccines alone are administered hundreds of millions of times each year as part of national public health efforts to prevent seasonal influenza epidemics. When vaccines are administered at such a large scale across the population, even extremely rare adverse reactions can generate a measurable number of claims within the compensation system.

Why Vaccine Injury Claims Are Hard to Win

Although the Vaccine Injury Compensation Program (VICP) provides a specialized forum for resolving vaccine injury claims, proving that a vaccine caused a particular medical condition can still be challenging. Many of the conditions alleged in vaccine injury litigation—particularly neurological and autoimmune disorders—can arise spontaneously or be triggered by multiple possible causes unrelated to vaccination. As a result, determining whether a vaccine actually caused the injury often requires extensive medical evidence, scientific literature, and expert testimony.

To obtain compensation in vaccine court, a petitioner must demonstrate that it is more likely than not that the vaccine caused the injury. This legal standard is known as preponderance of the evidence, which is lower than the burden of proof required in traditional civil litigation. Even so, petitioners must still present credible medical evidence supporting a causal relationship between the vaccination and the injury.

One reason vaccine injury claims can be difficult to prove is that many of the autoimmune and neurological conditions alleged in vaccine litigation are extremely rare diseases in their own right. Some of these conditions occur at rates of approximately one case per 100,000 individuals or fewer in the general population. When a medical condition is that rare, there are often no large epidemiological studies examining environmental triggers—including vaccines—because the condition itself occurs so infrequently.

The rarity of vaccine-related autoimmune injuries is also reflected in the overall mathematics of vaccination in the United States. Each year, approximately 200 to 225 million vaccine doses are administered nationwide across childhood and adult immunization programs. By comparison, the Vaccine Injury Compensation Program receives roughly 1,200 petitions per year. Even if every petition represented a valid vaccine injury—which is not the case—the incidence would still be extremely small. Based on this comparison, the potential rate of vaccine-related autoimmune injury would be approximately 0.0005 percent, making such events among the rarest adverse outcomes in modern medicine.

Government medical experts evaluating vaccine injury claims often look for epidemiological evidence showing that a vaccine increases the risk of a specific autoimmune disease. In many cases involving rare neurological or autoimmune conditions, that type of epidemiological evidence does not exist because the condition occurs so infrequently in the general population. As a result, petitioners frequently rely on medical theory, case-specific evidence, expert testimony, and scientific literature to explain the biological mechanism linking vaccination to the injury.

Finally, contested vaccine injury claims often require extensive litigation before the Office of Special Masters. When the government disputes causation, the case may proceed to expert reports, legal briefing, and sometimes trial. Trial calendars for vaccine injury cases can extend several years into the future due to the limited number of Special Masters currently assigned to hear cases. Many practitioners believe that at least four additional Special Masters would be necessary to address the current case inventory and provide more timely resolutions for injured individuals seeking compensation through the Vaccine Injury Compensation Program.

For these reasons, although the VICP was designed to provide a more accessible forum than traditional product liability litigation, vaccine injury claims—particularly those involving complex autoimmune or neurological disorders—can still be difficult to prove and may require significant time and expert analysis to resolve.

The Bottom Line

The Vaccine Injury Compensation Program represents a unique approach to resolving vaccine injury claims in the United States. It reflects Congress’s effort to balance two important public health goals: maintaining a stable vaccine supply while ensuring that individuals who experience rare vaccine-related injuries have access to meaningful compensation.

First, the VICP exists to provide compensation to the small percentage of individuals who suffer serious adverse reactions following vaccination. Although vaccines are overwhelmingly safe and remain one of the most effective tools in modern medicine, Congress recognized that when rare injuries occur, those individuals should not bear the financial burden alone.

Second, it is important to understand what the Vaccine Program does—and does not—do. Decisions within the VICP do not establish definitive scientific proof that a vaccine causes or does not cause a particular condition. Rather, the program evaluates whether the evidence in an individual case demonstrates that it is more likely than not that the vaccine caused the injury.

Third, the program is funded through a federal excise tax on each covered vaccine dose that is deposited into the Vaccine Injury Compensation Trust Fund. This structure ensures that vaccine manufacturers contribute to the compensation system rather than receiving liability protections without cost.

Fourth, the VICP provides a forum where injured individuals may pursue compensation under a more accessible evidentiary framework. Although civil lawsuits against pharmaceutical companies might appear attractive due to the size of potential verdicts, proving scientific causation in traditional civil courts is extraordinarily difficult. Civil courts apply stricter evidentiary rules and expert witness standards, including the Daubert standard, which can prevent expert testimony when scientific theories cannot be tested or conclusively validated. Vaccine court was designed to allow medically plausible theories of causation to be considered even when definitive scientific testing may not yet exist.

Finally, maintaining a robust compensation program that fairly and efficiently resolves vaccine injury claims fulfills the intent of the Vaccine Act. A system that recognizes and compensates legitimate injuries while supporting widespread vaccination helps preserve public confidence in both scientific institutions and national immunization programs.

But amid the political turbulence, one fundamental reality remains unchanged: the scientific evidence supporting vaccines—and the need to protect vulnerable populations—has not changed.

Changes to vaccine recommendations, lawsuits challenging federal policy decisions, and the growing influence of political health movements have created a moment of uncertainty for public health institutions.

At the center of many of these developments is Health and Human Services Secretary Robert F. Kennedy Jr., whose leadership has brought renewed attention to two concepts now appearing frequently in federal vaccine policy discussions:

• Shared clinical decision making in vaccine recommendations
• The broader influence of the MAHA movement

Supporters argue these ideas promote transparency and patient autonomy. Critics warn they risk undermining the scientific processes that have guided vaccine policy for decades.

Understanding these developments—and separating politics from science—is essential for evaluating where vaccine policy may be heading.

What Is Shared Clinical Decision Making in Vaccine Policy?

The concept of shared clinical decision making is not new in medicine.

In clinical practice, shared decision making refers to a process in which physicians and patients evaluate the risks and benefits of a medical intervention together before deciding on treatment.

The Centers for Disease Control and Prevention (CDC) already uses this framework in a limited number of vaccine recommendations where the benefits of vaccination may vary depending on individual patient risk factors.

Examples include:

• HPV vaccination in certain adult populations
• meningococcal B vaccines
• pneumococcal vaccination for specific risk groups

In these situations, physicians are encouraged to evaluate patient-specific risks rather than relying solely on universal recommendations.

Historically, however, shared clinical decision making has been used sparingly in vaccine policy. Most vaccines included in the childhood immunization schedule are recommended broadly because the scientific evidence supporting their safety and effectiveness is strong across populations.

Recent policy discussions suggest the framework may be applied more widely going forward—an idea that could significantly alter how vaccine recommendations are communicated to physicians and patients.

The Rise of the MAHA Movement

Much of the political momentum behind these policy discussions is tied to the Make America Healthy Again (MAHA) movement.

The MAHA movement has grown rapidly through political activism, social media networks, and grassroots advocacy aligned with Robert F. Kennedy Jr. and others who have long criticized aspects of the public health establishment.

Supporters of the movement frequently emphasize concerns about:

• chronic disease rates
• environmental toxins
• food system regulation
• pharmaceutical industry influence

The movement has attracted a diverse coalition of activists, influencers, and political figures. Its growing visibility is now influencing federal health policy discussions.

As a result, vaccine policy debates are increasingly being shaped not only by scientific institutions but also by political and cultural movements.

A Growing Political Divide Over Vaccine Policy

As the MAHA movement gains visibility, vaccine policy has become increasingly entangled with national politics.

Recent developments illustrate this shift:

• lawsuits challenging federal vaccine policy decisions
• states preparing responses to federal health directives
• political leaders debating how to engage with MAHA supporters ahead of upcoming elections

At the same time, public trust in federal health institutions has declined since the COVID-19 pandemic, creating an environment in which competing narratives about vaccine safety and policy can spread more easily.

Turning vaccine policy into a political battleground carries real risks.

Vaccination programs rely heavily on public trust, scientific credibility, and clear communication. When vaccine guidance becomes politically contested, that clarity can quickly erode.

Where the Scientific Consensus Stands

Despite the political debate, the scientific consensus on vaccines remains strong.

Major medical organizations continue to support routine vaccination based on decades of clinical research and epidemiological evidence.

These organizations include:

• American Academy of Pediatrics (AAP)
• American College of Obstetricians and Gynecologists (ACOG)
• American Medical Association (AMA)
• Infectious Diseases Society of America (IDSA)

These institutions rely heavily on recommendations from the Advisory Committee on Immunization Practices (ACIP), which evaluates clinical trial data, safety monitoring systems, and epidemiological evidence before issuing vaccine recommendations.

For most vaccines in the childhood immunization schedule, the scientific evidence supporting their use is extensive and well established.

Political leadership changes do not alter that scientific foundation.

Vaccines Remain Essential for Protecting Vulnerable Populations

Vaccines remain one of the most important tools in modern medicine.

They protect not only individuals who receive them but also the broader community through population-level immunity.

High vaccination rates protect:

• infants too young to receive vaccines
• elderly individuals
• patients undergoing cancer treatment
• individuals with compromised immune systems

When vaccination rates decline, outbreaks of preventable diseases often follow.

Recent measles outbreaks in communities with declining vaccination rates demonstrate how quickly these diseases can return when vaccination coverage falls.

Maintaining strong vaccination coverage remains essential for protecting the most vulnerable members of society.

Vaccine Policy Should Not Be Political

Public health policy inevitably intersects with politics. Leadership changes, regulatory priorities shift, and policy debates emerge.

But the scientific evidence supporting vaccines should not be subject to partisan swings.

Vaccines are not a Republican or Democratic issue.

They are a public health tool that has saved millions of lives.

Both political parties share a responsibility to ensure that vaccine policy remains grounded in credible scientific evidence rather than ideological agendas.

Innovation and Education Must Continue

The future of vaccine policy must also focus on continued scientific progress.

The United States should continue investing in:

• vaccine research and innovation
• robust vaccine safety monitoring systems
• public education about vaccine science
• transparent scientific review processes

Vaccinology has dramatically reduced the burden of infectious diseases over the past century, and continued innovation will remain essential to addressing future public health threats.

The Missing Piece in the Debate: The Vaccine Injured

While political battles over vaccine policy intensify, one group is often missing from the conversation.

Individuals who experience rare but serious vaccine injuries.

Congress recognized this risk decades ago when it created the National Vaccine Injury Compensation Program (VICP).

You can read more about how the program works in our earlier article.

Similarly, the unique challenges surrounding COVID-19 vaccine injury claims are explained here.

If vaccine policy is going to evolve in the coming years, the system designed to support these individuals must remain a central part of the discussion.

Ensuring that injured individuals receive fair and timely compensation is essential for maintaining public trust in vaccination programs.

The Path Forward

The debate surrounding RFK Jr., the MAHA movement, and shared clinical decision making in vaccine policy reflects a broader moment of transition in American public health.

Political leadership may change. Policy priorities may shift. Public health institutions may evolve.

But the scientific evidence supporting vaccines remains clear.

Vaccination continues to protect millions of lives each year.

The challenge going forward is not choosing between science and skepticism.

It is ensuring that vaccine policy remains grounded in credible evidence, that public trust is restored, and that individuals who experience rare vaccine injuries are not forgotten.

Maintaining that balance will be essential for the future of public health in the United States.

Subscribe for Updates on Vaccine Law and Policy

This publication analyzes:

• vaccine injury litigation
• federal vaccine policy developments
• the Vaccine Injury Compensation Program (VICP)
• COVID vaccine injury compensation claims

If you want clear, evidence-based analysis of vaccine law and policy developments, consider subscribing.

Subscribers receive new articles on:

• vaccine litigation
• federal policy changes
• emerging vaccine injury issues
• public health law

Subscribe to stay informed about the evolving intersection of vaccine science, law, and policy.

Subscribe now